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Abstract 
In children infected with human immunodeficiency virus (HIV) CD4 T-cell loss results 
in profound immunodeficiency and susceptibility to infection, however loss of CD4 T-
cells can be partially reversed by antiretroviral therapy (ART). Although the Children 
with HIV Early Antiretroviral Therapy (CHER) trial demonstrated significant reduction 
in morbidity and mortality from early ART among South African infants, the 
immunological and virological mechanisms by which this survival advantage occurs 
are not completely understood. 
The work described here used stored specimens of peripheral blood mononuclear 
cells and plasma from HIV-infected children in CHER and HIV-uninfected children 
from the Child Wellness Clinic, a cross-sectional study of healthy South African 
children. The overall aims were to explore the influence of HIV and ART on 
immunophenotypes, thymic and naïve B-cell output, HIV serostatus and HIV proviral 
DNA. 
The main outcomes included: development of haematological and immunological 
reference ranges for South African children; and an observation of a naïve/memory 
T-cell ratio of 1:1 within the first decade of life in South African children compared 
with the third decade in industrialised countries. Trajectories of thymic and naïve B-
cell output were created for healthy South African children. Overall early ART 
sustained thymic output and increased naïve B-cell output in CHER participants 
compared to healthy controls. Higher CD4 counts were significantly associated with 
increased thymic output, and deferred/interrupted ART or poor clinical outcome were 
  5 
associated with lower thymic and naïve B-cell output. Early ART and continuous HIV 
RNA suppression reduces HIV proviral DNA, however despite adequate viral 
suppression, immunological disturbances persist. Finally, almost half children 
receiving early ART were HIV-antibody seronegative by 2 years. 
These insights develop understanding of the interplay between the immunology and 
virology of HIV-infected children on ART, and could support further research to 
advance ART-strategies and optimise the immunological fitness and clinical health of 
HIV-infected children. 
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Chapter 1 
 
Introduction 
 
1.1 The Immune System  
 
The immune system protects the body from infectious agents and the damage they 
cause by four main tasks: immunological recognition, immune effector functions, 
immune regulation and immunological memory [1]. Immune responses are broadly 
divided into innate (non-specific) such as physical or chemical barrier and phagocytic 
responses, or adaptive (specific) responses that are developed during a lifetime as 
an adaptation following exposure to an organism with the crucial development of 
immunological memory.  
 
Most infectious agents activate the innate immune system and induce an 
inflammatory response. This usually commences with secretion of proteins called 
cytokines and chemokines which essentially initiates the process of inflammation, 
recruiting the cells and molecules required to attack the pathogen, while increasing 
the flow of lymph to nearby lymphoid organs and thereby activating the adaptive 
immune system. 
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Adaptive immunity is further divided into humoral i.e. production of antibodies, or 
cellular i.e. mediated through cells of the immune system. Lymphocytes are integral 
to both pathways, whereby B-lymphocytes (B-cells) produce antibodies and present 
antigens to T-Lymphocytes (T-cells), and T-cells can act as cytotoxic killing cells or 
helper cells to recruit or suppress other cells involved in the specific immune 
response. B-cell development occurs predominantly in the bone marrow but also in 
the fetal liver, whereas the development of T-cells takes place in the thymus.  
 
The bone marrow  
The pluripotent haematopoietic stem cell generates all the cells of the immune 
system initially committing to either lymphoid or myeloid lineage. These processes 
typically originate in the bone marrow where a specialized microenvironment 
provides signals that induce switching on of key genes that direct a developmental 
program. Non-lymphoid connective tissue stromal cells interact intimately with the 
developing lymphocytes by interactions between cell-adhesion molecules and their 
ligands, and also by providing soluble and membrane-bound cytokines and 
chemokines that control lymphocyte differentiation and proliferation. The lymphocyte 
progenitor is signaled to give rise to the common lymphocyte progenitor or the early 
T-lineage precursor, whereby the former differentiates into Pre-B-lymphocytes and 
Pre-Natural Killer cells, and the latter will migrate from the bone marrow to the 
thymus and become a thymocyte. 
 
B-cell development 
B-cell development occurs in two main phases. An initial antigen-independent phase 
in the bone-marrow where precursor B-cells mature into functional naïve B-cells and 
multiple rounds of first heavy- and then light-chain immunoglobulin gene 
rearrangements occur to generate a diverse range of functional receptors [2]. The 
progress of this phase of development is dependent on interactions with the bone 
marrow stromal cells and the cell does not progress to the next phase until a protein 
chain is produced. The antigen-dependent phase follows whereby mature B-cells are 
maintained by regeneration, turnover and selection processes. These selection 
processes include negative selection in the bone marrow whereby self-reactive 
immature B-cells are removed from the repertoire or die if over-stimulated by antigen. 
Mature B-cells migrate to peripheral lymphoid organs and are activated when bound 
to foreign antigen. 
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B-cells are specialized to recognize the surface antigens on pathogens living outside 
cells and when activated by these antigens they will differentiate into plasma effector 
cells that secrete antibodies and long-lived memory cells to target these pathogens. 
Antibodies are Y-shaped molecules whose arms are composed of two identical 
heavy and two identical light chains, and form two identical antigen-binding sites. 
These are highly variable from one molecule to another, however the stem on the Y 
(constant region) is far less variable and takes five main forms, known as 
immunoglobulin classes IgA, IgE, IgD, IgG and IgM, which determine the antibody’s 
function. Antibodies participate in host defense in three main ways: neutralization, 
opsonization and complement activation.  
 
T-cell development 
In contrast, T-cell development begins with haematopoietic stem cells, characterized 
by the presence of CD34 surface antigen, migrating from the bone marrow to the 
thymus where sequential stages of phenotypic maturation occur. Within the thymic 
cortex, double negative thymocytes that neither express CD4 nor CD8 cell-surface 
markers, differentiate into double positive thymocytes expressing both CD4 and CD8. 
During this time the T-cell receptor (TCR) is assembled through a non-specific 
process of recombinant rearrangement of two distinct lineages of T-cells from either 
αβ or γδ genes. The TCR beta chain is formed by rearrangement of the Variable 
(V𝛽), Diversity (D𝛽) and Joining (J𝛽) regions encoded in the genome with extra 
diversity acquired though random insertion and deletion of bases between these 
regions. The rearranged beta chain is then paired with a pseudo alpha chain to 
establish functional rearrangement before pairing with an actual alpha chain formed 
by rearrangement of V𝛼 and D𝛼 regions also with insertions and deletions of bases 
between the regions. Likewise, the γδ chains are formed concurrently in a similar 
manner, however more than 90% of circulating T-cells express αβ TCRs. These 
processes produce a desirable diverse range of TCRs to recognize foreign antigens. 
A by-product of this rearrangement are spliced and excised episomal DNA circles 
known as T-cell receptor excision circles (TRECs) which have been used as a 
measure of thymic output. 
 
The subsequent phase of T-cell development occurs in the thymic medulla where 
thymocytes undergo an extensive selection process to ensure self-tolerance and self- 
major histocompatibility complex (MHC) restriction eliminating autoreactive T-cells 
(negative selection) and preserving functional T-cells (positive selection). TCRs 
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recognise short linear peptides when presented in association with MHC-molecules 
on the surface of antigen-presenting cells. Only thymocytes whose receptors interact 
with self-peptides:self-MHC complexes can survive and mature, ensuring T-cells 
bearing receptors with high affinity for self-peptides that could result in autoimmunity 
and T-cells with receptors of very low affinity are deleted. At this stage it is also 
determined which T-cells will become single positive CD4 or CD8 T-cells [3]. These 
selection processes discard about 99% of all thymocytes and lead to the generation 
of naïve CD4 and CD8 T-cells frequently referred to as recent thymic emigrants 
(RTEs) [4] that enter the peripheral circulation. 
 
After leaving the thymus RTEs circulate through the spleen and lymph nodes, and 
enter a phase of homeostatic cell division. Within the peripheral lymphoid organs the 
T-cells may encounter their specific antigen and become activated, undergoing clonal 
expansion and differentiation into effector T-cells [1]. Effector T-cells are attracted to 
the site of an infection or inflamed tissue and can either kill infected cells or activate 
macrophages or antibody responses. 
 
The thymus and thymic output 
The thymus has no self-renewal properties and relies upon the continuous 
replenishment of new T-cell progenitors from the bone marrow [5]. Thymic size is 
maximal at around one year of age and thereafter, uniquely compared to all other 
organs of the body, the thymus demonstrates an age-associated involution [4, 6, 7]; 
there is reduction in mass, structure and cellularity, and correspondingly a decline in 
exported naïve T-cells from the thymus.  
 
Extremely high thymopoesis in the first 2 years of life is believed to correlate with 
thymic size [8-10]. In line with the involution of thymic epithelial tissue, it has been 
proposed that thymic export reduces in three phases: from 2 to 5 years, from 5 years 
to puberty, and thereafter from puberty into adulthood [11]. In adulthood, the T-cell 
pool is mostly maintained by peripheral proliferation and homeostasis with the 
thymus having a minimal role, reducing with age, in maintaining immune efficacy. 
  
There are several histological changes associated with aging in the thymus, namely a 
significant reduction in the volume of the cortex and medulla and replacement with 
adipose tissue, fibrosis and accumulation of senescent cells. Figure 1.1 presents the 
age-associated changes in histology from a large morphometric study of autopsied 
thymuses from 304 adults and children who died of sudden death without infectious 
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cause [12].  Several other studies have demonstrated that with age, the thymic 
microenvironment undergoes structural, phenotypical, and architectural changes 
including down-regulation of various thymic epithelial cell markers [5]. Extrinsic 
changes associated with ageing such as decreased IL-7, necessary for thymopoiesis, 
are likely to result in impaired T-cell development. 
 
These changes recognised to occur with ageing and result in decline of thymic output 
are believed to be associated with reduced T-cell diversity and thereby increased 
susceptibility to infection, autoimmune disease and cancer [5]. However these 
associations have not been well described, primarily due to the difficulties in 
quantifying thymic output since the complex interplay between naïve T-cell 
production, homeostatic proliferation and apoptosis can mean that peripheral blood 
sampling of naïve T-cells could be misleading. This association between thymic 
output, reduced T-cell diversity and increased susceptibility to infection could have 
particular relevance in children where compromise of thymic output in early childhood 
years, such as infection with Human Immunodeficiency Virus (HIV) could have crucial 
implications on their developing immune system and ability to fight infection long-
term. The vital role the adaptive immune system in fighting infection is illustrated by 
diseases of immunodeficiency, and particularly so by HIV, which succeeds in evading 
suppression of the adaptive immune response.  
Figure 1.1: Changes in histological proportions of the thymus with age [12]. 
 
Reduction of connective tissue, medulla, cortex and lymphocytic perivascular space is 
illustrated with proportional increase in adipose tissue. 
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1.2 The effect of HIV infection on the immune system 
 
The syndrome we now know as Acquired Immunodeficiency Syndrome (AIDS) was 
first described in 1981 when the first previously healthy patients were found to be 
suffering from severe immunodeficiency and dying from opportunistic infections. The 
cause of AIDS was identified in 1983 to be Human Immunodeficiency Virus [13], and 
30 years later, 60 million people have been infected with HIV and 25 million have 
died from AIDS [14]. The first antiretroviral drug was developed in 1986 and by 1996 
combination anti-retroviral therapy (ART) had been introduced, simultaneously 
targeting various stages of the HIV-lifecycle to control viral replication thereby 
preventing the deleterious impact of HIV upon the immune system and significantly 
reducing morbidity and mortality. 
 
HIV is a retrovirus from the Lentivirus family. Of the two isolates HIV-1 and HIV-2, 
HIV-1 is globally the commonest form and in this text it is referred to as HIV. There is 
evidence that HIV originated from Simian Immunodeficiency Virus (SIV) [15] and 
transferred to humans from chimpanzees and sooty mangabeys [16, 17]. 
Transmission of HIV occurs through transfer of bodily fluids such as blood, semen, 
vaginal fluids and breast milk, and infects vital cells of the immune system 
specifically CD4 T-helper cells, macrophages and dendritic cells. 
 
Three to four weeks following HIV-exposure there is rapid viral replication and 
development of a flu-like illness. Shortly afterwards, HIV-specific immune responses 
develop and antibodies to core (p24) and envelope (gp160, gp41, gp120) proteins 
are detectable in the blood [18]. During this acute phase, there is high viraemia and 
massive CD4 depletion, the cause of which is incompletely understood [19, 20]. 
There is evidence for direct viral killing of infected cells, killing of infected CD4 T-cells 
by CD8 cytotoxic lymphocytes, and immune-activated T-helper cells which undergo 
repeated rapid mitosis and thereby have increased susceptibility to the induction of 
apoptosis [4]. In addition, it has been suggested that regeneration of new T-cells may 
be defective in HIV-infected individuals since progenitor T-cells from within the 
thymus may be infected and destroyed [1].  
 
Three months following primary infection, CD4 levels partially recover and viraemia 
subsides, and this depicts the chronic phase, known as clinical latency. Although this 
phase is often asymptomatic, there is ongoing gradual CD4 T-cell loss [21]. When 
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CD4 T-cells decline below a critical level, cell-mediated immunity is lost and 
infections with a variety of opportunistic microbes appear. In the absence of ART, 
there is progressive immune collapse characterised by frequent opportunistic 
infections, followed by the development of AIDS and finally death (Figure 1.2).  
 
HIV enters T-cells through binding of viral glycoprotein envelope (gp120) to the cell 
surface molecule CD4 and either the co-receptor CCR5 or CXCR4 [23]. Inside the 
cell, viral RNA is transcribed into double-stranded proviral DNA by viral reverse 
transcriptase. Within the nucleus the proviral DNA is then integrated into the infected 
cell’s chromosomal DNA where it may remain as a latent reservoir in quiescent cells. 
However, if the host cell is activated proviral DNA is transcribed back into genomic 
RNA and is translated into viral proteins (Gag, Env, Gag-Pol) which bud from the 
infected T-cell and are then released as infectious virus [18]. However subsequent 
assembly and maturation of virus particles relies upon the activity of the HIV 
protease enzyme.  
 
Figure 1.2: Time course of HIV infection without ART [22]. 
The first few weeks are typified by an acute influenza-like viral illness with high titres of virus 
in the blood, (seroconversion). An adaptive immune response follows, controlling the acute 
illness and largely restoring levels of CD4 T-cells in the blood but does not eradicate the 
virus. The disease becomes symptomatic with opportunistic infections as the CD4 T-cell 
count begins to fall. When the CD4 count is <200 the patient has AIDS and death may be 
imminent without treatment with ART. 
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HIV has been effective in evading the immune system and numerous antiretroviral 
drugs for several reasons. HIV replicates at a rate of 109-1010 new virions each day, 
with a mutation rate of 3x10-5 nucleotide per cycle [1] which means that the adaptive 
immune system cannot generate sufficient HIV-specific memory cells and it is the 
ideal environment for drug resistance to develop. The HIV protein encoded by Env 
protrudes through the virion membrane and plays a role in bystander killing of 
uninfected T-cells [24]; the HIV protein Nef down-regulates the expression of various 
proteins that are needed for recognition by CD8 T-cells [25]; and the HIV gene Tat 
appears to up-regulate expression of BCL2 which inhibits cell death [26]. In later 
stages of the disease, the HIV protein Vpr arrests target cells in the G2 phase of the 
cell cycle and induces apoptosis in T-cells, peripheral blood lymphocytes and 
fibroblasts. HIV-specific CD8 T-cells have lower than required levels of perforin to 
effectively penetrate and destroy infected CD4 T-cells that are producing new HIV 
virions [27]. In addition, HIV-infection of CD4 memory cells, macrophages and 
dendritic cells establishes latent reservoirs that have potential to reactivate, release 
infectious virions and cause further immunocompromise.  
 
Reservoirs for persistence include the central nervous system, gastrointestinal tract 
and urogenital tract, however a major reservoir of HIV infection is lymphoid tissue, in 
which infected CD4 T-cells, monocytes, macrophages and dendritic cells are found. 
Macrophages and dendritic cells appear to harbour replicating HIV without being 
killed by it, so they are believed to be an important vessel of spreading infection [1] 
particularly to the brain. HIV is also trapped in the immune complexes on follicular 
dendritic cells becoming a further source of infective virions. 
 
HIV-infection causes a variety of B-cell dysfunctions [28, 29] which may alter 
differentially in children of varying ages [30], including decreased proliferative 
responses [31], loss of memory B-cells, altered differentiation of naïve B-cells and 
decline in neutralizing antibody responses [32]. This results in reduced quantity and 
diversity of antigen-specific antibodies [33] which could compromise virological 
control. The mutations that occur as HIV replicates allow the resulting virus variants 
to escape recognition by neutralizing antibody or cytotoxic T-cells and contribute to 
the long-term failure of the immune system to contain the infection. 
 
The use of combined ART in targeting several phases of HIV life cycle 
simultaneously has been effective in avoiding evolving drug resistance. Such 
antiretroviral pharmaceuticals include fusion inhibitors, nucleoside and non-
  28 
nucleoside reverse-transcriptase inhibitors, integrase inhibitors, and HIV-protease 
inhibitors [34]. ART reduces HIV-RNA replication and its associated CD4 T-cell 
destruction allowing immune reconstitution to follow with an increase in CD4 count 
[35]. However, the degree with which immune restoration occurs varies among 
patients and despite effective control of viral replication, some adult patients do not 
achieve a sufficient immunological recovery [36]. It is possible that differences in 
CD4 reconstitution may, in part, be due to variances in supply of naïve T-cells [7]. 
Thymic output along with homeostatic cell division is essential for the generation of 
naïve CD4 and CD8 T-cells and is especially important in early childhood years 
during the development of the child’s immune system. There is data to support the 
contribution of thymic output to immune-recovery in HIV-infected adults on ART [37] 
and it is therefore likely to play an important role in children. 
 
The main immunological effect of HIV infection is the destruction of CD4 T-cells that 
occurs through the direct cytopathic effects of HIV and through killing by CD8 
cytotoxic T-cells. HIV establishes a state of persistent infection in which the virus is 
continually replicating in newly infected cells. HIV combines the characteristics of a 
persistent infection with the ability to create immunodeficiency in its host and 
illustrates the importance of innate and adaptive immunity in an effective immune 
response against infection. The key to fighting pathogens such as HIV is the use of 
immunological research to develop our understanding of the immune system and its 
role in combating infection. 
 
 
1.3 HIV infection in infants and children  
 
Currently, an estimated 34 million people are living with HIV worldwide, including 3.4 
million children and adolescents [38]. With effective prevention of mother-to-child 
transmission (pMTCT) new infant infections have been declining, however there are 
still up to 450,000 new infant infections each year [39]. In South Africa, maternal-to-
infant HIV-exposure is now 32% with a transmission rate of 3.5% [40]. For the infants 
that are infected with HIV, it is vital that treatment strategies minimise disease 
adverse effects and treatment side effects, and ultimately optimize the development 
of a functional immune system that will protect them throughout their lives.  
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Numerous challenges exist in the treatment of infants and young children infected 
with HIV and these are magnified in resource-limited settings where the majority of 
the HIV-infected children reside. Due to healthcare infrastructure, availability of 
resources and the fact that virological testing was required to confirm HIV-infection 
status, identification of infected infants may have been delayed [41]. This is a 
significant obstacle since disease progression can be rapid, with peak mortality in the 
first few months of life [42], yet there are currently no reliable markers to predict rapid 
disease progression [43]. There is a limited range of antiretroviral drugs available for 
children especially in affordable, palatable and appropriate formulations. Moreover, 
dosing must be regularly readjusted in line with infant and child growth. Across 
childhood, but particularly in adolescents, continuous adherence to ART is often a 
huge challenge. Non-compliance may result in drug-resistance and thereby 
compromised clinical management from poor availability of second or third-line ART. 
There may also be potential metabolic, cardiovascular and neurological problems 
from long-term ART started early in life. 
 
Current international guidelines recommend commencing ART for children less than 
5 years of age [44] with strong evidence from the Children with HIV Early 
Antiretroviral Therapy (CHER) Trial that supports ART initiation before 1 year of age 
[45]. However, minimal evidence and guidance exists for how long to continue ART. 
The implications of ongoing ART are not insignificant in terms of compliance, drug-
resistance, drug-related side-effects, toxicity, and finance [46]. Continuous monitoring 
of these life-long medications are required to understand the multiple possible effects 
on the developing child. One such effect upon the immune system of ART started 
within months of birth and subsequent effective viral suppression is the increasing 
recognition of HIV-antibody seronegativity [47-51]. Therefore, some of the important 
clinical questions for management of HIV-infected infants and children are: how long 
should ART be continued in childhood, whether treatment interruption is safe, and if 
so, when, for whom, and for how long? To begin to answer these questions, further 
more detailed understanding of the immunology and virology of paediatric HIV-
infection is required. 
 
Perinatally acquired HIV may be transmitted from the mother in-utero, intrapartum or 
postpartum [52]. In view of the developing status of the immune system, the timing of 
infection might be an important determinant of outcome. The known effects of HIV on 
the immature immune system include limited production of cytokines, delayed 
cytotoxic lymphocyte activity, thymic aplasia and early depletion of naïve T-cells [53-
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56]. These factors, along with the size of the thymus and CD4 pool, may contribute to 
the high levels of viral replication that is characteristically seen in the newborn, the 
longer time required to decline to viral set-points [57-59] and the rapid disease 
progression with increased mortality that is seen in infants [60, 61]. Following the 
initiation of ART, the capacity of the thymus to restore the naïve CD4 pool after HIV-
induced depletion is likely to be crucial in children, particularly in infancy since a 
competent peripheral circulating TCR repertoire may not have been established. 
 
 
1.4 The role of thymic output in immune reconstitution  
 
The rate of CD4 loss with HIV infection, and the degree of restoration with ART, is 
determined by the complex interplay between rates of HIV-induced T-cell death, 
peripheral T-cell proliferation and thymic production of new T-cells [21, 62]. In view of 
the high thymic activity in young children, the export of new T-cells from the thymus is 
likely to have particular importance in HIV-infected children. In whom the aim of ART 
should be to preserve the child’s developing immune system and maximize 
successful immune reconstitution.  
 
Despite age-associated decline of thymic function, there does appear to be a role of 
the thymus in immune reconstitution in HIV-infected adults. Larger thymic size has 
been associated with improved recovery of total and naïve CD4 T-cells, increased 
TREC frequencies, and renewal of TCR repertoire diversity [37, 63]. CD4 T-cell 
restoration appears to be most successful within two years of infection, when it is 
likely that the thymus is more productive. In addition to chronic immune activation 
and ongoing viral replication in untreated HIV-infected individual, reduced thymic 
output might also, in part, explain the large variation in CD4 recovery after ART is 
initiated [64]. This is supported by surrogate measures such as naïve CD4 T-cell 
counts and percentage of recent thymic emigrants (CD4+CD45RA+CD31+ 
lymphocytes) that appear to predict potential for immune reconstitution [36, 65], 
however these analyses do not account for varying rates of peripheral cell division or 
death. 
 
A recent study of 60 HIV-infected children and adolescents suggested that age-
adjusted thymic output is reduced in untreated HIV-infected children but significantly 
increases with ART [66] and suggests that after starting ART, the thymus is able to at 
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least partly compensate for the loss of naïve CD4 T-cells by increasing thymic output. 
This finding reinforces the importance to further investigate the role of thymic output 
in immune reconstitution in HIV infection and how ART-strategies may be able to 
optimize immunity in HIV-infected children.  
 
 
1.5 Aims and structure of study 
 
As this chapter describes, in HIV-infected individuals CD4 T-cell loss results in 
profound immunodeficiency and susceptibility to infection, however loss of CD4 T-
cells can be partially reversed by ART. The benefit of early ART in terms of reduced 
morbidity and mortality is widely recognized, however there remain many 
unanswered questions regarding the influence of HIV and early ART on the child’s 
developing immune system, including thymic output, naïve B-cell output, HIV-
antibody responses, and HIV proviral DNA reservoirs.  
 
Increased understanding of the mechanisms by which HIV and ART affect the 
immune system of a child could help to address issues in ART management 
strategies for HIV-infected children such as how long to continue ART in childhood, 
and whether to have ART interruptions and if so, when. However, a detailed 
understanding of the paediatric immune system in healthy children from within 
comparable populations is prerequisite (Chapter 3).  With these data, comparison 
between healthy HIV-uninfected children and HIV-infected children is therefore 
possible to characterize the immunophenotypic response to HIV and ART (Chapter 
4). 
 
In view of the evidence that supports the contribution of thymic output to immune 
reconstitution [37], and to the preservation of a diverse and functional T-cell 
repertoire, it is necessary to understand the relationship between thymic output and 
HIV, with and without ART (Chapter 5). This understanding is likely to be enhanced 
by appreciating the potential relationship between naïve B-cell output and thymic 
output and the influence of HIV and ART on naïve B-cell output (Chapter 6). Current 
issues such as poor reactivity of HIV-antibody assays in children on ART from infancy 
(Chapter 7) and optimising strategies to reduce the peripheral HIV proviral DNA 
reservoir have also been examined (Chapter 8). 
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Specific aims: 
Immune parameters in healthy South African children: 
• To establish local reference ranges for haematological and immunological 
parameters of healthy South African children. 
• To describe differences between immunological markers in children from low and 
high disease-burdened settings. 
• To explore the effect of cryopreservation on immunological parameters. 
 
Immunological responses to HIV and ART in children: 
• To compare immunological phenotypes of healthy HIV-uninfected children with HIV-
infected children on or off ART. 
 
The influence of HIV and ART on thymic output in children: 
• To describe normal thymic output in healthy South African children. 
• To examine the impact of the CHER ART strategies on thymic output. 
• To explore the relationship between thymic output and HIV disease progression. 
 
Naïve B-cell output in healthy and HIV-infected children: 
• To define reference ranges for KRECs and naïve B-cell output in healthy children.  
• To examine the impact of the CHER ART strategies on naïve B-cell output. 
• To describe the relationship between thymic output and naïve B-cell output. 
 
HIV-seronegativity with early ART: 
• To compare the effect of early versus deferred ART on HIV-antibody serostatus. 
 
HIV proviral DNA reservoirs and early ART: 
• To examine the effect of the CHER ART-strategies on peripheral reservoirs of HIV. 
• To explore the relationship between HIV serostatus and HIV proviral DNA. 
 
The laboratory techniques for this study were learned at the Institute of Child Health 
(ICH), University College London (UCL) during the first 6 months of this fellowship. 
Two subsequent years were spent in South Africa collecting samples and performing 
the laboratory work at Stellenbosch University (SUN) immunology laboratory. The 
Child Wellness Clinic (CWC), a paediatric health promotion clinic in an informal 
settlement, was established to acquire healthy control participants. Peripheral blood 
  33 
mononuclear cells (PBMCs) and plasma specimens from HIV-infected children were 
taken from “The Children with HIV Early Antiretroviral Therapy (CHER) Trial”. 
Frequent visits were made to the two sites of the CHER trial: The Perinatal HIV 
Research Unit (PHRU), Witwatersrand University, Johannesburg and The Children’s 
Infectious Disease Clinical Research Unit (KIDCRU), Stellenbosch University, Cape 
Town to collaborate with the protocol co-chairs of the CHER trial throughout my 
fellowship. 
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Chapter 2 
 
Methods and Study Populations 
 
This chapter describes the two populations used in this fellowship: HIV-uninfected 
healthy South African children from “The Child Wellness Clinic” (CWC) and HIV-
infected children from the “Children with HIV Early Antiretroviral Therapy (CHER) 
Trial”. Also described are the specimens, laboratory techniques and statistical 
approaches applied for the six areas of analysis: immunological phenotyping in 
health and HIV-infection, thymic and naïve B-cell output, HIV-antibody and HIV 
proviral DNA quantification. 
  
 
2.1 The Child Wellness Clinic 
 
A “Child Wellness clinic” for children from birth up to 13 years of age was established 
at a community health clinic in the informal settlement of Wesbank, Eastern 
subdistrict of Cape Town. The primary aim of the CWC was the acquisition of HIV-
uninfected blood specimens to measure “normal” thymic output and to create 
haematological and immunological reference ranges in healthy children from South 
Africa. The clinic was also designed to benefit the participants and the wider 
community in terms of health promotion, education and screening. Sampling from 
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this population aimed to obtain a group of HIV-uninfected children, comparable to 
CHER participants in terms of socio-economic status, nutrition, vaccination and 
environmental exposure to infectious pathogens.  
 
Within the region of Wesbank 27% are unemployed, 62% of adults did not complete 
education to equivalent of GCSE level, and 39% of households earn below (R19,200 
per year = £1,422). 16% live in informal dwellings and only 5% of the population is 
above 65 years of age. The infant mortality rate for Wesbank is 23.2 deaths per 1000 
live births, 7% of babies are born to mothers aged under 18 years, and 20% of 
babies are born weighing less than 2.5kg [67].  
 
CWC attendance was voluntary but the criteria for recruitment was that the child was 
well at the time with no chronic medical condition, registered at Wesbank health 
clinic, attended with their biological mother and brought their “Road to health” (hand-
held child medical record) card with them. After informed consent was obtained in 
English or via translator in Afrikaans or Xhosa, the clinic session included clinical 
history and examination by a paediatrician, anthropometry plotted on road to health 
card growth charts, assessment of vaccination status with catch-up if necessary, 
provision of nutritional supplements (vitamin-enriched porridge and peanut butter) 
and a supermarket food voucher. Each participant had phlebotomy of 2-3mls of 
blood that was used for rapid HIV-antibody analysis, full blood count (FBC), basic 
immunological profile and thymic output.  
 
If the rapid HIV-antibody tested positive in a child less than 18 months of age, 
provision was made for blood to be sent to the local laboratory for HIV proviral DNA 
and for mother and child to be referred to the local family HIV service (unless already 
known). Any child found to be HIV-infected would not be included in the study. 
Children found to be HIV-exposed but not infected (HEU) were not included in the 
healthy control population, however thymic output was still measured from these 
children and used for subgroup analysis. Since a child older than 18 months with a 
negative HIV-antibody test may have been HIV-exposed, maternal HIV-status was 
also assessed verbally, by reviewing the child and mother’s clinic files and by 
accessing the National Health Laboratory Service (NHLS) database with the 
maternal facility number. 
 
The clinic ran for 2 mornings per week for 8 months. From a total of 487 recruited, 15 
did not meet criteria or it was not possible to obtain enough blood for research 
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purposes and 1 mother withdrew consent, therefore 471 met criteria and a blood test 
was acquired for research purposes. Although the CWC was initially designed to 
recruit children less than 2 years of age, the clinic was extremely popular and 
therefore, after 4 months, the CWC was extended to all children under the age of 5 
years, and for all children up to 13 years of age during school holidays.  
 
Appendices I – IV detail the following documents for the CWC: poster and flyers, 
information and consent form (which were also translated into Afrikaans and Xhosa), 
structure of the clinic session and CWC proforma completed for each participant. 
Appendix V details the components and definitions of information that were retrieved, 
coded and anonymously recorded from the proforma. When completed the proforma, 
consent form and blood test results were filed in the child’s medical notes at 
Wesbank clinic. 
 
Ethical considerations and public engagement of the CWC 
The recruitment of healthy controls for this study was registered as a clinical trial with 
ethics approved by the Health Research Ethics Committee (HREC) at Stellenbosch 
University. It was also approved by the CIPRA-SA committee, the Head of the 
Department of Paediatrics at Stellenbosch University, the Head of Community 
Division of Paediatrics, Tygerberg Hospital Managers Committee and the City of 
Cape Town Department of Health (Appendix VI: Ethical and Regulatory Approvals).  
 
The CWC participant information sheet was provided in the child’s guardian’s first 
language and a signed consent form was obtained from a guardian of each child 
participant via a translator in Afrikaans or Xhosa if required. One copy of the consent 
form was given to the guardian, one copy kept with the participants clinic file and a 
third kept in locked files at KIDCRU as part of quality control and governance. To 
maintain subject confidentiality each participant was given a study registration 
number and all data were anonymised and transcribed onto an encrypted electronic 
database. The blood sample for thymic output was coded with the study registration 
number and date of birth only, and the sample sent for FBC had initials and date of 
birth as patient identifiers. Full name and contact details were only retained at 
Wesbank clinic and all documents containing patient identifiers were kept in locked 
cabinets in secure locations. 
 
Every CWC participant had an HIV-antibody test performed. Since a positive test 
may reflect the mother’s HIV-status, counseling was given to the mother during the 
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consent-taking process. If any child were to be found HIV-antibody positive, every 
effort would be made to ensure that they attend their follow-up appointment with the 
local family HIV service while maintaining patient confidentiality. The risk of bruising 
and potential discomfort experienced during phlebotomy was explained to the 
parents and child. For those running the CWC, potential risks included the handling 
of HIV-infected blood. Universal precautions were applied during the taking of all 
samples and during laboratory processing of blood. Gloves were worn when 
collecting or handling blood, and goggles when there was danger of blood splashing. 
All needles and sharp objects were disposed in puncture-resistant containers.  
 
Aside from acquiring blood specimens from healthy children to establish local 
reference ranges and explore thymic output, the CWC had a number of concurrent 
benefits including health promotion, optimisation of vaccination, increased HIV-
screening in high risk groups, and public engagement with health research.  It 
transpired that a number of children attended the CWC had not been accessing 
routine paediatric care, therefore attending the CWC was an opportunity to catch-up 
on missed vaccinations, de-worming and vitamin A drops as well as to reinforce the 
importance of existing public health strategies. 
 
Good community relations are vitally important for the success of clinical research 
and KIDCRU has an extensive history of community projects with benefits to 
children. Regular meetings regarding this study were held with the Community 
Advisory Board (CAB), a group of people that aim to make a difference in the lives of 
HIV-infected people, caregivers and the research team. The KIDCRU CAB consists 
of parents, caregivers, legal guardians of HIV-infected children, service-providers, 
medical caregivers, and interested community members. The CAB functions to 
provide input from the community to the research team and to be the advocate 
between the research participant and the research team to facilitate informed 
decision-making. These individuals were best suited to receive information regarding 
the CWC study, progress updates and subsequently transmit the relevant findings to 
the community and participants of the study. Results were also presented and 
displayed in poster form in Wesbank community health clinic and Tygerberg Hospital.  
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Every effort was made to ensure that my presence, as a paediatrician, at Wesbank 
clinic would be helpful and would not undermine nor hinder the work of the clinic 
staff. Positive benefits have included increasing the paediatric skill base of the clinic 
assistant and translator, promotion of the profile of KIDCRU CAB and following the 
end of the CWC Wesbank community clinic continues to be used for further clinical 
research recruitment related to other KIDCRU studies. 
 
 
2.2 The Children with HIV Early Antiretroviral Therapy 
(CHER) Trial  
 
The CHER trial was a phase 3, randomized 3-arm trial conducted by the 
Comprehensive International Program for Research in AIDS (CIPRA). The CHER trial 
took place, and post-trial follow-up continues, at the Perinatal HIV Research Unit 
(PHRU), Johannesburg and the Children’s Infectious Diseases Clinical Research Unit 
(KIDCRU), Cape Town. The trial’s main hypothesis was that early limited ART started 
within 12 weeks of life, compared with deferred ART until clinical or immunological 
deterioration, would prevent disease progression and safely allow a subsequent 
period off ART.  
 
377 HIV-infected asymptomatic infants less than 12 weeks of age (median age 7.3 
weeks [IQR: 6.4-9.0]) were randomised to three arms: deferred ART until clinical or 
immunological criteria were met (Arm 1: ART-Def); and early ART for 40 or 96 weeks 
(Arm 2: ART-40W and Arm 3: ART-96W) followed by a period of ART interruption 
until clinical or immunological deterioration (Figure 2.1). The trial defined endpoint 
was time to death or failure of first-line ART, defined as CD4% <20%, CDC stage B/C 
events or regimen-limiting drug-related toxicity.  Criteria for starting or re-starting ART 
were CD4% <20% or CDC stage C or severe B, i.e. moderately or severely 
symptomatic with clinical conditions such as serious bacterial infections, 
encephalopathy or wasting syndrome. This was revised to CD4% <25% or 
<1000cells/µl in 2006 with international guidelines. First-line ART comprised 
zidovudine, lamivudine and lopinavir-ritonavir; and second-line ART was didanosine, 
abacavir and nevirapine or efavirenz. CHER participants were reviewed 4-weekly 
until week 24, 8-weekly until week 48, and then 12-weekly thereafter. Blood tests 
done at each review were: full blood count, aminotransferase levels and CD4 count. 
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In 2007, after a median follow-up of 40 weeks (IQR: 24-58), interim data showed that 
66% of infants in the deferred group had started ART. A 76% reduction in risk of 
death and 75% reduction in disease progression was observed with early ART (both 
ART-40W and ART-96W combined) compared to deferred ART (p=0.0002) [45]. As 
advised by the Drug Safety and Monitoring Board, infants randomised to defer ART 
were then reassessed by their clinicians to commence ART. Early ART initiation for 
all infants subsequently became the international standard of care, regardless of 
CDC staging or CD4 count/percentage. Almost all children from ART-Def 
commenced ART and were followed up as planned. To sufficiently power further 
analysis of the other randomised arms, ART-40W and ART-96W, 17 more children 
were recruited to each arm. 
 
At the trial end in June 2011, 341 of the original 377 children recruited (91%) had 
either completed follow-up or died (42/377, 11%) over a median duration of 250 
weeks (range 182-307 weeks). 34 (9%) were lost to follow-up and 2 (0.5%) withdrew 
consent. The deferred group received continuous ART (ART-Def) from median 20 
weeks (95% Confidence Interval (CI): 16-25). ART-40W received early limited ART, 
Figure 2.1: Overview of CHER trial randomisation and schedule. 
 
First-line ART was Zidovudine, Lamivudine and Lopinavir. Initially 126 children were recruited 
to each of the early ART treatment arms (ART-40W and ART-96W) and 125 children to ART-
Def (377 in total). However, following the discontinuation of ART-Def in 2007 due to the 75% 
increased risk of disease progression, ART-40W and ART-96W each had 17 more children 
recruited to sufficiently power further analysis. 
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interrupted after 40 weeks and restarted ART after a median of 33 weeks (IQR: 26-
45).  ART-96W received early limited ART, interrupted after 96 weeks and restarted 
after median 70 weeks (IQR: 35–109) (Figure 2.2 and more simplistically represented 
in Figure 2.3).  
Figure 2.2: Proportion of CHER participants on ART over calendar time (weeks) [68]. 
  
The rate of starting ART: ART-Def (dark blue), ART-40W (red), ART-96W (light blue). 
 
Figure 2.3: Overview of CHER trial treatment strategies and median duration on ART 
within arms. 
 
Median time to ART initiation in the deferred arm was 20 weeks (IQR 16-25); ART was 
otherwise started at age 7.3 weeks (IQR: 6.4-9.0). Median duration of ART-interruption for 
ART-40W was 33 (26-45) and 70 (35-109) weeks in ART-96W. Key: median time of deferred 
or interrupted ART (red), median duration of time on ART (green). 
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There were 48/125 (38.4%) children who met trial defined endpoints in ART-Def, 
including 21 (16.8%) deaths. Twenty-seven (21.6%) endpoints occurred while on 
ART (10 virological, 9 immunological and 8 clinical failures). In the early limited 
treatment groups, ART-40W and ART-96W, 32/126 (25.4%) and 26/126 (20.6%) 
endpoints were reached respectively, including 11 (8.7%) and 9 (7.1%) deaths, and 
endpoints that occurred while on ART were 21 (16.7%) and 17 (13.5%). There were 
no failures due to regimen-limiting toxicity. The hazard ratio for progression to severe 
CDC B/C or death in children with early limited ART compared to deferring ART was 
significantly reduced for both ART-40W (0.5 95% CI: 0.3 – 0.8; p=0.005) and ART-
96W (0.4 95% CI: 0.3 – 0.7; p=0.0003 [68]) as Figure 2.4 illustrates. This figure also 
suggests that there is no difference in progression rates between ART-40W and 
ART-96W from Week 40 to 72 when ART-40W interrupts compared to ART-96W 
continuing ART. However, following this period the rate of progression continued to 
increase in ART-40W above the rate of ART-96W.  
 
By the trial end at 248 weeks, median CD4% was above 30% in all arms, 
anthropometric data were within population standards and comparable between 
arms, and only 26 (6.9%) children on ART had a viral load >1,000 copies/ml of blood. 
Twenty-four (19%) and 40 (32%) of children in ART-40W and ART-96W respectively 
had not restarted ART and were clinically well.  The CHER database does not 
contain patient identifiers and information stored is protected by confidentiality 
Figure 2.4: Progression to severe CDC B/C or death in CHER [68]. 
 
Median time to ART initiation in ART-Def was 20 weeks (IQR 16-25). Median duration of 
ART-interruption for ART-40W was 33 (26-45) and 70 (35-109) weeks in ART-96W. 
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procedures approved and regulated by the HRECs of Stellenbosch and 
Witwatersrand Universities. 
 
Neurocognitive data  
At 2 and 5 years of age, the CHER participants at KIDCRU underwent a 
comprehensive Griffith’s neurodevelopmental assessment as part of a 
neurodevelopmental sub-study of CHER lead by Dr Barbara Laughton. The 
framework of the assessment included locomotor, language, eye-hand coordination, 
performance and practical reasoning. These data were made available for analysis 
alongside HIV proviral DNA estimates of the latent reservoir performed from samples 
taken at 96 and 248 weeks (approximately 2 and 5 years of age) to determine 
whether peripheral levels of proviral DNA from blood, might reflect levels in the CNS 
that may have had an impact on neurological development.  
 
Cytomegalovirus data  
Plasma from enrolment of CHER was used to assess CMV DNA-status and quantify 
CMV (copies/ml). Marvin Hsiao at the National Health Laboratory Service (NHLS) in 
Tygerberg, Cape Town performed these assays and the data were made available to 
explore the relationship between CMV and levels of HIV proviral DNA. 
 
Functional antibody responses to routine immunisations 
Sixty-six percent of children from CHER participated in CIPRA-4, a parallel study 
lead by Professor Shabir Madhi which examined the affect of HIV and ART on 
quantitative and qualitative antibody responses to pneumococcal (PCV7) and 
Haemophilus influenzae type B (Hib) conjugate vaccinations in infants [69]. In South 
Africa PCV7 is given at 6 and 14 weeks followed by 9 months of age, and Hib at 6, 
10 and 14 weeks followed by 18 months as part of the 5-in-1 vaccination alongside 
diphtheria, tetanus, pertussis and polio [70]. Antibody responses in the form of 
geometric mean concentrations (GMC) for the 7 serotypes of the PCV7 (4, 6b, 9v, 
14, 18c, 19f and 23f) and Hib were measured at 10, 14 and 18 weeks and again at 2 
years of age in CIPRA-4. Opsonophagocytic killing activity for serotypes 23f, 9v and 
19f and serum bactericidal assay were also measured. The relationship between 
these antibody responses after vaccination in infancy (n=30) and at 2 years (n=51) 
and naïve B-cell output estimates was explored within individual CHER participants. 
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2.3 Specimen preparation 
 
2.3.1 The Child Wellness Clinic specimens 
487 healthy infants and children were recruited from the CWC, from whom 471 blood 
specimens were obtained. The blood was used for immediate HIV-antibody analysis 
using Alere Determine® rapid tests, 500µl was sent for FBC analysis by the 
commercial laboratory BARC, 500µl was sent to NHLS in at Witwatersrand University 
Johannesburg for immunological profile by fresh whole blood assay (WBA), and the 
remaining blood (1-2ml) was cryopreserved at Stellenbosch University (SUN) 
Immunology laboratory for thymic output and immunological profile.  
 
Blood samples were taken between 9am and 1pm and stored in EDTA tubes at room 
temperature. If less than 3mls of blood was obtained, the tests were prioritised in the 
following order: (1) rapid HIV-antibody test, (2) thymic output, (3) FBC and (4) 
immune profile (section 2.4.2). There were a few weeks during the CWC when 
Witwatersrand laboratory was unable to receive samples, and it was not possible to 
obtain blood from 16 participants, therefore, of the 487 CWC attendees the following 
samples were obtained: 471 research samples, 425 FBCs and 381 immune profiles. 
 
Of the 471 research samples obtained, 1 child was excluded for severe malnutrition 
and 16 samples were not used for technical issues. These issues were: 4 freezer 
vials became stuck and broke in the freezer box, 3 samples were lysed from excess 
red cell lysis buffer, no Ki67 values were measured in 3 samples due to incorrect 
intracellular staining, and 5 PCR runs produced unusable TREC results (either no 
TRECs, no TRACs or high TREC/TRAC ratio resulting in negative thymic output due 
to mathematical constraints of the thymic output formula). Therefore 454 samples 
were used to explore thymic output in healthy South African children, and after 
excluding 19 HIV-exposed uninfected children, 435 samples were used to compare 
with measures of thymic output from HIV-infected children from the CHER trial.  
 
The data from the 425 FBCs and produced from the whole blood assay done on 381 
samples were used to establish haematological and immunological reference 
intervals for South African infants and children. The data were also compared to the 
same immunological parameters produced from the Cryopreserved-PBMCs (C-
PBMCs) in each child to identify differences in techniques and the impact of 
cryopreservation on the immunophenotypes examined.  
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2.3.2 The CHER trial specimens 
The routine blood tests that were performed at each clinical review during the trial 
were: haematology, biochemistry and immunology, and if consented, cryopreserved 
plasma and PBMCs for research purposes. A total of 5-10mls were taken at each 
review and participant refusal of consent for storage was <5%. For the first 24 weeks 
of the trial, the participants had 4 weekly clinical reviews, followed by 8 weekly 
reviews for 24 weeks, and 12 weekly thereafter. 
 
Up to 40 samples of cryopreserved PBMCs were randomly selected for each of the 
time-points required to fulfill the original objective of this fellowship: to examine the 
affect of HIV and ART on thymic output (see power calculation in section 2.5). At 
each time-point two-thirds of the samples were from PHRU and one-third from 
KIDCRU to accurately represent the proportion of patients from each centre. 
Samples were excluded if insufficient PBMCs were stored (i.e. <106 PBMCs), if they 
did not adhere to the treatment strategy of their randomisation arm, or if the stored 
specimen was acquired more than 6 weeks from the intended storage visit date. Due 
to these criteria and sample availability, in certain comparison groups less than 30 
samples were obtained. Exact numbers of specimens and their time-points are 
illustrated in Table 2.1 and 2.2.  
 
Table 2.1: Specimen numbers processed for thymic output and immunophenotypes at 
specific time-points of the CHER trial. 
CHER trial week 0 4 12 40 60 96 152 248 330-430 
ART-Def 46     39   11 
ART-40W 44  2  34 47 9 41 20 
ART-96W 48 30 28 33 36 45 19 36 13 
 
Table 2.2: PBMC specimens processed for HIV proviral DNA at specific time-points of 
the CHER trial. NB. There were some samples that were used for all three analyses: thymic 
output, immunophenotyping and proviral DNA. 
CHER trial week 40 96 156 204 248 252 
ART-Def 0 45 14 13 75 5 
ART-40W 0 0 0 0 56 0 
ART-96W 9 73 0 0 44 0 
 
Applications were made to both the HRECs of Stellenbosch and Witwatersrand 
Universities to waive consent for the use of the stored specimens to measure thymic 
output (Appendix VI: Ethics Approvals). This decision was made in view of minimal 
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risk of harm to the participants and as prior consent for storage and HIV-related 
immunological (non-genetic) research had already been given.  
 
The stored plasma from CHER were used for viral load analysis retrospectively since 
at the time of the trial viral load measurements were not standard of care. Funding 
has since become available however, during the analysis phase of this fellowship the 
dataset of viral loads was not fully complete especially during ART interruption. 
 
Although the CHER trial officially ended in June 2011, 75 CHER participants from 
KIDCRU were also enrolled in a neurological follow-up cohort (CHER PLUS). These 
include 20 from ART-Def, 31 from ART-40W and 24 from ART-96W. PBMCs were 
cryopreserved from yearly routine blood tests in this cohort and used to measure 
thymic output between 7 and 8 years of age (Weeks 330-430, Table 2.1), thereby 
capturing a longitudinal perspective of the affect of different ART-strategies used by 
CHER on thymic output (Appendices VII – VIII: Ethical Approval and patient 
information/consent forms).  
 
A small number of samples were used from HIV-infected children from a London 
clinic to establish and optimize the thymic output assays. Ethical approval through 
IRAS was not required for this purpose since there is existing ethical approval within 
the immunology department at ICH UCL that left-over blood from routine blood tests 
may be used for assay-optimisation. 
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2.4 Laboratory techniques 
 
2.4.1 PBMC isolation and cryopreservation   
All patient specimens of PBMCs that have been used in this study have been 
cryopreserved (CHER and CWC). PBMC specimens have been isolated and 
cryopreserved according to Clinical Laboratory Services protocol for CHER samples 
and according to ICH UCL protocol for CWC samples and CHER PLUS samples.  
 
PBMCs were isolated from fresh blood by Lymphoprep gradient separation and 
cryopreserved in 10% Dimethyl sulfoxide (DMSO) and 90% Fetal Calf Serum (FCS) 
at a ratio of between 7-15 x 106 cells/ml of freezing media for CWC specimens, and 
CHER specimens between 5-10 x 106 cells/ml. CWC and CHER PLUS samples were 
placed in a Thermo Scientific Nalgene freezing container (Mr Frosty®) for 24-48 
hours at -80°C, then at -80°C for 6 months, and transferred to liquid nitrogen 
thereafter (Appendix IX: PBMC isolation SOP). CHER specimens date from July 
2005 and have been kept in liquid nitrogen until used.  
 
Specimens were removed from liquid nitrogen or -80°C when required, thawed 
quickly in a water-bath at 37°C, removed from the cryovial and gently resuspended in 
60% FCS and 40% RPMI at 37°C. The cells were then washed twice in RMPI with 
2% FCS to remove traces of DMSO, counted and divided for flowcytometry 
(minimum 105 cells per panel), naïve CD4 T-cell isolation using magnetic columns 
and where enough cells were available, for quantification of kappa-deleting 
recombination excision circles (KRECs) from PBMCs (Appendices X-XI: SOPs for 
Thymic Output and for TREC/KREC quantification).  
 
2.4.2 Immunophenotyping of cryopreserved PBMCs 
Healthy infants and children had two panels for analysis (panels A and B below): 
• Panel A: viability marker, CD3, CD4, CD8, CD45RA, HLA-DR, Ki67  
• Panel B: viability marker, CD3, CD56, CD19, CD27, IgD, Ki67 
 
Of the 471 stored research samples, 461 children had Panel A and 444 children had 
Panel B (10 samples were unusable as described in section 2.3, and 17 samples had 
insufficient cells for both panel A and B). Surface staining was performed on thawed 
PBMCs using anti-human fluorochrome-conjugated antibodies and fixable viability 
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dye eflour®660 (Invitrogen, BioLegend or eBioscience) for 30 minutes at 4°C before 
fixation and permeabilsation with FOXP3 fixation/permeabilsation kit (eBioscience). 
Intracellular staining with Ki67 was subsequently performed for 30 minutes at 4°C.  
 
Antibody concentration was determined using titration experiments comparing the 
relative median fluorescence intensity i.e. the concentration that results in the highest 
signal of the positive population and lowest signal of the negative population [71]. 
Compensation was calculated by FACSDiva software, run weekly using PBMCs for 
the viability stain and compensation beads (BD CompBeads) for the fluorochromes.  
 
Cell analysis was performed on a FACSCanto flow cytometer using FACSDiva 
software (BD Franklin Lakes, NJ) and data were analysed using FlowJo software 
(Tree Star, Ashland, OR). Single-lymphocyte events were gated by forward scatter 
area versus height, then side versus forward scatter for size and granularity, followed 
by gating on live cells using the viability marker. Depending on number of cells 
available, 20,000 to 50,000 gated lymphocytes were analysed. The gating strategies 
for panels A and B are described in detail in Appendices XIV and XV, and gate 
positions were determined using the fluorescence-minus-one approach [72]. An 
example of the gating strategy for measurement of proliferating naïve CD4 T-cells is 
given in Figure 2.5. The immunophenotypes measured in both panels are listed in 
Table 2.3. 
 
Quality control measures applied to the gating strategies were as follows:  
• Lymphosum: sum of CD3, CD19 and CD56 should amount to 90-110% to ensure 
the lymphocyte population has been appropriately captured) [73]; 
• CD3 from both panels should be identical ±3% (recognised as potential variation 
between repeated samples [74]);  
• Weighted average calculations: subsets of CD4 and CD8 combined should equal 
the subset of the parent marker CD3 (±3%) i.e. CD3+HLA-DR+ cells should equal 
the sum of CD4+HLA-DR+ and CD8+HLA-DR+ per proportion of CD4/CD8; for 
example if CD4/CD8 ratio is 40:60 and CD4+HLA-DR+ T-cells are 5% and 
CD8+HLA-DR+ are 10%, CD3+HLA-DR+ T-cells will therefore comprise 8% of all 
CD3s ((0.4*5%)+(0.6*10%)=8%). 
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Preliminary work using fresh and frozen cells 
To explore the effect of cryopreservation on immunophenotypes of interest, 
flowcytometry was performed on 43 pairs of fresh and frozen PBMCs. PBMCs were 
isolated by Lymphoprep gradient separation and divided into cells for immediate 
flowcytometry staining and analysis, and cells to be cryopreserved (as per section 
2.4.1) for subsequent immunophenotyping. All samples were run on a BD 
FACSCalibur™, acquired using CellQuest™ Pro software and analysed using 
Flowjo™. The individuals comprised of 21 UK adults, 13 South African adults and 9 
HIV-infected children from the UK.  
 
  
Figure 2.5: Gating strategy example for proliferating naïve CD4 T-cells. 
 
Plot A gates on single-cells; plot B is a descendent of the single-cells, gating on lymphocytes by 
size and granularity; plot C gates on live lymphocytes not highlighted by the viability marker; 
plot D gates on CD4+ and CD45RA+ live lymphocytes; plot E gates on the proliferating naïve 
CD4 T-cells. 
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Table 2.3: Immunophenotypes measured by panels A and B from frozen PBMCs. 
 
Panel A 
Live % Live lymphocytes 
CD3+ T-cells 
CD3+CD45RA+ Naïve T-cells 
CD3+CD45RA+Ki67+ Proliferating naïve T-cells 
CD3+CD45RA- Memory T-cells 
CD3+CD45RA-Ki67+ Proliferating memory T-cells 
CD3+HLADR+ Activated T-cells 
CD3+Ki67+ Proliferating T-cells 
CD3+CD4+ T-helper cells (CD4) 
CD3+CD4+CD45RA+ Naïve CD4 T-cells 
CD3+CD4+CD45RA+Ki67+ Proliferating naïve CD4 T-cells 
CD3+CD4+CD45RA- Memory CD4 T-cells 
CD3+CD4+CD45RA-Ki67+ Proliferating memory CD4 T-cells 
CD3+CD4+HLADR+ Activated CD4 T-cells 
CD3+CD4+Ki67+ Proliferating CD4 T-cells 
CD3+CD8+ Cytotoxic T-cells (CD8) 
CD3+CD8+CD45RA+ Naïve CD8 T-cells 
CD3+CD8+CD45RA+Ki67+ Proliferating naïve CD8 T-cells 
CD3+CD8+CD45RA- Memory CD8 T-cells 
CD3+CD8+CD45RA-Ki67+ Proliferating memory CD8 T-cells 
CD3+CD8+HLADR+ Activated CD8 T-cells 
CD3+CD8+Ki67+ Proliferating CD8 T-cells 
 
Panel B 
Live % Live lymphocytes 
CD3+ T-cells 
CD19+ B-cells 
CD19+Ki67+ Proliferating B-cells 
CD19+IgD+CD27- Naïve unswitched B-cells 
CD19+IgD+CD27-Ki67+ Proliferating naïve B-cells 
CD3-CD56+ Natural killer cells 
CD3-CD56+Ki67+ Proliferating natural killer cells 
 
 
  
  50 
2.4.3 Whole blood assay for fresh blood immunophenotyping 
Immunophenotypic analysis by whole blood assay (WBA) on fresh blood was 
performed to establish immunological reference ranges in South African children. 
This was done in the NHLS flowcytometry laboratory at Charlotte Maxeke 
Johannesburg Academic Hospital by the team lead by Denise Lawrie.  
 
Blood samples were taken at the CWC between 9am and 1pm and 500µl were put 
into an EDTA tube, couriered at room temperature by air to Johannesburg and 
processed the following morning according to standard operating procedures. 
Directly labeled antibodies, including CD3 APC, CD3 FITC, CD16 PE, CD19 FITC, 
CD45 PerCP, CD45RO PE, CD45RA FITC, HLA-DR APC (Becton Dickinson 
Immunocytometry Systems (BDIS)), CD4 FITC, CD8 PE and CD56 PE (Beckman 
Coulter) were added in pre-titrated manufacturer optimised concentrations to tubes 
with 50µl of well-mixed whole blood. Stained samples were vortexed once and 
incubated for 30 minutes, after which the red blood cells were lysed using FACS 
Lysing Solution (BDIS). All samples were run on a Becton Dickinson FACSCalibur™, 
acquired and analysed using CellQuest™ Pro software.  
 
Prior to analysis, basic daily flow cytometer set-up included assessment of CalibriteTM 
3 and CalibriteTM APC beads (BDIS) to monitor laser, optics, fluidic alignment, 
linearity and instrument performance for the FACSCalibur™, according to the 
manufacturers’ standards. Listmode data was stored for retrospective analysis. 
External CD4 Quality Assessment for CD4 testing was performed through the UK 
National External Quality Assessment Service (NEQAS) Immune Monitoring scheme 
and the NHLS CD4 African Regional External Quality Assessment Scheme [75]. 
Lymphocyte subsets were expressed as a proportion of total lymphocytes, which was 
determined using bright CD45 expression and side scatter. Specific lymphoid 
subsets assessed included: CD3+, CD3+CD4+, CD3+CD8+, CD3-CD56+, 
CD16+56+, CD3+HLADR+, CD3+CD4+HLADR+, CD3+CD8+HLADR+, 
CD3+CD4+45RA+, CD3+CD4+45RO+, CD3+CD8+45RA+, CD3+CD8+45RO+ and 
CD19+ lymphocytes. Absolute cell counts were obtained using a dual platform 
method and total lymphocyte counts on all samples were obtained on a Beckman 
Coulter LH750 haematology analyser. All laboratory work and data analysis 
performed were blinded. 
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2.4.4 Thymic Output 
The mathematical formula used in this study to quantify thymic output combines 
measures of TRECs from purified naïve CD4 T-cells, absolute numbers of naïve CD4 
T-cells and Ki67 data to calculate the rate of peripheral naïve T-cell proliferation [11]. 
The formula devised by Bains et al used TRECs to determine the relative 
contribution of thymic export and post-thymic expansion and Ki67 expression to 
estimate the contribution of peripheral division. 
 
Naïve CD4 T-cells were identified by staining for CD4+CD45RA+ lymphocytes, and 
dividing naïve CD4 T-cells were determined using the proliferation marker Ki67 [76]. 
Ki67 is only expressed in proliferating cells in late stage GI then is subsequently 
rapidly degraded [76] therefore it can be used to represent the population of dividing 
cells. The dynamic formula for thymic export in terms of total naïve cell numbers, 
naïve cell TREC content and Ki67 expression is given as: 
 
 
Equation 1: 
 
Where y(t) is the fraction of naïve CD4 T-cells expressing Ki67, Δ is the duration of 
Ki67 expression, Τ (tau) is the TREC content of the peripheral naïve CD4 T-cell 
population, c is a constant representing the average TREC content of thymocytes 
entering the peripheral naïve population (0.6) [77], and N(t) is the total size of the 
naïve CD4 T-cell pool. The mean division of naïve CD4 T-cells is estimated to be 
12.4 hours (±0.97 hours), therefore Δ is made the constant value of 0.52 (i.e. 
12.4/24) [78]. N(t) is estimated by multiplying the number of naïve CD4 T-cells per 
microlitre of blood by the total body volume of blood  [0.97 x Log(body weight in 
kg)+4.93]  [79], then dividing this figure by 0.02 as blood lymphocytes account for 
approximately 2% of the body’s total lymphocyte population.
 
 
 
Equation 1 is a dynamic formula and relies upon more than one measurement in 
time. If thymic export is to be estimated at a single time-point the formula simplifies to 
Equation 2 as below: 
Equation 2:  
 
θ(t) = y × N × τ
Δ(c −τ )
Thymic Export (cells day-1) =        
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For example, a 3 year old child with a weight of 10kg will have a blood volume of 
800,000µl based on the formula [0.97 x Log(body weight in kg)+4.93]. A full blood 
count revealed a lymphocyte count of 2.8 x 109/L and flowcytometry on PBMCs 
showed 28.7% naïve CD4, therefore it is estimated that there are 795 naïve CD4 T-
cells per microlitre of blood and total of 3.2 x 1010 naïve CD4 T-cells in the body. This 
is calculated by blood volume multiplied by naïve Cd4 T-cells per microlitre of blood, 
then divided by 0.02 (since 2% of the body’s lymphocytes are in the blood). 
Flowcytometry reveals a proliferation proportion of 1.4% of naive CD4 T-cells which 
are positive for Ki67. DNA PCR performed on the purified naïve CD4 T-cells showed 
0.05 TRECs per naïve CD4 T-cell. This information put into equation 2 produces the 
explicit estimate of thymic output i.e. (0.014 x (3.2 x 1010) x 0.05) / (0.52 x (0.6 – 
0.05)) = 7.8 x 107 naïve CD4 T-cells exported from the thymus per day. 
 
This model of thymic output was produced by Bains et al using paediatric data from 
two independent studies: Hazenburg et al [80] from The Netherlands (n=25, age 
range 0.3-16 years) and Douek et al [81] from the USA (n=12, age range 0-20 
years). The model  [66, 67] is comparable to estimates of thymic output from size 
and cellularity of paediatric thymuses from birth to 20 years  [82-85] (Figure 2.6).   
 
Naïve CD4 T-cell isolation 
Purified naïve CD4 T-cells were obtained from the naïve T-cell isolation kit II (Miltenyi 
Biotec, Germany). Non-T helper cells and memory CD4 T-cells were indirectly 
magnetically labeled with a cocktail of biotin-conjugated monoclonal antibodies, as a 
primary labeling reagent, and anti-biotin microbeads, as a secondary labeling 
reagent. The cocktail included biotin-conjugated monoclonal antibodies against CD8, 
Figure 2.6: Mathematical modeling of thymic output by Bains et al [11]. 
 
A) Estimated rate of thymic export of CD4 T-cells (solid line=mean, dashed lines=2.5 and 
97.5% quantiles). B) Estimated thymic output (solid line) and volume of thymic epithelial 
space (dashed line). 
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CD14, CD15, CD16, CD19, CD25, CD34, CD36, CD45RO, CD56, CD123, TCRγ/δ, 
HLA-DR, and CD235a (Glycophorin A). Both incubation times were increased from 
the manufacturer’s instructions of 10 and 15 minutes to 30 minutes for both 
incubations to maximize purity. This was validated with a series of experiments and 
ensured that purity was consistently greater than 95%. The magnetically labeled cells 
were depleted as the solution was passed through MACS® LS columns in the 
magnetic field of a MACS separator, while the unlabeled naïve CD4 T-cells were 
eluted through the column and collected beneath. (Appendix X: Thymic Output SOP). 
 
DNA extraction of naïve CD4 T-cells 
DNA was extracted from purified naïve CD4 T-cells following isolation using the 
QIAGEN® QIAmp DNA extraction kit. After washing twice in PBS, cells were lysed 
with AL lysis buffer and digested with proteinkinase K at 56°C for 10 minutes. 
Ethanol was added and the sample was applied to a QIAmp mini spin column. The 
column was centrifuged at full speed, and filtrate reapplied to the column and spun 
again, washed twice with buffers AW1 and AW2 followed by buffer-free spin to 
remove buffer traces that might inhibit subsequent PCR. Extracted DNA was eluted 
from the mini spin column in AE buffer and stored at -20°C until PCR. Following the 
manufacturer’s instructions yield of DNA was approximately 60% for lymphocytes. 
 
TREC quantification  
T-cell receptor excision circles (TRECs) were measured from DNA extracted from 
naïve CD4 T-cells by a real-time quantitative PCR assay using primers and 
fluorogenic probes specifically designed for the detection of human TRECs. The 
technique uses standard PCR reaction methods [86] and separate primer pairs for 
the amplification of TRECs and a housekeeping gene, the T-cell receptor alpha-
constant gene (TRAC). The fluorogenic probe consists of an oligonucleotide labeled 
with a fluorescent reporter dye (either FAM or VIC) and a fluorescent quencher 
(TAMRA). By running standard control amounts of TRECs and TRACs in triplicate on 
the 96-well plate a standard curve was generated and used to establish the number 
of TRECs and TRACs in each sample. The standard curve was created in a 
logarithmic dilution series using known copies of plasmid containing signal joint 
TREC (donated by Dr Stuart Adams, Cameliar Botnar Laboratories, Great Ormond 
Street Hospital). To ensure the reliability of multiple PCR runs, the standard curve 
requires a slope of between -3.1 and -3.6, y-intercept 36 to 41, and R2 >0.97 to 
ensure accuracy of the results. Up to 20% of the standard curve may be omitted 
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however sample values measured above the highest point or below the lowest point 
of the standard curve cannot be reliable. The cycle threshold was consistently set at 
0.03 and the baseline set 3 cycles below the first amplification for analysis of all runs. 
There are two copies of the TRAC gene per cell, therefore it is possible to deduce 
the ratio of TRECs per cell ratio to use in the thymic output formula. 
 
TRECs were quantified by real-time PCR using the Applied Biosystems 7900HT Fast 
Real-Time PCR System (TaqMan, Life technologies). For each PCR reaction the 
assay includes 0.5µl of each primer at a concentration of 45µM, 0.5µl probes at a 
concentration of 10µM, 6µl nuclease free water and 12.5µl TaqMan Universal PCR 
Master Mix (Table 2.4 for primers and probes sequences). PCR conditions were 
50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 
60°C for 1 minute. Each standard and sample was run in triplicate with average 
TREC and TRAC values used for data analysis, a non-template control was used in 
every run and a run-control was used weekly. The run control used purified naïve 
CD4 T-cells from an adult, therefore tested the high-end of the standard curve for 
TRACs and low-end of the standard curve for TRECs (mean 0.005 TRECs per cell, 
SD 0.003). Samples were re-run when less than the 3 reactions amplified or if the 
values differed by greater than 2 standard deviations. (Appendix XI: TREC and 
KREC Quantification SOP). 
 
Table 2.4: Primers and probes sequences for the quantitative TREC PCR assay. 
Primer / Probe: Sequence: 
TREC forward 5í-CAC ATC CCT TTC AAC CAT GCT-3í 
TREC reverse 5í-TGC AGG TGC CTA TGC ATC A-3í 
TREC probe 5í-FAM-ACA CCT CTG GTT TTT GTA AAG GTG CCC ACT-TAMRA-3í 
TRAC forward 5í-TGG CCT AAC CCT GAT CCT CTT-3í 
TRAC reverse 5í-GGA TTT AGA GTC TCT CAG CTG GTA CAC-3í 
TRAC probe 5í-FAM-TCC CAC AGA TAT CCA GAA CCC TGA CCC-TAMRA-3í 
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2.4.5 Naïve B-cell output 
The thymic output formula has been adapted to estimate naïve B-cell output 
combining kappa-deleting recombination excision circles (KRECs) from DNA 
extracted from PBMCs, quantification and proliferation of naïve B-cells. Naïve B-cells 
are depicted by unswitched non-memory B-cells (CD19+IgD+CD27-) and therefore 
any proliferation captured by the intracellular marker Ki67 on this subset will reflect 
homeostatic proliferation and not antigen-induced proliferation. Equation 2 below is 
the same as the thymic output formula yet here represents output of naïve B-cells 
per day where y(t) is the fraction of naïve B-cells expressing Ki67, Τ (tau) is the 
KREC content of the peripheral naïve B-cell population, and N(t) is the total size of 
the naïve B-cell pool. N(t) is estimated by multiplying the number of naïve B-cells per 
microlitre of blood by the total volume of blood  [0.97 x Log(body weight in kg)+4.93]  
[79], then dividing this figure by 0.02 as blood lymphocytes account for approximately 
2% of the body’s total lymphocyte population. 
 
Equation 2:  
 
There are two assumptions the naïve B-cell output model makes based on limited 
published data available: average division of naïve B-cell (Δ = 0.52) per day [78] and 
average KREC content of naïve B-cells entering the peripheral circulation (c = 0.6)  
[77]. The replication history of the naïve mature B-cell subset in human peripheral 
blood has been reported to be an average of 2 cell divisions per day [87] although 
this is in adults. There are no published literature that describes mean KREC content 
of naïve B-cells entering the peripheral circulation, therefore the mean TREC content 
constant used in the thymic output formula (c = 0.6) has been adopted. 
 
In addition to using the modified thymic output formula to estimate naïve B-cell 
output, the following measures could also feasibly be used: KREC per PBMC ratio, 
KRECs per mililitre of blood; or using flowcytometry data as KRECs per million B-
cells (CD19+ lymphocytes) or per million naïve B-cells (CD19+IgD+CD27- 
lymphocytes).  
 
DNA was extracted from an aliquot of cryopreserved PBMCs using the QIAGEN® 
QIAmp DNA extraction kit as described in the previous section for the DNA extraction 
from purified naïve CD4 T-cells. KRECs were measured from DNA extracted from 
θ(t) = y × N × τ
Δ(c −τ )
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PBMCs by real-time PCR using custom-made primers and probes specifically 
designed for the detection of human KRECs and the housekeeping gene, TRAC 
(Table 2.5). The same methodology for the TREC-TRAC assay was used for the 
KREC-TRAC assay including the master mix concentrations, standard curve, 
equipment, PCR conditions and principles of analysis (Appendix XI).  
 
Table 2.5: Primers and probes for the quantitative KREC PCR assay. 
Primer/Probe: Sequence: 
KREC forward 5í-TCC CTT AGT GGC ATT ATT TGT ATC ACT-3í 
KREC reverse 5í-AGG AGC CAG CTC TTA CCC TAG AGT-3í 
KREC probe 5í-VIC-TCT GCA CGG GCA GCA GGT TGG-TAMRA-3í 
TRAC forward 5í-TGG CCT AAC CCT GAT CCT CTT-3í 
TRAC reverse 5í-GGA TTT AGA GTC TCT CAG CTG GTA CAC-3í 
TRAC probe 5í-FAM-TCC CAC AGA TAT CCA GAA CCC TGA CCC-TAMRA-3í 
 
In an attempt to put the significance of this novel measurement of naïve B-cell output 
in a clinical context, the relationships between naïve B-cell output estimates and 
vaccination responses to PCV7 and HiB were explored within individual CHER 
participants from the parallel study CIPRA-4 (Section 2.2).  
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2.4.6 HIV-antibody assays 
HIV antibody was measured on all available stored plasma samples at CHER trial 
week 84 (aged approximately 92 [IQR 90.6 – 93.4] weeks) from 2 of the 3 trial arms: 
ART-96W and ART-Def, thereby comparing early-limited ART with deferred ART 
started on clinical disease progression criteria (Centers for Disease Control and 
Prevention severe stage B/C disease) or CD4 <25%. Early ART was initiation of ART 
5.8-12 weeks of age (median age 7 weeks [IQR 7-8] for ART-96W) compared to 
deferring ART until beyond 12 weeks of age (median 23 weeks [IQR 18-32] for ART-
Def). At trial week 84, maternal antibody would no longer be detectable, all children 
in ART-96W were on ART and 89% of ART-Def had received at least 12 weeks ART. 
 
HIV antibody was measured using three methods from plasma stored at –80°C at 
trial week 84. All specimens were thawed, heat-inactivated at 56°C for 30 minutes 
and centrifuged at 2500 rpm for 5 minutes to remove cell debris. Supernatant was 
aspirated and aliquotted for 3 assays: 
(1) Automated serology: 4th generation microparticle enzyme immunoassay (EIA) HIV 
antigen/antibody combination (Abbott AXSYM system).  
(2) Rapid antibody test: HIV-1/2 qualitative immunochromographic rapid antibody test 
(Alere Determine®) assessed by an independent, blinded clinician. 
(3) Anti-gp120 ELISA: a sensitive in-house enzyme-linked immunosorbent assay  
(ELISA) to quantify anti-gp120 IgG and total IgG. 
 
Automated HIV serology  
Automated serology was performed at SUN NHLS laboratory using a 4th generation 
microparticle enzyme immunoassay HIV antigen/antibody combination (Abbott 
AXSYM system) using recombinant HIV antigens and HIV p24 monoclonal 
antibodies coated on microparticles to capture antibodies against HIV-1/2 and HIV 
p24 antigen respectively. Presence or absence of HIV-1/2 antibodies and/or p24 
antigen in the sample was determined by comparing the rate of fluorescence to a 
cutoff rate from the AxSYM HIV Ag/Ab Combo Index Calibrator [88]. “Weakly 
reactive” results were re-classified as seropositive for the purpose of binary analysis, 
however the difference between re-classification as seropositive or seronegative was 
demonstrated by logistic regression. 
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Rapid HIV-antibody tests 
Rapid HIV-antibody tests were performed by Alere Determine® HIV-1/2 [89], an in-
vitro, qualitative immunochromographic assay to detect antibodies to HIV-1/2 in 
human serum, plasma or whole blood. The results were read by an independent, 
blinded clinician with experience reading rapid HIV-antibody tests. 
 
Quantitative anti-gp120 antibody ELISA 
An in-house enzyme-linked immunosorbent assay (ELISA) established at the 
Johannesburg National Institute for Communicable Diseases was used to quantify 
anti-gp120 HIV-antibody [90, 91] (Appendix XII: Quantitative anti-gp120 antibody 
ELISA SOP). Two ELISAs were run in parallel, one measured anti-gp120 IgG (HIV-
specific antibody), and the second measured total IgG. Ninety-six well Maxisorp 
ELISA plates were coated overnight with either anti-human IgG coating buffer or 
gp120 coating buffer for the respective two ELISAs. The plates were washed with 
PBS and Tween20 solution, and then blocked with blocking agent (5% goat serum, 
5% milk, 0.05% Tween20 and PBS) for 1 hour before adding the standard dilution 
series and samples. Human IgG in goat serum or gp120 clade C monoclonal 
antibodies in dilution buffer, respectively, are diluted by a 3-fold series dilution for a 
16-point standard curve (100 to 7x10-6 ug/µl for IgG, 200 to 1.4x10-5 ug/µl for anti-
gp120). Aliquots of CHER plasma diluted 8-fold or more were added to the plate in 4-
fold dilution series over 8 wells per sample. Following an hour’s incubation, the plates 
were washed, incubated with goat anti-human total immunoglobulin-biotin (detection 
antibody) for a further hour; washed and incubated with anti-biotin-peroxidase 
antibody (capture antibody) for a final hour; thereafter washed and 
Tetramethylbenzidine (TMB) substrate added to each well. After 5 minutes, the 
reaction was stopped by sulfuric acid (1 molar) and the absorbance at 450nm read 
by a VersaMAX ELISA Plate Reader.  
 
Controls 
Each ELISA plate included one HIV seropositive and one seronegative control. 
Plasma from 18 HIV-uninfected unexposed, age-matched healthy South African 
children were used to determine the specificity of the anti-gp120 ELISA. All HIV-
uninfected controls were previously confirmed to be HIV negative by automated 
serology, corroborated by maternal health records. 
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2.4.7 HIV proviral DNA quantification 
HIV-1 proviral DNA, referred to as HIV proviral DNA throughout this text, was 
measured by quantitative PCR from DNA extracted from 334 samples of 
cryopreserved PBMCs collected at 12-weekly time-points from 40-252 weeks during 
the CHER trial (Table 2.2). The HIV proviral DNA PCR assay measures long terminal 
repeats (LTR) and does not differentiate between integrated and episomal LTR. 
Integrated DNA is commonly used to estimate the size of the latent reservoir; 
whereas episomal DNA reflects on-going replication [92] and is believed to contribute 
little to persistence since integration is required for production of HIV proteins and 
subsequent infectious virus [93]. To minimize inclusion of episomal DNA and avoid 
bias, samples were used from all virally suppressed children on ART for a minimum 
of 24 weeks with two consecutive viral loads below 400 copies/mm3 at least 3 
months apart [92]. Therefore any episomal DNA measured should be negligible [92]. 
Using these criteria, all available specimens from 40 (ART-96W), 96 (ART-Def and 
ART-96W) and 248 (all arms) weeks of the trial were included. Fifteen children from 
ART-Def who fulfilled these criteria at 3 or more time-points (96, 156, 204, 248 and 
252 weeks) were also included to describe patterns of proviral DNA decline on 
continuous ART.  
 
Cryopreserved PBMCs were thawed to room temperature and DNA extracted using 
the QIAGEN® QIAmp DNA extraction kit, as described for DNA extraction of naïve 
CD4 T-cells (section 2.4.4, Appendix X).  
 
Total HIV proviral DNA as copies of provirus were measured by real-time quantitative 
PCR assay using custom-made primers and fluorogenic probes (Table 2.6). The 
assay used standard PCR reaction methods [86], and separate primer pairs for the 
amplification of the region between LTR and gag, and pyruvate dehydrogenase 
(PDH) as the house-keeping gene. The standard curve was generated using a 6-
point logarithmic scale of 8E5 cell-line from 1 to 105 copies per reaction. 8E5 is a cell 
line produced by American Type Culture Collection (ATCC), ideal for this purpose 
since there is exactly one copy of HIV provirus per cell [94]. To ensure reliability on 
multiple PCR runs the criteria for the standard curve include a slope of -3.1 to -3.6, y-
intercept 36 to 41, and R2 >0.97. Sample values measured above the highest point 
or below the lowest point of the standard curve may be unreliable. Both samples and 
standards were run in triplicate, and repeated if any of the standard curve criteria 
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were not fulfilled or if amplification was not in triplicate. Any undetectable measures 
of LTR were repeated for confirmation. 
 
HIV proviral DNA was quantified by real-time PCR using the Applied Biosystems 
7900HT Fast Real-Time PCR System (TaqMan, Life technologies). For each 25µl 
PCR reaction the assay includes 12.5µl of QIAgen Multiplex PCR Master Mix, 0.25µl 
of each PDH primer at a concentration of 10µM, 0.25µl of LTR primers at a 
concentration of 20µM, and 0.25µl of each PDH and LTR probe at a concentration of 
10µM. To maximize the sensitivity of the assay 600ng of extracted DNA were added 
to each reaction well and the volume of extracted DNA made up to 11µl with 
nuclease free water. The maximum sensitivity of the assay was therefore 1 copy per 
105 PBMCs, with results reported per 106 PBMCs in line with current publications.  
 
PCR conditions were 95°C for 15 minutes, followed by 45 cycles of 94°C and 60°C 
for 1 minute each. A non-template control was used in every run, and each standard 
and sample were run in triplicate with average values used for data analysis. 
Samples were re-run when less than the 3 reactions amplified or values differed by 
greater than 2 standard deviations. There are 2 copies of PDH per cell, and although 
there are 2 LTR circles in each HIV gene only one is detected in this assay, hence 
the primer concentration is doubled for LTR. Therefore the explicit quantity of 
provirus per 105 PBMCs is the output value of LTR divided by PDH (Appendix XIII: 
HIV Proviral DNA quantification SOP).  
 
Table 2.6: Primers and probes used for quantitative HIV proviral DNA PCR assay. 
Primer / Probe Sequence: 
PDHTaq1 primer 5’ -TGA AAG TTA TAC AAA ATT GAG GTC ACT GTT -3’ 
PDHTaq2 primer 5’- TCC ACA GCC CTC GAC TAA CC -3’ 
PDHTaqPR probe JOE-CCC CCA GAT ACA CTT AAG GGA TCA ACT CTT 
AAT TGT TAMRA 
HIV1LTRTaq1 primer 5’- GCC TCA ATA AAG CTT GCC TTG A- 3’ 
HIV1LTRTaq2 primer 5’ -GGC GCC ACT GCT AGA GAT TTT- 3’ 
HIV1TaqPR probe FAM -TGT GAC TCT GGT AAC TAG AGA TCC CTC AGA C 
TAMRA 
 
Relationships were explored between HIV proviral DNA and clinical or immunological 
characteristics from the CHER trial, including 3-6 monthly viral loads, CMV DNA-
status and quantification at baseline, serostatus and quantitative HIV-specific 
antibodies at trial week 84, and where available, immunophenotypes such as naïve 
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and memory proportions of CD4 and CD8 T-cells, activation and proliferation 
subsets. 
 
Preliminary work on HIV-infected children in the UK 
Preliminary work using the HIV proviral DNA assay was performed on 30 HIV-
infected children and adolescents from a London clinic. To try to maximize the 
sensitivity of the assay, 22 samples were divided into aliquots of PBMCs, and 
PBMCs for MACs® isolation of memory CD4 T-cells. Four of these samples were 
further divided into memory CD4 T-cells and central memory CD4 T-cells. Memory 
CD4 T-cells were isolated by negative selection using magnetic bead separation, and 
central memory CD4 T-cells were further separated by positive selection using 
CD197 (CCR7)-PE and Anti-PE MicroBeads. DNA was subsequently extracted from 
these purified subsets and the aliquots of PBMCs.  
 
Two samples of DNA extracted from PBMCs had undetectable provirus, although 
provirus was detected in the purified memory CD4 T-cells confirming the increased 
sensitivity of this approach. However, due to the division required the quantity of 
DNA per PCR reaction well was suboptimal (i.e. less than 600ng), thereby 
compromising the overall sensitivity of the assay, therefore subsequent analysis of 
CHER samples was performed on DNA extracted from PBMCs only. Excluding 
children who were virally unsuppressed, no relationship was identified between 
levels of HIV proviral DNA and last CD4%, proportion of life on ART or years before 
starting ART (n=19, p-values all >0.05).  
 
Neurocognitive state and HIV proviral DNA 
CHER participants at KIDCRU underwent Griffith’s neurocognitive assessments at 
approximately 2 and 5 years of age including locomotor, personal/social, language, 
eye-hand coordination, and pattern reasoning performance tests. CNS 
macrophages, astrocytes and dendritic cells are recognised to harbour latent HIV, 
therefore the results of the Griffith’s assessment have been analysed with HIV 
proviral DNA quantification from 96 and 248 weeks of the trial (n=29 and 65) to 
explore whether peripheral measures of HIV proviral DNA might reflect HIV-
associated CNS disease and impact upon neurocognitive performance.  
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2.5 Statistical analysis  
 
Sample size  
At the time of designing this study there were no existing data on the variability of 
thymic output therefore estimation of sample size was inherently compromised. 
TREC data from a substudy of 33 HIV-infected children starting ART in the PENTA 5 
trial [95] was instead used to calculate the number of samples required to give 
sufficient power for the comparisons in this study. The power to detect a given 
difference in Log10(TRECs) between two groups at a 5% significance level, 
assuming standard deviation (SD) of 0.5 for Log10(TRECs) has been calculated for 
the following sample sizes (Table 2.7). A sample size of 40 was chosen for the 
comparisons of thymic output in this study. 
 
Table 2.7: TRECs variability, power and sample size calculation done with assistance 
from Professor Babiker and Trinh Duong at the MRC Clinical Trials Unit. 
Difference in log 
(TRECs) 
Number of children per group 
30 40 50 
0.3 0.61 0.73 0.82 
0.4 0.85 0.93 0.97 
0.5 0.96 0.99 0.998 
 
Statistics for immunological reference ranges, international 
comparisons and fresh-frozen analysis 
Exponential regression curves were produced with the assistance of Dr Martin 
Nieuwoudt. The cell counts or percentages of each lymphocyte subset were 
regressed against age for a continuous exponential curve using a three-parameter 
model: Y(t) = B0 + B1 * (1 – exp(B2 * t)). t is age in weeks and the Betas (B0,1,2 etc.) are 
the constants in the equation describing each lymphocyte subset. Best-fit (median) 
and 95% CI parameters were determined by minimizing the sum of the square of 
residuals using MS-Excel’s Solver function with the Generalized Reduction Gradient 
nonlinear solver engine and a constraint precision of 0.0001. To account for the non-
normal distribution of the residuals, upper and lower 95% confidence intervals (CIs) 
were fitted to the data independently. Comparisons were made between data from 
CWC and two international studies (Comans-Bitter et al from The Netherlands and 
Shearer et al from The USA) using the Chi-squared test, and for overall distributional 
differences between the median values of each cell group using the non-parametric 
Wilcoxon Rank Sum test. Subgroups of children with certain clinical characteristics 
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from the CWC were examined to determine whether their lymphocyte subsets 
differed from the rest of the CWC participants. This was achieved by comparing 
exponential regression fits and Wilcoxon Rank Sum tests for the subgroups with the 
remaining children from the cohort. For the reference intervals, median and 95% 
percentiles were calculated from both the haematological and immunological data 
sets stratified by age group. 
 
Comparison of fresh WBA and cryopreserved PBMC was done by: Welch’s t-test, 
visual comparison of fitted exponential curves, comparing the overall distribution of 
the groups using Wilcoxon Signed Rank tests, and by Bland Altman graphs with 
linear fits for each paired group. Mean percentage and direction of change from fresh to 
frozen was calculated by: 
 
Equation 3:  
 
The survival ratio was introduced to examine the direction and magnitude of change 
from the number of lymphocytes in a subset measured by fresh WBA to that 
quantified by the cryopreserved PBMC assay. This was calculated by the number of 
cells from a subset measured by fresh WBA subtracted from the number of cells from 
the same subset measured by cryopreserved PBMCs, then divided by the number of 
cells from the subset by fresh WBA i.e. survival ratio = (fresh WBA – frozen PBMCs) 
/ fresh WBA. Variables that might influence the integrity of thawed subsets were 
explored using Pearson’s rank correlation. Chi-squared tests were used to compare 
median and IQRs of the difference seen between WBA versus cryopreserved 
PBMCs in each cell subset.  
 
Thymic output analysis  
Clinical data from the CWC including gender, infant feeding practices, weight-for-age 
Z-score, vaccination status, recent illnesses, and relevant antenatal, neonatal and 
medical events were explored as factors that might influence thymic output. Thymic 
output in a log scale was compared between groups using the t-test and ANOVA in 
unadjusted analyses, and linear regression for adjusted analyses. ART-96W and 
HIV-uninfected children were compared at selected time points at equivalent ages. A 
non-linear curve was fitted to the data acquired from healthy controls, and individual 
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measures from all CHER samples were then directly compared to this curve. The 
non-linear curve was generated with assistance from Dr Joanna Lewis using b-
splines, minimising squared distance of the data from the line or by fitting a quantile 
regression which is robust to uncharacteristic distributions. The same formula was 
used to fit the distribution of CD4 counts from the healthy South African children of 
the CWC from which age-adjusted Z-scores were calculated, as the difference from 
expected CD4 count for age (X). The formula for a Z-score = (X - µ) / σ. 
 
Naïve B-cell output analysis  
As per the thymic output analysis, naïve B-cell output was explored using the clinical 
and immunological data from the CWC and CHER, and a non-linear curve was fitted 
to the data from healthy controls as per the b-splines approach described above. 
Naïve B-cell output has been compared between groups using t-test and ANOVA in 
unadjusted analyses.  
 
HIV-antibody analysis 
Welch’s t-test was used to compare the 3 HIV-antibody assay results between ART-
Def and ART-96W. The chi-square test was used to further compare the two arms. 
Spearman’s rank correlation to describe relationship between antibody quantity and 
cumulative viral load or age of ART initiation. Cumulative viral exposure at trial week 
84 was summarised by area under the time-versus-log(viral load) curve, from 
randomization to week 84. This measure was calculated in each child from the 
available viral loads using the trapezium rule [96]. Logistic regression was used to 
model the relationship between the probability of a positive automated serology 
result and the following variables: age at ART initiation, time on ART by trial week 84, 
CD4 count/percentage, cumulative viral load and clinical progression.  
 
HIV proviral DNA analysis  
Log-transformation was undertaken to provide normalized data where appropriate. 
Welch’s t-test was used to compare quantitative results between ART-Def and ART-
96W, and ANOVA to compare results between the 3 trial arms. Pearson’s correlation 
and regression analyses were used to measure the association between proviral 
DNA and weeks of ART adjusted for weeks of continuous HIV RNA suppression, 
CD4 count and quantitative HIV-specific antibody (anti-gp120 IgG). Duration of HIV 
RNA suppression was estimated by the sum of weeks between suppressed viral 
loads measured at 12-24 weekly intervals throughout the trial. Predictive factors were 
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assessed using a case-control design i.e. “cases” were children with <100 copies of 
provirus/106 PBMCs compared to “controls” who had >100 copies of provirus/106 
PBMCs; children with undetectable proviral DNA were then compared to those with 
any detectable proviral DNA. 
 
All analyses were performed using the software R version 2.15.1 [97]. 
 
 66 
 
 
 
 
 
 
 
Chapter 3 
 
Immunophenotypes in healthy South 
African children 
 
3.1 Background 
 
The importance of appreciating the evolving dynamics of the paediatric immune 
system is indisputable, particularly its relevance for understanding the pathogenesis 
and recovery of immunological disorders. A fundamental element of this 
understanding is the knowledge of what is “normal” in the healthy child within their 
natural environment. This chapter addresses the deficit of local, contextually 
appropriate immuno-haematological reference intervals for South African children by 
establishing these reference ranges from a population of healthy South African 
children seen at the Child Wellness Clinic. Potential differences in normal 
immunological profiles between children in low and high disease-burdened settings 
have been described. Finally, since a large majority of immunological research is 
performed on cryopreserved specimens, the effects of cryopreservation on normal 
immunological parameters have also been examined.  
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3.1.1 Local reference ranges 
A detailed knowledge of the normal range of haematological and immunological 
parameters in healthy infants and children from a the population in which they reside 
is not only essential for appropriate clinical practice, but is also vital for the 
interpretation of the immunological responses of HIV-infected children to different 
ART-strategies. It is not uncommon for healthcare providers within the laboratory and 
daily clinical care in resource-limited settings to use reference ranges adopted from 
studies that have acquired data from healthy children in resource-rich countries [99-
101]. However, it is plausible that the influence of both genetics and environment 
could influence haematological and immunological profiles that are considered to be 
normal in healthy children. Since treatment guidelines such as antiretroviral therapy 
(ART) initiation are based on immunological parameters, it is crucial that these 
reference ranges are appropriate to the population for whom they will be used. South 
Africa’s paediatric haematology and immunology reference ranges currently used in 
national clinical practice have been obtained from studies in children from the United 
States and Europe [99, 102, 103] and therefore may not be entirely applicable for 
South African infants and children considering the ethnic, genetic and environmental 
differences that exist [104].  
 
Differences in haematological cell populations between industrialised and resource-
poor countries have been reported in several studies [105-110] including non-genetic 
neutropenia in people of African origin [111], and lower platelet counts [112, 113] 
when compared to reference ranges from the US and Europe [99]. There are also a 
few published studies that have explored differences in lymphocyte parameters 
between resource-rich and resource-limited countries. In one study, lower CD4 and 
higher CD8 T-cell subsets [110], reduced naïve T-cell proportions and increased 
activated CD4 and CD8 T-cells were reported in Ethiopian compared to Dutch adults 
[114]. In another study, lower B-cell and higher NK-cells were demonstrated in 
Tanzanian, Ethiopian and Ugandan adults compared to German adults [115]. There 
is less data from African children. CD4 percentages have been reported to be lower 
in children from Cameroon [116], Kenyan [117] and Uganda [118] compared to 
reference ranges from resource-rich countries. This is supported by a Malawian 
study that showed 35% of healthy children under 1 year and 18% of children aged 1-
3 years had CD4 percentages below World Health Organisation (WHO) thresholds 
and 13% of children under 18 months old had a CD4:CD8 ratio of <1.0 [119]. 
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While local reference ranges in Africa are increasingly being established [105, 116, 
117, 120, 121], the range of immunological parameters is often limited and statistical 
comparison across populations have not been explored in detail. Although it is 
recognised that lymphocyte populations change with age, the rate of change has 
also not been explored between populations internationally. The data produced from 
healthy South African children who participated in the Child Wellness Clinic has been 
published [98] and will be used to establish comprehensive local haematological and 
immunological reference ranges for all South African children including activation 
markers, naïve and memory subsets. In addition, these data have been used to 
explore the immunophenotypes and dynamics of children from two distinct 
environments, South Africa and three industrialised countries, Germany [122], The 
Netherlands [123] and The USA [103].  
 
3.1.2 Research using cryopreserved peripheral blood 
mononuclear cells 
Clear information regarding the effect of cryopreservation and comparing different 
approaches to immunophenotyping is invaluable for the interpretation of phenotypic 
studies performed on cryopreserved PBMCs. This is especially important, as the use 
of cryopreserved cells is the most practical option for laboratory research, particularly 
so in large clinical trials as it minimises operator dependent inter-assay variability and 
optimises available resources. The difficulties and controversies of laboratory 
research using cryopreserved PBMCs are frequently cited in published literature 
[124-127], especially in functional studies and examining T-regulatory cells. There 
are less conflicting views regarding phenotypic research using cryopreserved 
PBMCs [128-130], however study numbers are small and usually in adults.  
 
The immunological data acquired from fresh whole blood analysis from blood 
samples from healthy South African children in this study have been compared with 
the same immunophenotypes measured from PBMCs cryopreserved from the same 
aliquot of blood. This analysis intends to determine whether preferential cell 
preservation or death occurs within lymphocyte subsets. The analysis aims to 
describe how common lymphocyte subsets change with cryopreservation and other 
differences in methodologies, whether some subsets change more than others, 
whether changes are constant or variable, and what factors may determine the 
integrity of thawed subsets i.e. proportion of live thawed cells, gender, age, recent 
illness and intercurrent infections such as HIV.  
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3.2 Results  
 
3.2.1 Child Wellness Clinic population characteristics 
The structure and organisation of the Child Wellness Clinic (CWC) is described in 
detail in Chapter 2, section 2.1. The distributions of maternal and infant age are 
illustrated in Figure 3.1, and the demographics and participant characteristics 
presented in Table 3.1. The child’s weight, length and head-circumference were 
measured and weight-for-age Z-score recorded from the child’s Road-to-Health card 
(hand-held medical records). These growth charts are derived from The National 
Centre for Health Statistics standards from US surveillance data [131]. The weight- 
for-age Z-score was approximately normally distributed around -1 to 0 of the 
reference population (Figure 3.2).   
 
Figure 3.1: CWC distribution of: A) Maternal age at child’s birth; B) Age of children. 
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Table 3.1: Characteristics of Child Wellness Clinic participants (n=471). 
 n (%) or median  [IQR] 
Decimal age at CWC 1.5   [0.5 – 3.4] 
Maternal age at child’s birth 25.6  [20.8 – 31.6] 
Ethnicity Black:  105 (22.3)  
Mixed ethnic ancestry:  356 (77.7)  
Gender Female:  243 (51.6)  
Male:  228 (48.4)  
Antenatal event  
(No. & percentage of all 
CWC recruits) 
 
 
46 (9.7) 
Maternal HIV-infection 19 (4) – of which 3/18 did not receive PMTCT; 
Syphilis 10 (2.1); TB 4 (0.8); Mental illness 3 (0.6); Alcohol/drug 
abuse 4 (0.8); Hepatitis B 2 (0.4); UTI 2 (0.4); Diabetes 1 (0.2); STD 
1 (0.2); Growth restriction 1 (0.2) 
Neonatal events  
(Events which required 
hospital admission or 
neonatal medication*) 
52 (11) 
Prematurity 28 (5.9); ART 16 (3.4); Suspected infection 5 (1.1); 
Jaundice 5 (1.1); LBW 3 (0.6); HIE 3 (0.6); Feeding difficulties 2 (0.4); 
Meningitis 1 (0.2); Pneumonia 1 (0.2); Eye infection 1 (0.2)  
Medical history 
(Past admission, chronic 
illness or poor growth*) 
55 (11.7) 
Pneumonia 14 (3.0); Gastroenteritis 10 (2.1); TB 10 (2.1); Faltering 
growth 7 (1.5); Seizures 4 (0.8); Asthma 2 (0.4); Croup 2 (0.4); PUO 
2 (0.4); Pyelonephritis 2 (0.4); Other 6 (1.3): Bacteraemia, Herpes 
simplex, Meningitis, PUJ obstruction, Reactive arthropathy, Trauma 
Recent illness  
(>1wk ago but within past 
month*) 
64 (13.6) 
LRTI 24 (5.1); Gastroenteritis 15 (3.2); URTI 13 (2.7); Skin infection 8 
(1.7); Otitis media 2 (0.4); PUO 2 (0.4); Measles 1 (0.2) 
No family/social support  8 (1.7) 
Reported alcoholism, drug 
abuse or violence at home 
11 (2.3) 
Feeding in first 6 months  Exclusive breast feeding:  287 (60.9) 
Formula feeding only:  58 (12.2) 
Mixed breast and formula:  126 (26.8) 
Growth status Growing well:  438 (93) 
Growing well but history of poor growth:  8 (1.7) 
Plateau growth:  24 (5.1) 
Severe faltering growth:  1 (0.2) 
Immunisation status Fully immunized (records confirm):  400 (84.9) 
Fully immunized (parental verbal report):  4 (0.8) 
Immunisation not up-to-date:  67 (14.3) 
*Some children had >1 event listed. NB. The one child with severe faltering growth was 
excluded from subsequent analysis. 
 
464/471 (98.5%) infants had a rapid HIV-antibody test performed and all were negative. 
The remaining 7 infants were less than 18 months, HIV-exposed and had a record of a 
negative HIV DNA PCR in their clinic notes; therefore the HIV-antibody test was not 
performed. 14/19 HIV-exposed children had a negative PCR documented in the clinic 
files, the remaining 5 children had no record of PCR results however, they were all over 
the age of 2 years and rapid HIV-antibody test performed were all negative.  
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3.2.2 Local population reference ranges 
Methods sections 2.4.1-3 describe specimen processing and immunology panels. 
The fresh whole blood assay that measured a detailed immune profile from 381 
CWC recruits done by the NHLS at Charlotte Maxeke Johannesburg Academic 
Hospital, and the full blood counts performed by a BARC Global Central Laboratory 
for clinical trials, have been used to create immunology and haematology reference 
ranges for paediatric clinical practice in South Africa since the ranges currently used 
are derived from US and European studies. These reference ranges have adopted 
the age categories of Shearer et al [103] i.e. 0-3 months, 3-6 months etc.  
 
Tables 3.2, 3.3 and 3.4 detail the reference ranges calculated from CWC data. 
Figure 3.3 demonstrates an alternative way to present this data using exponential 
regression graphs. The steep, exponential change of lymphocyte subsets with age, 
especially in infancy, is well-recognised and presentation of the healthy child data-set 
using exponential regression allows reference intervals to be read directly from the 
graph or be generated for the specific age of the child examined using appropriate 
laboratory software. Exponential fits were possible for all lymphocyte subsets 
examined in Panels A and B, as listed in Table 2.3. Absolute cell count curves for all 
lymphocyte subsets descended with age towards an asymptote, a straight line that 
continually approaches a given curve but does not meet it at any finite distance. 
Those for cell percentages either increased or decreased, but also tended to an 
asymptote. Further exponential graphs for these lymphocyte subsets are presented 
in section 3.2.3.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2: Reference intervals for components of the full blood count from the CWC 
(n=381). Values are reported as medians with 95% confidence intervals (CI) from each age 
group measured. 
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3.2.3 International comparison of lymphocyte subsets 
381 of the 471 children recruited from the CWC were included in this international 
comparison study and population characteristics were similar to those described in 
Table 3.1 for all 471 children who were seen and had phlebotomy performed.  
 
Three independent studies have been used to compare the lymphocyte subsets from 
the CWC population of healthy South African children with those from the US or 
Europe: Shearer et al (North America [103]), Comans-Bitter et al (The Netherlands 
[123]) and Huenecke et al (Germany [122]). Shearer et al and Comans-Bitter et al 
used age-categorisation albeit different choices of age groups i.e. 0-3 months or 0- 2 
months, whereas Huenecke et al presented their data using exponential regression 
curves. The CWC lymphocyte populations have therefore been compared according 
to the presentation of data in each publication. These US and European studies were 
selected for comparison as the first two are currently used for reference ranges in 
South Africa, and the latter enabled comparison of the populations using exponential 
regression techniques. All three studies used a whole-blood lysis assay to measure 
the lymphocyte subsets of interest. The immunological parameters available for 
comparison are listed in Table 3.5. 
 
Clinical conditions included as normal for this population 
Figure 3.4 illustrates the distribution of CD4 and CD8 (cells/µl) from the CWC recruits 
including subgroups of clinical conditions common in this population, that might be 
presumed to affect the child’s developing immune system and thereby influence the 
spread of data and reference ranges derived, although no evidence currently exists 
to confirm that this is the case. These conditions include a) past history of a serious 
childhood illness e.g. TB, meningitis (n=11); b) acute recent illness within the past 
month but more than a week ago e.g. upper respiratory tract infections, 
gastroenteritis (n=69); c) maternal conditions during pregnancy e.g. TB, HIV, syphilis 
(n=28); and d) prematurity <32 weeks (n=13). The exact exponential fit of the 
regression line for each lymphocyte subset examined (as per CWC column of Table 
3.5) did not alter when each of the four clinical subsets were in turn removed from 
the analysis therefore justifying the inclusion of these children 
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Table 3.5: Immunophenotypes compared between international studies. Corresponding 
immunophenotypes were compared between the South African cohort (CWC) and three 
published studies: Comans-Bitter et al [123], Shearer et al [103] and Huenecke et al [122]. 
Both cell count/µl and percentage was available for each subset.  
Subset CWC Comans-BItter 
et al 
Shearer et al Huenecke et al 
No. children 381 358 851 80 
Age range 2 wks – 13 yrs 1 wk – 16 yrs Birth – 18 yrs 2 mths – 18 yrs 
Country South Africa Netherlands USA Germany 
Total 
lymphocytes 
SSC/CD45 and 
FSC/SSC 
FSC/SSC FSC/SSC FSC/SSC 
T-lymphocytes CD3+ CD3+ CD3+ CD3+ 
T-helper  CD3+CD4+ CD3+CD4+ CD4+ CD3+CD4+ 
Cytotoxic  CD3+CD8+ CD3+CD8+ CD8+ CD3+CD8+ 
CD4/CD8 ratio CD3+CD4+ / 
CD3+CD8+ 
CD3+CD4+ / 
CD3+CD8+ 
NA CD3+CD4+ / 
CD3+CD8+ 
Naïve CD4+  CD4+CD45RA+ NA CD4+CD45RA+ CD3+CD4+CD45RA+ 
Memory CD4+  CD4+CD45RO+ NA CD4+CD45RO+ CD3+CD4+CD45RO+ 
Naïve/Memory 
ratio of CD4+ 
CD4+CD45RA+ / 
CD4+CD45RO+ 
NA NA CD3+CD4+CD45RA+ / 
CD3+ CD4+CD45RO+ 
Naïve CD8+  
T-cells 
CD8+CD45RA+ NA CD8+CD45RA+ CD3+CD8+ 
CD45RA+CD28+ 
Memory CD8+  CD8+CD45RO+ NA CD3+CD4-
CD45RO+ 
CD3+CD8+CD45RO+ 
Naïve/Memory 
ratio of CD8+  
T-cells  
CD8+CD45RA+ / 
CD8+CD45RO+ 
NA NA CD3+CD8+CD45RA+
CD28+ / 
CD3+CD8+CD45RO+ 
Activated T-cell CD3+HLADR+ CD3+HLADR+ NA NA 
Activated CD4+  CD3+CD4+HLADR+ NA CD4+HLADR+ CD3+CD4+HLADR+ 
Activated CD8+  CD3+CD8+HLADR+ NA CD8+HLADR+ CD3+CD8+HLADR+ 
CD19+ B-cells CD19+HLA-DR+ CD19+ CD19+ CD19+ 
Natural Killer 
(NK) cells 
1) CD3-
CD16+CD56+ 
2) CD3-CD56+ 
1) NA 
 
2) NA 
1) 
CD16+CD56+ 
2) NA 
1) NA 
 
2) CD3-CD56+ 
 
“Maternal conditions during pregnancy” was further divided to explore the effect of 
maternal HIV on the lymphocyte subsets (n=14). Differences were detected using the 
Wilcoxon rank sum test between these 14 children and the rest of the cohort with 
lower B-cells (CD19+HLADR+, p=0.001) and lower memory CD4 cells 
(CD3+CD4+CD45RO+, p<0.0001) in the HIV-unexposed children. However, 
removing them from the entire dataset did not affect the exponential regression 
curves at all, therefore the decision was made to include these children as part of this 
“healthy” population from the CWC (Figure 3.5). 
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Exponential regression curves between South African and German 
children 
A selection of 6 graphs with fitted regression curves of common lymphocyte 
phenotypes: absolute lymphocyte count, CD3, CD4 and CD8 T-cells, B-cells 
(CD19+) and NK-cells (CD3-CD56+CD16+) are illustrated in Figure 3.6. Best-fit, 95% 
and 5% exponential regression curves are fitted for the CWC cohort (black lines) and 
Huenecke’s data from healthy German children for comparison (red lines). 
Comparisons were made by assessing the difference between the central line of 
best-fit of the South African and German children by Wilcoxon Rank Sum. This was 
the most feasible analysis approach without access to the raw data of Huenecke’s 
study. Differences by were found in NK-cells, activation markers (Figure 3.7), and 
particularly within the naïve (CD45RA+) and memory (CD45RO+) subsets. A trend 
towards higher absolute counts of CD8 T-cells was seen at a younger age in South 
African children compared to German children, and higher B-cells in the older 
childhood years.  
 
Marked differences were seen for both CD4 and CD8 T-cell memory populations 
particularly within the first 3 years of life, as illustrated by the change in naïve-
memory ratios with age in Figure 3.8 (respectively p=0.07 and 0.01 overall). While 
Huenecke’s data suggests naïve-memory ratios do not reach a 1:1 status [122] until 
the third or fourth decade of life, it is apparent that this is occurring by 11 years of 
age within this South African cohort. 
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Figure 3.6: Comparison of regression lines for six common lymphocytic markers 
between South African and German children. 
 
X-axis is age in months; y-axis is absolute cell counts in microlitre of blood. Black circles 
represent individual data-points from the South African cohort. Black lines represent the 
exponential regression curves delineated the best-fit, 95% and 5% of the data from the South 
African cohort. Red lines indicate best-fit, 95% and 5% of Huenecke’s German data set [122]. 
From left to right, top to bottom: absolute lymphocyte count (cells/µl, p=0.6), T-cells (CD3+ 
cells/µl, p=0.8), T-helper cells (CD4+ cells/µl, p=1.0), cytotoxic T-cells (CD8+ cells/µl, p=0.2), 
B-cells (CD19+ cells/µl, p=0.3), and NK cells (CD56+ cells/µl, p=0.002). P-values represent 
the difference between the central line of best-fit of the South African and German children by 
Wilcoxon Rank Sum.  
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Figure 3.7: Activated subsets of CD4 and CD8 T-cells of South African children. 
 
a) Percentage of CD4+HLA-DR+ of all CD4+ lymphocytes; b) Percentage of CD8+HLA-DR+ 
of all CD8+ lymphocytes compared to German children (p=0.001). X-axis is age in months; y-
axis is absolute cell counts in microlitre of blood. Black circles represent individual data-
points from the South African cohort. Black lines represent the exponential regression curves 
delineated the best-fit, 95% and 5% of the data from the South African cohort. Red lines 
indicate best-fit, 95% and 5% of Huenecke at al [122]’s data set. The p-value represents the 
difference between South African and German children by Wilcoxon Rank Sum. 
CD4+HLADR+ T-cells were not available from Huenecke’s data set. 
 
Figure 3.8: Comparison of naïve/memory ratios of CD4 and CD8 T-cells between South 
African and German children. 
a) Ratio of naïve/memory CD4+ T-cells in cells/µl (left, p=0.07). b) Ratio of naïve/memory 
CD8+ T-cells in cells/µl (right, p=0.01). X-axis is age in months; y-axis is absolute cell counts 
in microlitre of blood. Black circles represent individual data-points from the South African 
cohort. Black lines represent the exponential regression curves delineated the best-fit, 95% 
and 5% of the data from the South African cohort. Red lines indicate best-fit, 95% and 5% of 
Huenecke at al [122]’s data set. P-values represent the difference between the central line of 
best-fit of the South African and German children by Wilcoxon Rank Sum.  
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Increased levels of activation of both CD4 and CD8 T-cells correlate positively with 
respective naïve/memory ratios. By simple linear regression there is a significant 
relationship between naïve/memory ratio and activation. For CD4 T-cells the 
parameters for linear regression are as follows: F(1,379)=9.2, p=0.003 with R2=0.02; 
and the parameters for CD8 T-cells are: F(1,378)=21.4, p<0.0001 with R2=0.05. For 
CD4 T-cells, predicted naïve/memory ratio is equal to 2.9-0.13(CD4+HLADR+ 
percentage of total CD4s), and for CD8 T-cells 5.0-0.13(CD8+HLADR+ percentage 
of total CD8s). This means that for every 1% increase in HLADR the naïve/memory 
ratio will decrease by 0.13 for CD4 T-cells and by 0.13 for CD8 T-cells (Figure 3.9). 
However, there appear to be children who do not fit this pattern, who have both low 
levels of activation and a naïve/memory ratio of less than one. 
 
Age-categorised data between South African and US or Dutch children 
The most significant finding when examining the distribution across all age groups 
(denoted by the overall p-value in Table 3.6) alongside the exponential regression 
curves were the increased proportions of CD4 and CD8 T-cells memory subsets 
across the entire age range of children from the CWC compared to their American 
and European counterparts. The CWC children also had lower CD4 and CD8 naïve 
subsets, particularly at less than 1 year of age. Both CD4 and CD8 T-cell naïve-
Figure 3.9: Relationship between naïve/memory ratios of CD4 or CD8 T-cells with levels 
of activated CD4 or CD8 T-cells. 
 
X-axis reflects naïve/memory ratios calculated using the absolute cell count of the CD4 or CD8 
T-cells naïve and memory subsets. Y-axis reflects percentage of activated CD4 or CD8 T-cells 
identified by the cell-surface activation marker HLA-DR. 381 samples were used from South 
African children from the CWC. 
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memory ratios appear to differ dramatically at less than a year of age, but not 
significantly so thereafter.  
 
Additional differences were identified between lymphocyte subset distributions within 
individual age-categories in South African children versus those from North America 
and Netherlands. Significant differences found in the CWC cohort included: lower B-
cells in children aged from 15 months to 13 years; higher percentage of CD8 T-cells 
in 10-16 year olds and higher activation of CD8 T-cells and T-cells overall in children 
below 15 months (Table 3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6: Differences in immunophenotype measurements within specific age groups 
between South African children and US (Shearer at al [103]) or Dutch children 
(Comans-Bitter et al [123]). A) Naïve-memory subsets. B) Activation markers and CD8 T-
cells. C) B-cells. Information is displayed in the reference ranges of each data set. Measured 
data from the Child Wellness Clinic (CWC) has been calculated to match the age groups of 
the comparison studies. Reference ranges from Shearer et al are medians with 10th-90th 
centiles, and for Comans-Bitter et al are medians with 5th-95th centiles. Age-group 
comparisons were performed using the Chi-squared test and those with significant 
differences are highlighted in red: * indicates significance p<0.05, **p<0.01, *** p<0.001. 
Note: Shearer et al included 807 healthy children up until 18 years, although explicit numbers 
per age group were not published, each category included approximately 90 children except 
3-6 months (81-89). The ‘overall p-value’ is the non-parametric Wilcoxon Rank Sum test for 
differences in the rank order of the median distributions between the South African study 
population and the comparison study in question i.e. Shearer et al or Comans-Bitter et al. 
  86 
 
  87 
 
  88 
3.2.4 Immunophenotyping from fresh and frozen cells 
 
Preliminary work using fresh and frozen cells 
The results in Table 3.7 indicate that no significant difference exists by t-test across 
all parameters explored comparing immunophenotypes between fresh and frozen 
PBMCs.  
 
Table 3.7: Pilot data comparing immunophenotypes from 43 pairs of fresh and frozen 
PBMCs. *95% confidence interval that the true difference in means is not equal to zero. 
Phenotype 
percentage  
Fresh PBMCs Frozen 
PBMCs 
t-test 
p-value 
95% 
confidence 
interval*  Median [IQR] 
CD3+% 
of all lymphocytes  
72.1 
[68.2 – 82.1] 
73.8 
[66.3 – 81.7] 
0.96 
 
-3.98 to 4.17 
CD4+% 
of all lymphocytes  
36 
[30.1 - 42] 
37 
[28 – 41.1] 
0.96 -4.63 to 4.88 
CD4+CD45RA-% 
of all lymphocytes  
17.8 
[14.1 – 20.7] 
17.2 
[10.4 – 19.5] 
0.89 -3.35 to 3.86 
CD4+CD45RA+% 
of all lymphocytes 
17.7 
[12.4 – 20.9] 
17.1 
[13.9 - 21] 
0.92 -3.50 to 3.15 
Ki67% 
of all CD3+ 
lymphocytes 
2.1 
[1.8 – 3.0] 
1.7 
[1.3 – 2.9] 
0.37 -0.53 to 1.41 
Ki67% 
of all CD4+ 
lymphocytes 
2.3 
[1.9 – 3.9] 
2.2 
[1.6 – 3.0] 
0.99 -1.62 to 1.61 
Ki67% of all CD4+ 
CD45RA- 
lymphocytes 
3.8 
[2.2 – 4.5] 
2.7 
[1.7 – 4.0] 
0.43 -1.50 to 2.10 
Ki67% of all CD4+ 
CD45RA+ 
lymphocytes 
1.6 
[1.0 – 4.1] 
1.7 
[1.0 – 3.8] 
0.67 -2.11 to 1.38 
 
There was no relationship between the percentage of live cells in the frozen aliquot 
and difference in lymphocyte subset measured compared to the expected value i.e. 
from the fresh PBMC aliquot. The percentage recovery of PBMCs and percentage of 
live cells has been recorded and presented in Table 3.8 for preliminary test-runs of 
32 specimens each from the CWC and CHER. Of the CHER specimens, one had 
insufficient PBMCs and another had 100% dead cells after thawing therefore were 
excluded from subsequent analysis.  
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Table 3.8: Recovery of viable PBMCs from cryopreserved specimens. Pilot study of 30 
specimens from CHER and 32 specimens from the CWC. Dead cells were identified by the 
viability marker efluor 660®, and live cells were therefore determined by flowcytometry by 
gated upon the unstained population of cells.  
 Median [IQR] 
% Cells recovered, 
counted manually 
% Dead,  
counted manually 
% Live,  
by flowcytometry 
CHER, n=30  60.6 [42 – 86.1] 18.15 [5.9 – 24.2] 70.8 [56.9 – 80.4] 
CWC, n=32 57.7 [26 – 85.2] 2.0 [0-6.5] 85.6 [75.2 – 88.8] 
 
Although there is a difference between the manual count of live cells and percentage 
live cells by flowcytometry, there was a good correlation between counted dead cells 
and cell-viability (Pearson’s correlation coefficient -0.62, p-value = 0.0001). The 
Clinical Laboratory Services cryopreservation protocol recommends 5-10 PBMCs x 
106/ml of freezing media, however of the 32 CHER specimens processed, 9 were 
below the recommended concentration (minimum 1.4 x106/ml) and 2 above 
(maximum 1.0 x108/ml). 3 of the 11 suboptimal freezing concentrations had less than 
60% viability, although in suboptimal low concentrations there was no correlation 
between freezing concentration and cell-viability in these 30 specimens (r = 0.03, p-
value = 0.88). 
 
Comparison of fresh whole blood assay with cryopreserved peripheral 
blood mononuclear cells (C-PBMCs) 
To examine the effect of cryopreservation and methodological differences on 
immunophenotyping, 273 pairs of immune profiles as per Table 3.9 from the CWC 
(median age 1.4 years (range 0.05–12.3)) were compared: fresh whole blood assay 
(WBA, Methods section 2.4.3) against C-PBMCs (Methods section 2.4.2).  In 
addition, 806 measures of CD4 from fresh WBA were available for comparison with 
CD4 measured from C-PBMCs from the same sample, from HIV-infected children 
from CHER on and off ART as per the trial ART-strategies [68].  
 
Table 3.10 describes the differences between the fresh and frozen measures for 
each immunophenotype examined within each age group as used for the local 
reference ranges. The percentage change in the median between fresh to frozen is 
represented, along with the direction of change and whether the difference is 
statistically significant across all age-categories using Wilcoxon signed rank test. In 
all age groups, the median percentage of live cells thawed was greater than 82%. 
Almost all immune parameters demonstrated a significant difference between the 
fresh and frozen measures with the exceptions of CD3+ lymphocytes and CD4+ 
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memory lymphocytes. Some parameters increased with the cryopreservation/thawing 
process (CD8+, CD19+, CD8+ memory and all activated lymphocyte subsets), 
whereas others decreased (CD3+, CD4+, naïve and memory CD4+, naïve CD8+ and 
CD56+ lymphocytes). 
 
Table 3.9: The immunophenotypes used to compare lymphocyte subsets between the 
fresh whole blood assay and cryopreserved PBMCs. 
Name of subset Whole-blood assay Cryopreserved PBMCs 
CD3+ T-cells CD3+ CD3+ 
CD4+ T-helper cells CD3+/CD4+ CD3+/CD4+ 
CD8+ Cytotoxic T-cells CD3+/CD8+ CD3+/CD8+ 
Naïve CD4+ T-cells CD4+/CD45RA+ CD4+/CD45RA+ 
Memory CD4+ T-cells CD4+/CD45RO+ CD4+/CD45RA- 
Naïve CD8+ T-cells CD8+/CD45RA+ CD8+/CD45RA+ 
Memory CD8+ T-cells CD8+/CD45RO+ CD8+/CD45RA- 
Activated CD3+ T-cells CD3+/HLA-DR+ CD3+/HLA-DR+ 
Activated CD4+ T-cells CD3+/CD4+/HLA-DR+ CD3+/CD4+/HLA-DR+ 
Activated CD8+ T-cells CD3+/CD8+/HLA-DR+ CD3+/CD8+/HLA-DR+ 
CD19+ B-cells CD19+/HLA-DR+ CD19+ 
Natural Killer cells CD3-/CD56+ CD3-/CD56+ 
 
The differences between fresh WBA and C-PBMCs within lymphocyte subsets 
across age groups appeared fairly constant with the percentage of live thawed cells, 
CD3+ and CD4+ lymphocytes, CD4+ naïve and CD56+ lymphocytes. CD4+ memory 
and CD8+ naïve lymphocytes had no particular pattern of differences across the age 
groups, with differences appearing to be quite erratic. Whereas in other lymphocyte 
subsets there appeared to be more of a pattern: the difference between fresh and 
frozen generally increased in all activated subsets (CD3+HLADR+, CD4+HLADR+ 
and CD8+HLADR+) with age; and in B-cells the difference between fresh and frozen 
was much larger in children over 2 years of age. These different patterns of change 
between fresh and frozen measurements of the same parameters are illustrated in 
Figure 3.10. 
 
 
 
 
Table 3.10: Comparison of immunophenotypes between fresh whole blood assay 
versus cryopreserved PBMCs. Results in absolute cell count x109/dL of blood (Median and 
95% confidence interval (CI)). *p-values represent the significance of the difference between 
fresh and frozen across all age-groups and were determined by Wilcoxon Signed Rank Test.  
ƗMean % and direction of change from fresh to frozen are reported. 
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Further factors that might influence the integrity of thawed subsets were explored 
including gender, recent illness and haematological components of blood. No 
relationship between gender and the difference between measures of WBA and C-
PBMCs within each subset were identified. Monocyte and lymphocyte percentage 
had a significant positive correlation with the difference between fresh and frozen in 
activated CD3 and CD4 subsets (p-values all <0.04) i.e. the higher the white blood 
cell percentage, the less the difference between WBA and C-PBMCs; however the 
spread of data was wide (R2 all <0.07) therefore the relationship is unlikely to be 
linear and directly related to white blood cell subset. In contrast granulocyte and 
eosinophil percentage had a negative correlation with activated CD3 and CD4 
Figure 3.10: Regression curves to illustrate the variability of the difference between 
fresh and frozen measures of common immunophenotypes from birth to 12 years old. 
 
X-axis is age in months, and y-axis is absolute cell count in cells per microlitre of blood. Red 
data-points reflect fresh values and black reflects frozen data. The regression curves, 
calculated by Dr Martin Nieuwoudt, were estimated separately for fresh and frozen data. 273 
pairs of data were examined and all children had both sets of fresh and frozen values. A) 
CD3+ lymphocytes (no significant difference between fresh and frozen). B) CD19+ 
lymphocytes (overall significantly different). C) CD8+HLADR+ lymphocytes (increasingly 
significant difference with ageing). D) Naïve CD8+ lymphocytes (decreasing significant 
difference with ageing). 
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subsets (p-values all <0.04) i.e. the higher the white blood cell percentage, the 
greater the difference between WBA and cryopreserved PBMCs, yet again R2 is low. 
All other lymphocyte subsets explored did not demonstrate an association with any of 
the haematological components available from routine full blood count. 
 
The CWC recorded whether the child participant had a recent illness, defined as 
between 1-4 weeks ago (n=44, 16%). Comparing differences in WBA and 
cryopreserved PBMC values between those who had a recent illness and those who 
did not, revealed the difference in WBA and cryopreserved PBMCs to be significantly 
less in naïve and memory CD8 T-cells (p=0.0001 and p<0.0001 respectively), and 
naïve CD4 (p=0.01) in those with recent illness.  
 
Effect of HIV/ART on differences in fresh and frozen immunophenotypes 
To explore the differences between immunophenotypes measured from a fresh WBA 
and cryopreserved PBMCs in HIV-infected children, 806 pairs of CD4 measurements 
were examined from participants of the CHER trial. The difference in CD4 cells 
between fresh and frozen was a median of 2.5% higher in frozen cells (IQR -1.7 to 
6.2%, range: -41.7 to 30.4%). This was not largely dissimilar to the differences seen 
in the CWC healthy child cohort, median 2.9% lower in frozen (IQR -8.9 to 1.3%, 
range: -34.3 to 19.8%). No significant relationship exists by logistic regression 
between the age at which the sample was taken and difference between fresh WBA 
and cryopreserved PBMCs for CHER (OR 1.0 [95% CI: 1.0-1.0] or for CWC (OR 1.1 
[95% CI: 0.6-1.8]. No relationship was seen between CHER trial arm and the 
difference between CD4 percentage by fresh WBA versus cryopreserved PBMCs. 
However if a child had reached a trial-defined endpoint (i.e. immunological, clinical, 
or virological failure of first-line ART or death) they were more likely to have a 
significant difference between fresh WBA and cryopreserved PBMCs (OR 7.1 [95% 
CI 1.7-29.1], p=0.007) than those who did not reach a trial endpoint. 
 
The role of percentage of live thawed PBMCs 
Whether the percentage of PBMCs that died during the cryopreservation-thaw 
processes might determine the integrity of thawed subsets was explored by 
examining the percentage of live thawed PBMCs with the differences between fresh 
and frozen lymphocyte subsets in healthy children, and also the CD4 measures 
available from the CHER trial. As described in Methods section 2.5, the difference 
between fresh and frozen was quantified as a survival ratio in cells/µl (i.e. [fresh WBA 
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– frozen PBMCs] / fresh WBA). However, in neither CWC nor CHER were any clear 
relationships evident between the live percentage and the survival ratio of each 
lymphocyte subset. This was true when examining all CHER data together and the 
arms separately. Although the data is widespread, in frozen specimens with less than 
50% live cells, there appears to be a greater “survival ratio” i.e. when there are >50% 
dead cells it appears more likely that the frozen cell count would over-estimate the 
true fresh cell count (Figure 3.11).  
 
This relationship was further investigated using two approaches: linear regression 
between percentage of live thawed PBMCs against the survival ratio, and Bland-
Altman plots comparing the mean of fresh and frozen against the survival ratio 
(illustrated in Figure 3.12). Both formats demonstrate a wide spread of data (R2 at 
best was 0.2 for CD4+ T-cells), making it difficult to determine any particular pattern 
other than making a general observation that for most lymphocyte subsets, a greater 
proportion of dead cells appears to decrease the accuracy of the results from the 
cryopreserved specimens. 
 
Use of fresh “anchor” values in research on cryopreserved PBMCs 
Finally, the utility of having a fresh whole blood measure as an “anchor” value for the 
rest of the immune profile obtained from C-PBMCs was explored i.e. if the fresh CD4 
value did not differ significantly from the frozen measure of CD4, would this indicate 
that other immunophenotypes measured from frozen would also not differ 
Figure 3.11: Relationship between the percentage of live thawed PBMCs and CD4 
survival ratio. 
 
A) All CHER data. B) All CWC data. The x-axes represent the percentage of live cells. The y-
axes of both graphs represent the survival ratio (“[fresh-frozen]/fresh” = cells/µl of WBA 
subtracted from cell/µl of cryopreserved PBMCs, then divided by cells/µl of WBA).  
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significantly? This was explored using CD3, CD4 and CD8 as the anchor marker in 
the CWC data set, however no relationship was identified between the comparability 
of the anchor marker and the comparability of the rest of the immunophenotypes 
examined. 
Figure 3.12: Relationship between percentage of live thawed cells and difference between 
fresh whole blood assay (WBA) and cryopreserved PBMCs illustrated by three lymphocyte 
subsets: naïve CD4 T-cells, activated CD8 T-cells and CD19 B-cells.  
 
The y-axes of all graphs represent the survival ratio (“fresh-frozen/fresh” = cells/µl of WBA 
subtracted from cell/µl of C-PBMCs divided by cells/µl of WBA). The x-axes of the 3 graphs to the 
left represent the percentage of live cells, and the 3 graphs to the right are Bland-Altman plots, 
therefore the x-axes of these graphs are the mean of the WBA and C-PBMCs.   
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3.3 Discussion 
 
3.3.1 Data from the Child Wellness Clinic 
A substantial number of specimens and supporting data were obtained from the 
Child Wellness Clinic. The distributions of maternal age and Z-scores for the child’s 
weight were approximately normally distributed indicating that this sample population 
may be a fair representation of the CWC population, although it was normally 
distributed around -1 to 0 Z-score for weight-for-age suggesting the CWC population 
was of a lower weight-for-age than the reference population. The proportions of 
antenatal events, neonatal events and medical history of note are not atypical for an 
informal settlement in South Africa according to clinicians with experience working in 
the region. Clinic attendance was voluntary and might have led to selection bias, 
however the participants’ parents appeared to come from a variety of backgrounds 
and had different motivations for participation. The majority of children were recruited 
opportunistically as they attended for routine paediatric care. Others learned about 
the clinic through word of mouth and desired a paediatrican’s “check-up” and more 
specifically, the blood test to “check everything was okay”. The HIV-test itself was 
also motivation for a few, as was the philanthropic belief that their child would take 
part in research that could potentially benefit other children, especially those infected 
with HIV. There was a proportion from poorer home-environments whose attendance 
was clearly driven to acquire the nutritional supplements and food voucher. Often in 
these cases, the mother and child were not accessing routine care, and it was an 
opportunity to engage the mother with the clinic’s services and get the children up-to-
date with vaccinations, vitamin drops and de-worming.  
 
There may have been selection bias introduced by the classification of the CWC 
participants’ ethnicity. In South Africa, the ethnicity referred to as “coloured” implies 
heterogeneous ancestry from Europe, South Asia or Indonesia with a native Khosian 
or Bantu tribes of Southern Africa, although it could also indicate any degree of 
admixture. The region of the Western Cape is known to have the highest levels of 
mixed ancestry in the world, however genetic contribution to the coloured population 
of this region has been found to come mostly from Khosian populations [132] and 
therefore the distinction between whether an individual is of pure Khosian descent 
(“black”) or distant mixed ancestral descent (“coloured”) may not always appear 
obvious. It is also worth noting the history of “imposed ethnicity” during the apartheid 
era [133], and reports that several Indian and indigenous African groups chose to be 
  99 
classified as “coloured” since there were certain advantages over being classified as 
“black” [134]. The South African assistant employed to help with recruitment, 
translation and the running of the CWC guided the distinction of ethnicity, 22% black 
and 78% coloured. Therefore without formal genetic differentiation, analysis of the 
haematological and immunological parameters or thymic output with regards to 
ethnicity is limited by the system of classification used in this study. While maternal 
age and socioeconomic status are comparable to the majority of the South African 
population for the purpose of the local reference ranges study, and to the CHER 
participant demographics for the thymic output comparisons, ethnicity does differ as 
79% of the South African population [135] and 96% of the CHER participants are 
classified as black, and this will be a limitation of any comparisons made with the 
CWC. 
 
3.3.2 International comparison of lymphocyte subsets 
As health provision improves and molecular diagnostics make diagnosis more cost 
effective and accessible in sub-Saharan Africa, the number of patients receiving 
treatment for HIV and other infectious diseases, as well as the number of clinical 
trials undertaken is expected to increase substantially. Although there are published 
studies detailing reference ranges for children in African countries [118, 120], 
particularly for children with HIV [117], the dearth of local paediatric reference range 
data in South Africa [136] prompted this substudy to establish a relevant local set 
laboratory reference values to ensure that health care, treatment and monitoring is 
appropriate for the population of children being assessed. These reference ranges 
have since been published by South African Medical Journal (Appendix XVI, [98]). 
The data generated should be representative of lymphocyte subsets in these children 
living in impoverished communities who are more likely to be exposed to a significant 
diseases, such as TB and HIV, than their counterparts in industrialised countries.  
 
The main finding of the international comparison substudy was the dramatic 
differences in the ratio of naïve to memory T-cell populations occurring in the South 
African children studied here. Parity between these populations of cells was reached 
some 20-30 years earlier than observed in European studies [103, 122, 123]. This 
has been noted before [137, 138]; and may be explained by a reduction in thymic 
output with depletion of the naïve T-cell pool and/or accompanied by expansion of 
memory cells as naïve T-cells encounter antigen and memory populations proliferate. 
Until now, characterisation of this transition throughout the first decade of life has not 
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been described, nor compared across continents where genetics, nutrition and 
environmental antigenic exposure differ extensively. 
 
Increased proportions of CD8 T-cells, natural killer cells and activated T-cells were 
demonstrated in healthy South African children compared to their US or European 
counterparts. Increased CD4 or CD8 activation was indeed associated with 
decreasing naïve/memory ratio. These findings contribute to the explanatory 
hypothesis that environmental exposure to common pathogens such as herpesvirus, 
cytomegalovirus and Epstein-Barr virus; alongside microbial translocation, may drive 
the switch from naïve to memory T-cells. The burden of poverty undoubtedly plays a 
role in the abundance of environmental pathogens [139], and combined with poor 
nutritional status is likely to affect rates of microbial translocation [140] and even 
immune responses to such pathogens [141, 142]. 
 
The burden of acquired immunodeficiency, such as paediatric HIV infection, lies in 
Sub-Saharan Africa, whereas the vast majority of primary immunodeficiencies and 
allergic conditions appear to occur in industrialised countries. This may simply be 
due to availability of advanced clinical care and diagnostics, however it might also be 
related to evolution of the paediatric immune system within an environment deficient 
in immunological stimulus. It is conceivable that such environmental pathogen-
stimulation and subsequent early naïve-to-memory transition is not only a typical 
process, but also prerequisite for the immune system to establish a repertoire of 
functional immune responses. Darwin’s evolutionary theory argues that all life comes 
from the same ancestral source, and that diversity and survival occur through a 
branching pattern of evolution by adaptation to our changing environment [143]. 
Whether the differences we have observed represent an environmental adjustment 
or an evolutionary change in the paediatric immune system cannot be answered by 
this data, yet it presents the intriguing question as to which paediatric immune 
system is more evolutionarily normal.  
 
Our data is consistent with several studies in African settings showing that early 
environmental exposure to infection can program human immune responses [144-
146] reinforcing the Hygiene Hypothesis which suggests that infections in early life 
may prevent development of pathological immune responses to allergens and 
autoallergens [147].  
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It is not possible to determine whether differences seen are related to environmental 
exposure or genetics. The European studies for comparison do not describe 
ethnicity, and although the US study reports the majority of their cohort to be of 
African-American race (58%), the genetics may be quite different from an African 
population. While our cohort broadly represents the general population of South 
Africa in terms of socio-economic background, it does not represent approximately 
25% of the South African population that are relatively wealthier with well-equipped 
and sanitised home and school environments [135], and thereby might have 
comparatively less disease exposure and presumably different “normal” 
immunological phenotypes compared to the participants of the CWC.  
 
The inclusion of the children with histories of significant illnesses, maternal infections 
during pregnancy, recent illnesses and prematurity less than 32 weeks gestational 
age in the CWC healthy cohort might be a source of debate. However, since the 
prevalence in the CWC cohort is not atypical compared to the study population and 
there is no clear biological evidence to implicate the effect of these conditions on the 
child’s developing immune system it may be acceptable to include these conditions. 
The sub-analyses performed on the 14 children who were born to HIV-infected 
mothers did not affect the overall regression curves in this study due to the small 
number and age distribution of the group. A larger study might be warranted to 
explore these potential differences in more detail, especially since only 3.7% of 
children in our cohort were HIV-exposed compared to recent estimates of 32% of 
infants born in the public sector in South Africa [40]. This low rate of HIV-exposure 
might be explained by the fact that the clinic was promoted as a “healthy child” clinic 
where a HIV test would be done on all children, and this may have deterred mothers 
who knew they were HIV-infected. 
 
There are numerous limitations to the outcomes of the comparison of lymphocyte 
subsets between South African children and the three studies in children from the US 
and Europe. These three cohorts come from contrasting environments to South 
Africa, and the data is generated from studies that used non-identical methodologies. 
There are multiple practical factors that might influence data derived from 
flowcytometric studies including sample transport, storage and preparation, choice of 
fluorochrome-conjugated antibodies and immunological markers to define subsets of 
interest. This makes direct comparison between such studies challenging. In an 
attempt to minimize the affect of these factors, exponential regression curves were 
used to compare the changes in immunological parameters across the age-range 
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examined, as this approach should help to reduce the influence of confounding 
factors. 
 
One of the limitations of this study is that the mathematical method applied to create 
exponential curves from these data does not account for the possibility that cell 
counts may increase and peak during the first year of life with subsequent decline, 
however ongoing work by my collaborators will further explore this issue.  
 
There is potential for multiple statistical comparisons, as those that were done and 
represented in Table 3.6, to lead to significant differences detected that might be due 
to chance rather than biological plausibility. These calculations were not adjusted for 
multiple comparisons, therefore a degree of caution should be applied in the 
interpretation of any significant finding that was not replicated by other analyses 
across the studies examined. A combination of statistical approaches have been 
applied to the analysis of these data-sets, however regardless of the statistical 
approach employed, the main findings of rapid and early transition of naïve T-helper 
and cytotoxic T-cells to their respective memory populations in the CWC, was 
concordant across all 3 of the compared international studies. This seems most likely 
due to the induction of activation markers by increased exposure to environmental 
pathogens as seen in the South African study population.  
 
There were two main aims of setting up the CWC. The first was to acquire research 
specimens to establish and explore what may be normal thymic output and enable 
comparison with thymic output measured from the CHER trial (Chapter 5). The 
second was to collect immunological data from healthy South African children to 
establish local reference ranges. These immunophenotypes measured have also 
been used for comparison with immunophenotypes from HIV-infected children on 
different ART-strategies (Chapter 4).  
 
In South Africa clinicians and laboratories currently use a combination of the 
reference ranges published by Comans-Bitter et al and Shearer et al where children 
from better socioeconomic backgrounds comprise the study groups. A number of 
important differences between the CWC and international studies were found, 
highlighting value of having contextually appropriate reference ranges available. 
Although no gross difference was identified with the lymphocyte markers most 
commonly used in clinical practice such as CD4, CD8 and CD4/CD8 ratios, a 
dramatic and significant difference was demonstrated in the rapid early decline of the 
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naïve-memory ratios of both CD4 and CD8 T-cells alongside increased lymphocyte 
activation in this paediatric population. While providing valuable insight into the 
developing paediatric immune system within an African context, the long-term health 
implications of these findings certainly require further investigation.  
 
3.3.3 Immunophenotyping from fresh and frozen cells 
This substudy aimed to outline the differences between immunophenotypes 
measured by fresh whole blood assay and cryopreserved PBMCs. A number of 
significant differences were observed, and where possible the causes were explored. 
While some differences may be directly related to the effect of cryopreservation, 
there are a number of methodological differences that need to be taken into account. 
 
The direct comparison of fresh and frozen PBMCs done, as preliminary work did not 
reveal any significant differences between the parameters investigated. However, in 
the much larger study of healthy children from the CWC, most immune parameters 
differed to some extent between whole blood assay and cryopreserved PBMCs, with 
the exceptions of total CD3 lymphocytes and CD4 memory lymphocytes. Although 
statistically significant, on examining the actual numerical differences many are 
unlikely to be of clinical importance. Exceptions include activated CD4 and CD8 
subsets, naïve CD4 and memory CD8 T-cells that demonstrate a much larger 
change from fresh to frozen. Although isotype controls and fluorescence-minus-one 
gating strategies were applied, inter-operator variation between the two scientists 
analysing the data at each site may play a role in explaining why such a difference 
might occur. Although CD4 and CD8 subsets are unlikely to be activated by the 
cryopreservation-thaw process, this phenomenon could possibly be explained by 
soluble HLA-DR that attaches during the cryopreservation-thaw process. For 
activated CD3 and CD4 T-cells, a higher percentage of circulating monocytes and 
lymphocytes appeared to be associated with less difference between the whole 
blood assay and cryopreserved PBMCs, in contrast to higher percentage of 
granulocytes and eosinophils associated with a greater difference. Since this 
relationship was not apparent with any of the other lymphocyte subsets examined, it 
is more likely to be an incidental finding than due to preferential loss of a leukocyte 
class.  
 
Unless appropriate control groups are used applying strict cryopreservation, storage 
and thawing protocols, caution should be applied in the interpretation of research 
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studies that investigate immune-reconstitution and functional responses to HIV using 
frozen PBMCs. These findings are reflective of a smaller study (n=40) which showed 
that cryopreservation induces a decrease in naïve CD4 T-cells and an increase in 
effector CD8 T-cells [129]. 
 
Exploration of the impact of recent illness on differences between fresh and frozen 
cells revealed less difference between the two assays. This might be explained by 
the longevity of the lymphocytes themselves, as younger lymphocytes, or those with 
less replicative history, may be less sensitive to the cryopreservation and thawing 
processes. Following an infection, new effector memory CD8 T-cells are likely to be 
in circulation and the high thymic output in healthy children may compensate for the 
loss of naïve T-cells as they differentiate into memory cells.  
 
The primary finding when examining the difference between the measures of CD4 T-
cells by the whole blood assay and cryopreserved PBMCs in both the CWC and 
CHER was that the healthy children had 2.9% less and the HIV-infected children had 
2.5% more CD4 in the cryopreserved specimens. This may be explained by the 
storage protocol used for the CWC specimens with initial storage at -80°C for 6 
months and thereafter transferred to liquid nitrogen, whereas all CHER PBMCs were 
stored in liquid nitrogen after gradual cooling in a Nalgene® freezing container over 
24 hours. There is good evidence that PBMC specimens can remain viable for up to 
12 years with correct cryopreservation and storage[148]. Although literature suggests 
up to 18 months at -80°C is acceptable for immunophenotyping purposes[149], 
temperature fluctuation [150] may have affected cell viability. In contrast, the modest 
increase in the cryopreserved CD4 of the CHER participants could possibly be due to 
preferential cell death from cryopreservation-thawing of a combination of cell groups 
(e.g. monocytes, natural killer cells and CD8 T-cells) since analysis performed on 
individual cell groups did not reveal a single cause. 
 
The other finding of the CHER whole blood assay versus cryopreserved PBMCs 
analysis was the increased odds of a difference, either an increase or decrease, 
between fresh whole blood assay and cryopreserved PBMCs if the child had reached 
a trial-defined endpoint. This might suggest clinical deterioration and/or poor 
virological control could cause immunological instability that could make CD4 T-cells 
more vulnerable during cell preparation or the cryopreservation-thaw process.  
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Due to the wide variability of the difference between the whole blood assay and 
cryopreserved PBMCs within subsets seen here and also reported elsewhere [128], 
it is difficult to interpret the significance of the live cell percentage. It is vital that a 
viability stain is used with cryopreserved PBMCs since dead cells can generate 
artifacts as a result of nonspecific antibody binding or uptake of fluorescent probes. 
Establishing a minimum value for the percentage of live cells required to preserve an 
accurate distribution of lymphocyte subsets is appealing. One study reports a cut-off 
of 75% live cells to be appropriate [151], however data presented here indicates that 
no cut-off reliably identifies an optimal viability quotient.  
 
This study compiles data from three separate analyses to piece together the effect of 
cryopreservation and differences in methodology on immunophenotypes of 
lymphocyte subsets (fresh versus frozen PBMCs, whole blood assay versus 
cryopreserved PBMCs in healthy children, and whole blood assay versus 
cryopreserved PBMCs in HIV-infected children). Although relatively small numbers, 
the fresh versus frozen PBMC analysis offers the most direct comparison and 
demonstrates the least differences. This suggests that differences in methodologies 
are likely to play a more important role. In the whole blood assay versus 
cryopreserved PBMCs in healthy children a number of factors may have influenced 
the results: overnight shipping by airfreight [152], processing 24 hours after 
venipuncture (may reduce PBMC yield [153]), different fluorochromes, 
flowcytometers and gating-strategies analysed by different individuals, even use of 
different buffers and media have been reported to influence results [154].  
 
With the exception of activated T-cells, the differences seen between the whole 
blood assay and cryopreserved PBMCs are unlikely to have significance in clinical 
practice, however statistical adjustment for these changes in large clinical and 
epidemiological studies may be a reasonable consideration [155]. No clear pattern 
for preferential cell death was identified, inferring that either the effect of 
cryopreservation is entirely non-specific or more complex than explored here. 
However, where possible PBMC cryopreservation and storage should probably avoid 
-80°C and use liquid nitrogen for optimal cell viability. The causes of the differences 
between the whole blood assay and cryopreserved PBMCs are largely likely to be 
methodological, therefore caution must be applied when comparing studies with 
different methodologies for immunophenotyping, and also when interpreting studies 
performed on frozen cells unless appropriate comparison groups are used.  
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Chapter 4 
 
Immunophenotypic responses to HIV and 
ART in children 
 
4.1 Background 
 
The deleterious effect of HIV on CD4 T-cells is a defining feature of HIV infection and 
the critical role of CD8 T-cells in the cellular immune response to HIV is widely 
recognized; however there is much that is not well understood about the immunology 
of HIV infection in paediatrics and the child’s immune recovery with ART. The use of 
immunological research is key to develop our understanding of the immune system 
and its role in combating infections such as HIV. 
 
Primarily we need to appreciate the range of immunological disturbances that exist 
with HIV infection in children, and whether these changes can be resolved with ART. 
As ART strategies evolve, it is imperative to describe the immunological response to 
ART-interruption in the short and long term, and whether these responses off ART 
are dependent on the age of the child and stage of the developing immune system.  
Understanding the range of immunophenotypic responses to HIV and ART might 
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help identify novel treatment modalities or mechanisms of therapeutic monitoring to 
improve the care of HIV-infected children and optimise their immunological health. 
 
Each measurement of thymic output from the Child Wellness Clinic (CWC) or CHER 
cohort was complemented by a profile of immunological phenotypes. These profiles 
have been used to describe some of the immunological responses to HIV and ART 
by comparing HIV-uninfected unexposed South African children with HIV-infected 
children from the CHER trial, and within HIV-infected children according to the CHER 
ART-strategies used. The large numbers of specimens and children examined from 
both the CWC and the CHER trial present a unique opportunity to further understand 
the immune dynamics of HIV infection and immune recovery with ART. It is also 
intended that these findings might help contextualize the outcomes of the thymic 
output analysis of Chapter Five. 
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4.2 Results 
 
4.2.1 Immunophenotypes of HIV-uninfected South African 
children compared with HIV-infected participants from CHER 
The immunophenotypes measured by Panels A and B (Table 2.3, section 2.4.2) in 
both the CWC and ART-96W from the CHER trial have been compared and 
presented in Table 4.1. Here the age groups are different to the previous chapter 
because sampling took place around specific CHER trial study visits (i.e. 1-2 months, 
2-4 months etc). Initial exploration of the data revealed the immunophenotypic 
measurements were not normally distributed but skewed towards the left, therefore a 
log-scaled t-test has been used to analyse these data. 
 
The majority of the significant differences are in the first two age groups: where ART 
had not been commenced and therefore virological control had not yet been attained 
(Figure 5.11, Chapter 5), and the immunological benefits of ART are not seen. 
Compared to the HIV-uninfected healthy controls, children from ART-96W aged 1-4 
months had significantly higher total, naïve, memory, overall proliferation and 
activation of cytotoxic T-cells; higher total, naive and proliferation of B-cells; higher 
total and proliferation of natural killer cells; and lower CD4/CD8 ratio. From 4 months 
to 2 years, the benefits of continuous ART are demonstrated by ART-96W since 
many of the lymphocyte subsets became similar to the HIV-uninfected controls.  
 
However when ART was interrupted at 2 years, immunophenotypic differences 
returned in the 2-4 year age group, despite 35% of the samples examined being on 
ART, with higher naïve CD4 T-cells and naïve CD4 T-cell proliferation; higher total, 
naïve, naïve-proliferation and activation of CD8 T-cells; and lower CD4/CD8 ratio 
than the HIV-uninfected controls. In the final age group (4-8 years) 49% of ART-96W 
had resumed ART and the overall group had higher total T-cells, higher naïve CD4 
T-cells, continued higher levels of total, naïve, overall proliferation and activation of 
CD8 T-cells; and continued lower CD4/CD8 ratio than the controls. Further analysis 
of the 2-4 year age group from ART-96W revealed no significant differences in each 
lymphocyte subset between those on or off ART (data not shown, all p-values >0.1), 
likely due to a plausible delay in achieving virological control after re-commencing 
ART. At 4-8 years a few significant differences were seen with children from ART-
96W off ART having higher proliferation of both naïve and memory CD8 T-cells, and 
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higher activated and memory CD8 T-cells, and lower proliferation of natural killer 
cells (data not shown, all p-values <0.05) than children from ART-96W on ART.  
However, when comparing children on ART from ART-96W aged 4-8 years (n=24, 
median 144 [IQR 132-244] weeks since recommencing ART) with healthy HIV-
uninfected children from the CWC at the same age (n=61), a number of significant 
differences are apparent: higher naïve CD4, naïve CD8*, CD8* and activated CD8 T-
cells, and lower CD4/CD8 ratio*, memory CD4*, proliferating naïve CD8, B-cells and 
naïve B-cells, and total CD3 T-cells (data not shown, all p-values <0.05, *indicates p-
value <0.0001). 
 
The main exception to the above-described pattern of immunological dynamics in 
response to ART is the significantly lower memory CD4 T-cells seen continuously in 
ART-96W from 1 month to 8 years of age regardless of ART-status.  
 
 
 
 
  
  110 
 
  111 
 
 
  112 
 
  113 
 
  114 
 
 
  115 
4.2.2 Impact of CHER ART-strategies on immunophenotypes 
A) Early versus deferred ART 
Comparison of early versus deferred ART is detailed in Table 4.2 comparing all 
available data from ART-Def (n=200 samples) and ART-96W (n=311 samples) from 
enrolment until 8 years. The data demonstrates a number of differences between 2 
to 8 months, but thereafter the parameters are quite comparable. The most 
significant changes are higher CD3, total, naïve CD4, naïve and memory CD8, and 
lower memory and memory-proliferation of CD8 and CD4/CD8 ratio in the 4-8 month 
age group. It is important to note that 79% of children aged 8-12 months in ART-Def 
had commenced ART, and 100% of children by 1-1.5 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2: Comparison of immunophenotypes of ART-Def and ART-96W. HIV-infected 
children who initiated ART at clinical/immunological progression then continued on ART 
(ART-Def, n=200 samples from 82 children) compared with children started on ART at 
enrolment of the CHER trial (median 7 weeks of age), ART-interrupted after 96 weeks (~2 
years of age) and restarted ART after median 70 weeks interruption (ART-96W, n=331 
samples from 107 children). No more than one sample per child was included in each age 
group. Lymphocyte subsets are represented in cells per microlitre of blood. 
Immunophenotypes were obtained from cryopreserved PBMCs in both cohorts. Welch’s t-test 
compares log-transformed values from each lymphocyte subset within each age group; 
*highlighted in red indicates p-value statistical significance <0.05. Within the available 
samples measured, the percentage of children on ART is represented in the header of the 
table. 
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B) ART-interruption after 40 or 96 weeks ART 
The effect of ART-interruption after 40 weeks of ART was shown by comparing 
immunophenotypes of ART-40W with ART-96W at 60 weeks which was when ART-
40W interrupted for a median of 20 [IQR: 18.5-20] weeks (since 26% had restarted 
ART by 60 weeks, n=27) and ART-96W would still be on ART (n=35)(Table 4.3). 
ART-40W at 60 weeks had significantly lower CD4/CD8 ratio with lower CD4, naïve 
and memory CD4. At 60 weeks ART-40W also had significantly higher memory CD8 
with higher CD8 memory proliferation and higher CD8 activation, and lower overall 
B-cells and naïve B-cells. 
 
At 96 weeks 29/47 (62%) children examined from ART-40W had recommenced 
ART. Many of the differences seen at 60 weeks had resolved with the exceptions of 
on-going significantly higher memory CD8 and activated CD8. The CD4/CD8 ratio 
also remained lower in ART-40W but to a less significant extent. Subsequently at 
152 and 248 trial weeks none of the immune parameters compared were significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3: Comparison of immunophenotypes of ART-40W and ART-96W. ART-40W 
(n=129 samples in 68 children) compared to ART-96W (n=134 samples in 70 children), 
compares the impact on immunophenotypic profiles of ART-interruption after 40 or 96 weeks 
of ART, at approximately one or two years of age respectively. In both groups ART was 
initiated at age 7.3 weeks (IQR: 6.4-9.0). Median duration of ART-interruption for ART-40W 
was 33 (26-45) and 70 (35-109) weeks in ART-96W. Lymphocyte subsets are represented in 
cells per mircolitre of blood. Immunophenotypes were obtained from cryopreserved PBMCs. 
Welch’s t-test compares log-transformed values from each lymphocyte subset within each 
age group; *highlighted in red indicates p-value statistical significance <0.05. Within the 
available samples measured, the percentage of children on ART is represented in the header 
of the table. NB. B-cell markers were not performed at week 152.  
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TABLE 4.3: 
 
Cell group (cells/µl) 
Median: 
[IQR]: 
 
% on ART in ART-40W: 
% on ART in ART-96W: 
Age ranges / CHER trial weeks 
 
Week 60 
1.3 yrs 
(n=27 vs 35) 
 
26% 
100% 
Week 96 
2 yrs 
(n=47 vs 44) 
 
62% 
100% 
Week 152 
3 yrs 
(n=9 vs 17) 
 
89% 
35% 
Week 248 
5 yrs 
(n=41 vs 36) 
 
66% 
50% 
CD3+ 
 
 
 
p-value 
ART-40W 3069 
[2492-4014] 
3058 
[2211-4160] 
2670 
[2323-3305] 
2152 
[1803-2783] 
ART-96W 
 
3849 
[2606-4770] 
0.21 
3081 
[2629-4000] 
0.65 
3141 
[2134-3625] 
0.77 
2350 
[1953-2723] 
0.56 
CD4+ 
 
 
 
p-value 
ART-40W 1206 
[1005-1780] 
1351 
[985-1798] 
1249 
[1017-1505] 
1018 
[683-1335] 
ART-96W 
 
 
1897 
[1207-2766] 
0.002* 
1808 
[1137-2129] 
0.06 
1190 
[870-1802] 
0.90 
1029 
[704-1307] 
0.85 
CD4+ 
CD45RA+ 
 
 
p-value 
ART-40W 977 
[746-1360] 
1005 
[705-1254] 
908 
[736-1092] 
647 
[424-914] 
ART-96W 
 
 
1463 
[859-2277] 
0.004* 
1256 
[804-1598] 
0.06 
842 
[625-1324] 
0.86 
663 
[432-887] 
0.99 
CD4+ 
CD45RA+ 
KI67+ 
 
p-value 
ART-40W 15 
[13-26] 
16 
[11-21] 
10 
[5-22] 
15 
[8-28] 
ART-96W 
 
 
22 
[15-34] 
0.05 
21 
[16-30] 
0.03 
11 
[8-19] 
0.65 
13 
[9-25] 
0.91 
CD4+ 
CD45RO+ 
 
 
p-value 
ART-40W 285 
[205-424] 
371 
[296-518] 
309 
[281-500] 
340 
[216-431] 
ART-96W 
 
 
440 
[282-582] 
0.002* 
400 
[351-530] 
0.17 
376 
[255-477] 
0.90 
325 
[248-378] 
0.79 
CD4+ 
CD45RO+ 
KI67+ 
 
p-value 
ART-40W 58 
[36-73] 
56 
[35-83] 
34 
[28-46] 
41 
[30-57] 
ART-96W 
 
 
56 
[47-83] 
0.18 
61 
[41-80] 
0.18 
40 
[33-57] 
0.75 
46 
[31-57] 
0.94 
CD8+ 
 
 
 
p-value 
ART-40W 1566 
[1154-2418] 
1555 
[1152-2292] 
1381 
[1080-1709] 
1297 
[927-1626] 
ART-96W 
 
 
1863 
[1041-2308] 
0.46 
1609 
[1098=1963] 
0.33 
1503 
[1099-1988] 
0.77 
1357 
[1071-1714] 
0.31 
CD8+ 
CD45RA+ 
 
 
p-value 
ART-40W 1046 
[742-1378] 
1021 
[745-1661] 
1006 
[795-1272] 
843 
[652-1249] 
ART-96W 
 
 
1234 
[825-1712] 
0.50 
1231 
[824-1479] 
0.90 
1056 
[668-1531] 
0.96 
868 
[702-1178] 
0.58 
CD8+ 
CD45RA+ 
KI67+ 
 
p-value 
ART-40W 69 
[46-97] 
65 
[38-114] 
40 
[27-62] 
54 
[36-72] 
ART-96W 
 
 
56 
[31-105] 
0.16 
59 
[36-85] 
0.48 
39 
[24-87] 
0.99 
53 
[36-85] 
0.62 
CD8+ 
CD45RO+ 
 
 
p-value 
ART-40W 449 
[294-903] 
380 
[287-685] 
372 
[309-438] 
324 
[253-424] 
ART-96W 
 
 
305 
[179-509] 
0.01* 
296 
[186-513] 
0.03* 
348 
[271-854] 
0.62 
399 
[286-560] 
0.10 
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TABLE 4.3: 
 
Cell group (cells/µl) 
Median: 
[IQR]: 
 
% on ART in ART-40W: 
% on ART in ART-96W 
Age ranges / CHER trial weeks 
 
Week 60 
1.3 yrs 
(n=27 vs 35) 
 
26% 
100% 
Week 96 
2 yrs 
(n=47 vs 44) 
 
62% 
100% 
Week 152 
3 yrs 
(n=9 vs 17) 
 
89% 
35% 
Week 248 
5 yrs 
(n=41 vs 36) 
 
66% 
50% 
CD8+ 
CD45RO+ 
KI67+ 
 
p-value  
ART-40W 195 
[79-251] 
69 
[38-138] 
56 
[23-86] 
50 
[28-81] 
ART-96W 
 
 
58 
[32-128] 
0.0001* 
52 
[37-98] 
0.31 
57 
[38-120] 
0.47 
73 
[32-99] 
0.12 
CD4+ 
HLADR+ 
 
 
p-value 
ART-40W 106 
[82-142] 
139 
[94-192] 
119 
[84-139] 
98 
[69-135] 
ART-96W 
 
 
130 
[107-160] 
0.12 
127 
[102-156] 
0.89 
114 
[82-140] 
0.76 
86 
[64-119] 
0.56 
CD8+ 
HLADR+ 
 
 
p-value  
ART-40W 1107 
[573-1853] 
885 
[517-1463] 
802 
[707-1044] 
710 
[461-967] 
ART-96W 
 
 
543 
[330-1231] 
0.005* 
594 
[405-817] 
0.002* 
972 
[545-1694] 
0.56 
721 
[586-1059] 
0.25 
CD19+ 
 
 
 
p-value 
ART-40W 903 
[562-1185] 
735 
[548-984] 
NA 
 
300 
[212-408] 
ART-96W 
 
 
1274 
[945-1833] 
0.003* 
838 
[539-1212] 
0.31 
NA 361 
[287-443] 
0.29 
CD19+ 
KI67+ 
 
 
p-value  
ART-40W 50 
[35-69] 
38 
[28-68] 
NA 21 
[16-30] 
ART-96W 
 
 
62 
[39-80] 
0.27 
41 
[33-59] 
0.90 
NA 25 
[17-32] 
0.47 
CD19+ 
IGD+ 
CD27- 
 
p-value 
ART-40W 658 
[430-1020] 
565 
[369-701] 
NA 195 
[128-276] 
ART-96W 
 
 
1046 
[775-1498] 
0.002* 
650 
[409-991] 
0.08 
NA 240 
[196-329] 
0.23 
CD19+ 
IGD+ 
CD27- 
KI67+ 
p-value  
ART-40W 28 
[20-43] 
21 
[13-34] 
NA 7 
[5-12] 
ART-96W 
 
 
40 
[27-58] 
0.17 
28 
[17-37] 
0.18 
NA 9 
[7-15] 
0.44 
CD56+ 
 
 
 
p-value 
ART-40W 258 
[172-329] 
207 
[148-357] 
NA 162 
[119-271] 
ART-96W 
 
 
270 
[192-379] 
0.07 
251 
[157-385] 
0.82 
NA 151 
[102-280] 
0.97 
CD56+ 
KI67+ 
 
 
p-value  
ART-40W 41 
[25-65] 
32 
[22-72] 
NA 24 
[16-39] 
ART-96W 
 
 
41 
[29-68] 
0.16 
35 
[26-54] 
0.87 
NA 24 
[15-38] 
0.85 
CD4/CD8 
Ratio 
 
 
p-value  
ART-40W 0.72 
[0.45-1.19] 
0.89 
[0.69-1.22] 
0.91 
[0.78-0.96] 
0.81 
[0.6-1.08] 
ART-96W 
 
1.29 
[0.97-1.82] 
0.0004* 
1.21 
[0.77-1.44] 
0.01* 
0.95 
[0.71-1.13] 
0.78 
0.69 
[0.5-0.92] 
0.25 
  123 
C) CHER Long-term perspective 
The immunophenotypic profiles of the 3 arms of CHER (ART-Def, ART-40W and 
ART-96W) were compared at 7-8 years of age and very few differences were 
revealed (data not shown). Naïve CD4 T-cells were highest (p=0.06) and naïve CD4 
proliferation was lowest (p=0.006) in ART-Def, those who had received the longest 
continuous ART. In contrast, total CD8 T-cells (p=0.01) and naïve CD8 proliferation 
(p=0.07) were highest in ART-96W who received the least time on ART overall. 
CD4/CD8 ratio was also lowest in ART-96W (p=0.07). Compared to ART-Def and 
ART-40W, ART-96W received the least ART overall due to its CHER ART-strategy: 
early ART for 96 weeks followed by ART interruption until clinical or immunological 
deterioration. This strategy appeared to allow a longer period off ART compared to 
ART-40W, and a shorter time on ART compared to ART-Def [68]. 
 
4.2.3 Immunophenotypic predictors of ART failure 
Whether immunophenotypes at CHER trial enrolment at <12 weeks of age, could be 
predictive of clinical, virological or immunological failure has been explored using a 
case-control analysis approach. Children from CHER who reached the trial-defined 
endpoint were defined as “cases” and included if stored specimens were available at 
both enrolment and up to a month prior to reaching the endpoint. “Controls” were 
children who did not met an endpoint at any stage throughout the trial, adhered to 
their randomization arm and had stored specimens available at enrolment and age-
matched to a “case” at the time of the “case’s” endpoint. The CHER trial endpoint 
was death or failure of first line ART, defined as CD4 <20%, HIV disease 
progression to CDC stage C or severe B, CD4% <20%, or regimen-limiting toxicity 
[68]. Cases and controls were matched by trial arm, gender, ethnicity and study site 
(PHRU or KIDCRU). 
 
The immune parameters available from enrolment were examined using only the 
early ART arms (ART-40W and ART-96W combined). The analysis revealed a large 
number of immunophenotypes that were significantly different between “cases” and 
“controls” at enrolment. In “cases” there were significantly lower CD4% (paired T-
test, p=0.009), lower CD4 count (p=0.03), higher CD8 count (p=0.007), lower 
CD4:CD8 ratio (p=0.001), lower CD56 count (p=0.004), higher memory CD8 count 
(p=0.02), higher activated CD8 count (p=0.0004), higher naïve CD8 proliferation 
count (p=0.02) and higher memory CD8 proliferation count (p=0.04; Figure 4.1).  
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Univariate logistic regression was used to model the relationship between each 
immunological parameter and the probability of reaching a trial-defined endpoint 
(clinical, virological or immunological failure, or death). Table 4.4 presents these data 
with “cut-off values” which suggest the level of an immune parameter to give 80% or 
95% probability of reaching a trial-defined endpoint in children who have 
commenced ART at <12 weeks.  
 
Immunological markers from around the time of reaching trial endpoints were also 
examined between “cases” (children reaching endpoints) and “controls” in the early 
ART arms and the following significant differences were identified in cases: lower 
CD4% (t-test, p=0.002), higher CD8% (p=0.003), higher CD8 count (p=0.03), higher 
Figure 4.1: Immunophenotypes that significantly differ in CHER case-control analysis. 
 
“Cases” are children who reached a trial-defined primary endpoint: death, failure of first line 
ART, progression to CDC stage C or severe B, CD4% <20%, or regimen-limiting toxicity. 
“Cases” (red) and “controls” (gray) are compared at CHER trial enrolment and time of trial-
defined endpoint in the early ART groups combined (ART-40W and ART-96W). Pairs of cases 
and controls at enrolment: ART-40W n=20, ART-96W n=17; and at trial-defined endpoint: 
ART-40W n=18, ART-96W n=12. Key: aCD8 = activated CD8 T-cells, mCD8 = memory CD8 
T-cells, mCD8 Ki67 = proliferating memory CD8 T-cells, nCD8 Ki67 = proliferating naïve CD8 
T-cells. All comparisons are by Welch’s t-test and p-values are all <0.05 in this figure.  
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activated CD8 count (p=0.03) and lower CD4:CD8 ratio (0.006) (Figure 4.1).  
 
Table 4.4: Immunophenotypes at enrolment that might be predictive of a trial-defined 
endpoint. Levels of lymphocyte subsets measured from ART-40W and ART-96W combined 
at trial enrolment (n=74) that have 80% or 95% probability of reaching a trial-defined endpoint 
(clinical, virological or immunological failure, or death). Counts are in cells/µl blood. 
 
Immune parameter 
Endpoint probability  
>80% >95% 
CD4% of all lymphocytes <28.5% <23.5% 
CD4 count <570 <495 
CD8 count >2800 >3300 
CD56 count <135 <110 
Activated CD8 count >1750 >2200 
Memory CD8 count >690 >860 
Memory CD8 proliferation count >335 >430 
CD4/CD8 ratio <0.72 <0.61 
 
Immunological markers before and after an episode of pneumonia in CHER 
participants were examined (“pneumonia-cases”) and compared with age- and arm-
matched children who did not have pneumonia (“pneumonia-controls”). “Pneumonia-
cases” had lower CD4% and total count, and CD4/CD8 ratios before and after 
pneumonia (paired T-test p=0.0004, 0.0009 and 0.02 respectively combining pre- 
and post- measures) compared to “pneumonia-controls” despite small numbers 
(n=14 pairs of “pneumonia-cases” and “pneumonia-controls”). Before “pneumonia-
cases” had lower naïve CD4, higher memory CD4 T-cells and higher activated CD4 
T-cells (non-significant trend T-test p=0.06, 0.06 and 0.07); and after “pneumonia-
cases” exhibited higher naïve CD4 proliferation, higher memory CD8 and lower 
naïve CD8 T-cells, and less CD3 T-cells overall (T-test p=0.003, 0.02, 0.02 and 0.09) 
than their respective controls. 
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4.3 Discussion 
 
Immunological responses to HIV and ART are described in detail in this chapter to 
further understand the immune dynamics of HIV infection. During the first 4 months 
of life HIV-infected children starting ART, compared to HIV-uninfected children, had 
a host of immune disturbances: lower CD4/CD8 ratio, higher CD8 subsets including 
activated CD8 T-cells, NK-cells, naïve B-cells and increased proliferation of all of the 
above mentioned immunophenotypes. Thereafter, rates of proliferation decline with 
time on ART and most lymphocyte subsets return to what is considered normal in 
healthy South African children, however on interrupting ART many of the 
immunological responses seen prior to ART-initiation reoccur. However, when ART 
is reinitiated the changes do not appear to normalise entirely and further analysis 
revealed numerous immunological disturbances for ART-96W on ART up to 8 years 
of age, despite prolonged duration of ART. On-going activation and cytotoxic activity 
despite clinical stability on ART may be caused by immune-activation, low-level viral 
replication and/or co-infection that is more common in an immunocompromised child.  
 
These findings are supported by the analysis comparing ART-Def versus ART-96W, 
and ART-40W versus ART-96W demonstrating that ART-Def off ART especially in 
the first 8 months of life, and ART-40W while interrupting ART had greater 
immunological disturbances (increased cytotoxic T-cells, proliferation, activation and 
decreased naïve T-cells, natural killer cells and CD4/CD8 ratio) than their 
counterparts on ART (ART-96W). Although these immunological disturbances exist 
while off ART, the differences tend to resolve when ART resumes, although as 
shown previously not to equal those of HIV-uninfected children. Due to the ART-
strategies of the CHER trial, it is not known whether early and continuous 
uninterrupted ART might preserve and maintain an immunophenotypic profile that 
may not differ from that of an HIV-uninfected child.  
 
While the effect of ART-interruption was captured in ART-40W demonstrating 
disturbed immune dynamics, the immediate effect of interrupting ART after 96 weeks 
on the immunophenotypic profile has not been captured by the sampling strategy 
used here. Therefore it is not possible to say whether the same immunological 
disturbance would occur after interrupting ART following 96 weeks of ART rather 
than just 40 weeks. Never the less, by 3 and 5 years of age no differences appear to 
exist, inferring any differences might only be short-lived and that interrupting ART 
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after 40 weeks is probably not inferior to 96 weeks in terms of long-term 
immunological dynamics in the immunophenotypic profile measured here. 
 
The finding of highly significant and constant low memory CD4 T-cells in ART-96W 
regardless of ART-status has been recognized elsewhere [30] but is difficult to 
explain. It could plausibly be due to increased trafficking of memory CD4 T-cells to 
lymphoid organs and/or potential low-level HIV RNA replication, infection and 
destruction of CD4 memory T-cells. Alternatively, it may not be a true finding due to 
the immunophenotyping strategy used since some memory CD4 T-cells express 
CD45RA but are negative for CD27, thereby underestimating the proportion of 
memory CD4 T-cells.  
 
While several differences have been identified, unless the differences follow a 
particular trend, caution should be applied when interpreting multiple statistical 
comparisons as 1:20 tests could result as being significant by chance. In addition, 
the statistical difference may not always make biological sense or have clinical 
relevance. Further limitations of these findings exist because the analyses were 
done on cryopreserved PBMCs and the cryopreservation-thawing processes might 
have influenced the differences detected, although the differences in 
immunophenotypes do appear to follow a plausible pattern of being deranged while 
off ART. 
 
Interestingly, the “endpoint-cases” and “pneumonia-cases” did not demonstrate 
concurrent responses. The immune profiles from the “endpoint-cases” prior to their 
trial-defined endpoint demonstrated increased activated, memory and total CD8 T-
cells alongside proliferation of both naïve and memory CD8 subsets, and decreased 
NK-cells and CD4/CD8 ratio. Decreased CD4/CD8 ratios and higher memory CD8 
were also seen in the “pneumonia-cases”, however in contrast to the “endpoint-
cases”, higher naïve CD4 proliferation and memory CD4 were shown. The 
responses are largely from CD8 T-cells in the “endpoint-cases” and likely reflect 
cytotoxic activity directed at virally infected cells, whereas the “pneumonia-cases” 
mostly reflect T-helper responses presumably from encountering new antigen from 
the intercurrent infection with increased proliferation of naïve CD4 to compensate for 
the switch from naïve to memory CD4, or perhaps clonal proliferation of a restricted 
T-cell receptor reservoir, which would increase susceptibility to intercurrent infection. 
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The endpoint case-control framework permitted the analysis of immune profiles at 
enrolment to determine which cell-surface markers measured at <12 weeks of age 
might be predictive of poor clinical outcome. This information could be valuable for 
clinical management by identifying children at risk and providing more individualised 
care for example frequent follow-up, prophylactic antibiotics or nutritional 
supplementation, however such a tool may not be feasible for children in Africa were 
access to diagnostics are limited. 
 
The consequences of these immunological disturbances, particularly an on-going 
proliferative state are not fully known although it is plausible that there may be loss of 
functionality, immune exhaustion and increased apoptosis further driving 
proliferation. This raises the question of whether suppression of HIV RNA should not 
be the sole goal of therapeutic management in HIV-infected children and whether 
clinicians should also be aiming to normalise the immunophenotypic profile to 
optimise the immunological health of HIV-infected children; such approaches might 
include anti-inflammatories and broadly neutralising antibodies. Long-term studies of 
clinical and detailed immunological outcomes alongside molecular measurements of 
telomere length providing inferences on T-cell replicative histories may be of value 
here to further examine and understand the consequences of the immunological 
disturbances that have been seen here.  
 
From a long-term perspective, despite the numerous potentially detrimental 
differences in immunophenotypes described in ART-96W compared to the CWC 
children, the findings of significantly higher naïve CD4 T-cells and total CD3 T-cells 
at 4-8 years in ART-96W is likely to reflect the long-term advantage of ART in 
augmenting thymic output beyond that of a HIV-uninfected child, as has been 
observed elsewhere [66]. While promising findings, these outcomes need to be 
consistent with improved clinical health for any real value to be placed upon them. 
This is generally true in CHER since ART-96W had less HIV-associated clinical 
events [68] however further longitudinal studies are required to establish this 
association in more detail. 
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Chapter 5 
 
Thymic output in paediatric HIV 
 
5.1 Background 
 
In this chapter the influence of HIV and antiretroviral therapy (ART) on thymic output 
in infants and children are examined. Thymic output is likely to have an important 
role in restoring the naïve CD4 T-cell pool following HIV-induced depletion, 
particularly so in early childhood years while a competent T-cell receptor repertoire is 
being established. However, there is currently limited understanding of the impact of 
HIV and effect of ART upon thymic output largely due to the difficulties involved in 
measuring thymic output. 
 
There are several limitations in previous methods for reliably measuring thymic 
output. It is difficult to quantify thymic output due to it’s inconvenient location in the 
anterior mediastinum, the variable rate of production of naïve T-cells [156], and lack 
of appropriate markers. In addition, numerous factors are presumed to influence 
thymic output and might affect long-term or day-to-day thymic activity. These include 
genetics, nutrition, hormones, vaccination, intercurrent infection and environmental 
exposure to microbes and allergens [157-160].  
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Attempts to quantify thymic output range from serial ultrasound scans, computed 
tomography (CT) and position emission tomography (PET) [161], to cell surface and 
intracellular markers detected by flowcytometry and molecular approaches; however 
all have their advantages and limitations [162]. Ultrasounds are cheaper and safer 
than CT and PET yet are dependent upon performance expertise and are no longer 
possible when the sternal bone has become calcified at approximately 2 years of 
age. Studies have used in vivo deuterium-labeled water (2H2O) to quantify the 
turnover rates of a range of immunophenotypic markers such as naive CD4 T-cells 
[163-165] since it is incorporated by new naïve T-cells that are produced in both the 
thymus and the periphery. Deuterium is safe at controlled doses but requires regular 
sampling so is impractical on a large scale and especially in paediatrics. 
 
Immunophenotyping of circulating naïve T-cells is compromised by variable rates of 
peripheral expansion and/or lifespan, and previously used markers such as CD31 or 
PTK7 can also be markers of activation [166] or apoptosis [167] respectively.  
Molecular measurement of T-cell receptor excision circles (TRECs) by DNA PCR has 
been used marker of recent thymic emigrants [168]. TRECs are episomal DNA circles 
that are by-products of the rearrangement of the variable (V), diversity (D) and joiner 
(J) genes of the TCR α and β chains [63] (Figure 5.1).  
 
 
In healthy children and adults TREC levels decline with age [169] and thymic size; 
however, since TRECs are stable and do not duplicate during mitosis, they are 
diluted upon cell division making absolute measurements of TRECs potentially 
Figure 5.1: Formation of T-cell receptor excision circles (TRECs), an episomal remnant 
of DNA that is spliced and excised during TCR gene rearrangement [63]. 
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misleading [84, 170, 171], especially in cases of increased peripheral proliferation as 
occurs in HIV-infection [81, 170, 172, 173]. These proliferative effects have been 
seen to directly correlate with total CD4 T-cell counts [174]. In one paediatric study, a 
decrease in TRECs has been observed over 96 weeks of ART in 33 children aged 
between 0.3 and 15.5 years [175], however this effect may be attributable to the 
reduction of peripheral T-cell death and cell-division secondary to ART-induced viral 
suppression. 
 
The issue of TREC dilution upon cell-division may be avoided using a mathematical 
formula established by Bains et al [11, 82]. The formula combines TREC 
quantification with total body naïve CD4 T-cells and naïve CD4 T-cell proliferation 
using the marker Ki67 [174] (described in detail in Chapter 2, section 2.4.4) to create 
an explicit measure of thymic output expressed as the number of naïve CD4 T-cells 
exported from the thymus to the periphery per day. 
 
This method was used in a recent study of 60 HIV-infected children and adolescents 
which suggested that age-adjusted thymic output is reduced in untreated HIV-
infected children but significantly increases with proportion of life on ART [66]. 
“Proportion of life on ART” was used rather than “time on ART”, since children were 
of different ages at the time of measuring thymic output and ART was started at 
different ages too. Although limited by heterogeneity of age and ART history, this 
study importantly suggested that after starting ART, the thymus is able to at least 
partly compensate for the loss of naïve CD4 T-cells by increasing thymic output.  
 
Therefore in this chapter, thymic output was estimated by combining the 
measurement of TRECs from purified naïve CD4 T-cells with quantities of naïve CD4 
T-cells and rates of proliferation in the mathematical model established by Bains et 
al. Samples from healthy HIV-uninfected children at the Child Wellness Clinic (CWC) 
in South Africa were used to characterize and explore normal thymic output. 
Alongside CWC estimates of thymic output, a large number of stored PBMCs from 
HIV-infected children from the Children with HIV Early Antiretroviral Therapy (CHER) 
Trial were selected to measure thymic output enabling a comparison between 
children on ART with HIV-uninfected children. The estimates from the CHER trial 
also enable comparison of thymic output between the different CHER ART 
strategies, and the association between thymic output and clinical outcome.  
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5.2 Results 
 
Thymic output preliminary work 
Figure 5.2 illustrates declining thymic output across the age-range from 3 – 66 years 
for 43 individuals who participated in the preliminary work establishing this assay. 
These included 34 HIV-uninfected healthy adults (21 UK, 13 South African) and 9 
HIV-infected children and adolescents from a London clinic. The South African 
measures of thymic output appear higher, however the PCR assay was performed 
on a different Taqman machine which uses an ultraviolet laser rather than an infrared 
laser therefore these results cannot reliably be compared. 
 
 
5.2.1 Thymic output in healthy HIV-uninfected children 
454 samples were used to explore thymic output in healthy HIV-uninfected children 
from the Child Wellness Clinic (CWC), aged 2 weeks to 13 years. Each child 
contributed one measure of thymic output each to generate the normal range of 
thymic output in healthy South African children. The CWC structure and organization 
is described in detail in section 2.1 with the demographics and clinical characteristics 
of these children are described in section 3.2.1. All children with antenatal, neonatal 
and past medical histories	  (Table 3.1) were included in the “healthy” South African 
cohort with exception of maternal HIV-exposure (n=19). These subgroups have been 
Figure 5.2: Thymic output in Log10(cells/day) across age.  
 
43 samples aged from 3-67 years (UK data: black circles, South African data: red circles). The 
regression curve is plotted through UK data only.  
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included since these are frequent conditions in this population and the children 
fulfilled the clinic recruitment criteria (currently well, no chronic medical condition, 
registered at the clinic, attended with biological mother and hand-held medical 
records). However each subgroup has been independently explored. 
 
The elements of the thymic output model, described in section 2.4.4, are: total 
number of naïve CD4 T-cells per child, proliferation rates of naïve CD4 T-cells 
determined by Ki67 labeling and TRECs per naïve CD4 T-cell, and these are 
represented in Figure 5.3. These data combined in the mathematical model in Figure 
5.4 demonstrate an increasing thymic output during the first 6 months of life with a 
characteristic peak between 6-12 months, followed by a decline until approximately 2 
years and subsequent plateau throughout the remaining childhood years. However, 
in the first 2 years of life there is up to a 5-log variation in absolute thymic output 
measures (median 1x108 [IQR 4.3x107 to 2.7x108] naïve CD4 T-cells per day. The 
distribution across age is illustrated in Figure 5.4, and Table 5.1 presents the data as 
reference ranges using the age-categories as used for the normal immunological 
parameters study and ranges derived from both the raw data and the exponential 
curve.  
 
 
 
Figure 5.3: Elements of the thymic output model. 
 
Plot A: Naïve CD4 T-cells, defined as CD3+CD4+CD45RA+ lymphocytes, in cells per 
microlitre of blood. Plot B: Proportion of Ki67+ naïve CD4 T-cells. Plot C: TRECs per naïve 
CD4 T-cell (maximum y-axis limited from 0.5 to 0.25 omitting 3 data-points to allow better 
visualization of the data). 
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Figure 5.4: Distribution of thymic output across age in healthy South African children 
from the CWC (Linear and Logarithmic scales).  
 
 
The distribution is presented using non-linear regression to delineate the best fit of the data 
(n=435). Solid red line indicates median, surrounding dashed lines are 25th and 75th centiles. 
The non-linear regression curve was done with support from Dr Joanna Lewis (Methods 
section 2.5). 
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Table 5.1: Reference ranges for thymic output in healthy South African children from 
the CWC (n=435). The central value is derived from the non-linear regression curve, as 
illustrated in Figure 5.4. 
Age-
group  
n Log10 median 
[IQR] 
Log10 mean  
(SD) 
Log10 central  
value [95% CI] 
0 – 3 
months 
63 7.9 
[7.4 – 8.2] 
7.8 
(0.60) 
7.9  
[7.6 – 8.1] 
3 – 6 
months 
52 8.1 
[7.5 – 8.4] 
8.0 
(0.65) 
8.0 
[7.8 – 8.3] 
6 -12 
months 
65 8.2 
[7.5 – 8.5] 
8.0 
(0.75) 
8.0 
[7.8 – 8.3] 
1 -2 
years 
87 8.0 
[7.7 – 8.4] 
8.0 
(0.58) 
8.0 
[7.8 – 8.1] 
2 – 6 
years 
119 8.0 
[7.8 – 8.5] 
8.1 
(0.65) 
8.1 
[7.9 – 8.2] 
6-13 
years 
49 8.1 
[7.6 – 8.4] 
8.0 
(0.57) 
8.1 
[7.8 – 8.3] 
 
 
Demographic and clinical factors that might influence thymic output  
The relationship between thymic output and numerous demographic and clinical 
characteristics recorded from the CWC were explored by comparing the regression 
curves from the subgroups of interest with superimposed regression curves of the 
children from the remaining population. A difference was determined by whether the 
best-fit curve of the subgroups of interest falls within the 95% confidence range of the 
remaining data. The characteristics and subgroups investigated were: gender (male 
48%), ethnicity (black 22%), growth status (plateau growth n=23), extremes of 
weight-for-age Z-score (underweight z-score <-3 n=27, overweight z-score >3 n=6), 
immunisation status (not up-to-date n=72), feeding during first 6 months of life 
(breast, formula or mixed; n=270, 58 or 126), prematurity (<32 weeks, n=14), past 
medical history of meningitis or TB (n=10), maternal HIV-exposure but HIV-
uninfected (n=19), and recent illness (1-4 weeks ago, n=66). The main variations 
found from the expected thymic output curve from all healthy children are presented 
in Figure 5.5. Otherwise if the sub-group best-fit median curves and 95% confidence 
intervals of the entire dataset largely overlap, it was presumed that no evidence of a 
significant difference was identified and the data are not represented.  
 
Thymic output between male and female children does not appear to differ overall in 
the first 4 years of life. The male median curve does not feature the characteristic 
peak of thymic output in the first 6-12 months of life, however the 95% confidence 
interval for that line does capture the initial peak in thymic output. Between 4-10 
years of age girls appear to have a higher thymic output than boys. Children with 
reported recent illnesses demonstrated higher thymic output than normal until 5 
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years of age, especially in the first year of life. The characteristic first peak of thymic 
output occurring at 6-12 months of age is much higher than the entire dataset in the 
small cohort of HIV-exposed uninfected children, and a second peak instead of a 
plateau follows the decline by 2 years. Similarly, the children who had a past medical 
history of either tuberculosis or meningitis had vastly different thymic output: far 
higher prior to 4 years and far lower thereafter.  For children who had a less than or 
equal to -3 weight-for-age Z-score, the pattern of thymic output is erratic, fluctuating 
and difficult to interpret, but notable is the diminishing instead of increasing thymic 
output in the first 6 months of life. Although the confidence intervals of the two 
categories of feeding in the first 6 months of life largely overlap, breast-fed children 
had a higher peak of thymic output within the first year of life. 
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5.2.2 Thymic output in HIV-infected children on ART 
 
HIV-infected children on ART versus to HIV-uninfected healthy children 
Measures of thymic output at single time-points in HIV-infected infants on early ART 
(CHER trial arm: ART-96W, n=321 from 4.3 weeks to 7.8 years of age) have been 
compared to measures of thymic output from CWC HIV-uninfected infants and 
children (n=435 from 2 weeks to 8 years). ART-96W infants started ART at CHER 
trial enrolment at 7.4 weeks (IQR 6.4 - 9) and continued ART for 96 weeks; then as 
per trial ART-strategy these children underwent ART-interruption for a median for 70 
weeks (IQR 35-109) resuming ART if clinical/immunological progression occurred. 
Regression curves of all available data from both cohorts were superimposed (Figure 
5.6). Although there's no overall difference and substantial overlap with the 
confidence intervals, it does seem that a different pattern of thymic output is 
occurring. Dips in thymic output may correspond with the effect of not being on ART 
until 7 weeks of age, and ART-interruption that occurred at approximately 2 years of 
age. Since average duration of interruption for the children examined was 34 weeks, 
this might roughly correspond with rising thymic output after recommencing ART. 
The confidence interval for data between 7-8 years of age is wider since less 
samples were available at this age. 
 
In the thymic output curve for healthy children every sample used from the CWC was 
from a different child, however in ART-96W 321 samples were used from 107 
children. To assess whether the presence of duplicates affected the shape and 
magnitude of the thymic output curve duplicates were removed at random and the 
curve was re-plotted, demonstrating minimal change in the shape and quantity of 
thymic output overall for the line of best-fit and surrounding 95% confidence intervals 
(Figure 5.7). 
 
To examine the differences in thymic output as illustrated by these regression lines, 
the “difference-from-expected thymic output” of each ART-96W child was calculated 
by comparing individual values of ART-96W thymic output with the regression curve 
made from all CWC children at the precise age of interest. Since CHER 
measurements of thymic output have been made at 4, 8 or 12 weekly intervals 
corresponding to their clinical visits during the trial, the “difference-from-expected 
thymic output” at these time-points have been examined in Table 5.2. Therefore, the 
significant differences from expected are demonstrated at 7 (p=0.003), 19 (p=0.05), 
67 (p=0.02) and 140 (p=0.04) weeks of age. For the children from ART-96W, this 
corresponds with initiation of ART (at 7 weeks), probable viral load suppression (19 
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weeks), after approximately one year of viral suppression on ART (67 weeks), and 
approximately a year after ART-interruption (140 weeks). 
 
 
Where longitudinal data were available, the pattern of thymic output illustrated by the 
ART-96W curve in Figure 5.6 was reflected by the profiles of individual children 
(Figure 5.8). Although there is a great deal of variability, thymic output tends to fall in 
the first 24 weeks then resurge or normalise thereafter. 
 
 
 
  
Figure 5.6: Regression of thymic output of CWC versus ART-96W. 
 
Healthy children from the CWC with 95% CIs of the central value (blue line and surrounding 
blue borders, n=435) with best-fit regression are compared to 95% CIs of ART-96W (pink line 
with surrounding pink borders, n=321 samples from 107/144 (74%) of children from ART-96W). 
ART-96W commenced ART at median 7 weeks of age, continued for 96 weeks, followed by 
ART-interruption for median 34 weeks (IQR 0-152) for these 107 individual children. Pink 
shaded areas indicate time on ART for ART-96W.  
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Table 5.2: Difference-from-expected measures of thymic output from ART-96W using 
the CWC regression curve. ART-96W divided into age groups and compared with expected 
value (i.e. zero). *Indicates significance at ≤0.05. 
Approximate age 
(age range in weeks) 
Number  
per group 
Median log difference 
from expected, [IQR] 
T-test 
p-value 
7 (4 – 8) 32 0.3 [0.19 – 0.67] 0.003* 
11 (9 – 14) 39 0.07 [-0.4 – 0.46] 0.60 
19 (15 – 30) 52 -0.25 [-0.5 – 0.14] 0.05* 
47 (38 – 57) 49 -0.08 [-0.44 – 0.24] 0.22 
67 (66 – 74) 26 0.2 [-0.002 – 0.52] 0.02* 
103 (102 – 108) 29 0.04 [-0.18 – 0.36] 0.73 
140 (115 – 165) 25 -0.22 [-0.4 – 0.07] 0.04* 
192 (170 – 215) 10 -0.004 [-0.41 – 0.14] 0.20 
256 (252 – 261) 35 0.04 [-0.19 – 0.19] 0.68 
366 (327 – 404) 13 0.08 [-0.05 - 0.4] 0.14 
 
 
 
 
  
Figure 5.8: Longitudinal profile of 27 individual children from ART-96W with 4-8 
separate measures of thymic output. These children commenced ART at week 0 (median 
7 weeks of age) and remained on ART until 96 weeks. 
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Impact of CHER ART-strategies: Deferred ART versus early ART 
The effect of deferring ART (ART-Def) until clinical or immunological progression was 
examined in comparison to ART started within 12 weeks of birth (ART-96W) in age-
matched groups at enrolment, 40 and 96 weeks of the trial. The difference between 
observed and expected thymic output was compared (“difference-from-expected” 
thymic output) i.e. the difference between each individual CHER participant’s thymic 
output and what would be expected for a normal South African child at that exact age 
as derived from the CWC regression curve.  
 
No significant difference in “difference-from-expected” thymic output between ART-
Def and ART-96W were identified at enrolment (n=35 vs. 40, Welch’s t-test 
difference-from-expected Log10(thymic output in cells/day)  p=0.51), 40 CHER trial 
weeks (n=39 or 31, p=0.41) or 96 weeks (n=38 vs. 44, p=0.09; Figure 5.9A). Of the 
39 children from ART-Def at 40 weeks, only 9 (23%) remained off ART and 30 had 
commenced ART albeit at different trial weeks as per initiation criteria or DSMB 
recommendation. The difference-from-expected thymic output at 40 weeks was not 
significantly different between ART-96W on ART (n=31), ART-Def on ART (n=30), 
and ART-Def off ART (n=9; ANOVA p=0.61), although ART-Def off ART 
demonstrated the lowest median estimate of thymic output (7.98 Log10(cells/day)). 
Similarly at 96 weeks of the trial, only 3 (7.9%) of the 38 ART-Def available at this 
time-point remained off ART and 35 had commenced ART albeit again at different 
trial weeks. Once more, no significant difference in difference-from-expected thymic 
output were detected between ART-96W on ART (n=44), ART-Def on ART (n=35), 
and ART-Def off ART (n=3; ANOVA p=0.16) although ART-Def off ART continued to 
demonstrate the lowest median estimate of thymic output (7.8 Log10(cells/day)).  
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Impact of CHER ART-strategies: ART-interruption after 40 or 96 weeks 
ART 
The effects of having a planned ART-interruption during the second (ART-40W) or 
third (ART-96W) year of life on thymic output were examined at 60, 96, 152 and 248 
weeks of the CHER trial. No differences were found between the arms at each of the 
time-points examined (Welch’s T-test difference-from-expected log(thymic output)  
n=32 vs. 35 p=0.11 at 60 weeks for ART-40W and ART-96W respectively; n=47 vs. 
44 p=0.86 at 96 weeks; n=9 vs. 19 p=0.84 at 152 weeks; n=41 vs. 36 p=0.15 at 248 
weeks; Figure 5.9B). Stratifying both arms by ART-status at each time-point (e.g. at 
152 weeks four groups can be compared: ART-40W on or off ART and ART-96W on 
or off ART) still did not reveal any significant differences in thymic output. There was 
one exception: ART-40W off ART had significantly higher thymic output than ART-
96W off ART at 248 weeks (n= 14 vs. 18, median 8.3 [IQR: 8.2–8.7] vs. 8.1 [7.8–8.2] 
Log10(cells/day), p=0.03) and higher than both ART-40W and ART-96W on ART by 
Welch’s t-test comparing difference-from-expected log(thymic output) (p=0.04). 
Examining total duration of ART by trial week 248 in the early-ART arms (ART-40W 
and ART-96W combined) in children who recommenced ART did not demonstrate 
any correlation between cumulative duration of time on ART and thymic output. 
 
Sixty-seven paired samples were available at both 96 and 248 weeks, therefore the 
size and direction of the change in thymic output, adjusted by what is expected for 
age, was examined in the early-ART arms, stratified by ART-status i.e. continuous 
ART, interrupted-and-remained-off ART or interrupted-and-recommenced ART 
between 96 and 248 weeks in ART-40W or ART-96W. In each of these subgroups 
there was no significant difference in thymic output identified with one exception: 
there were 3 pairs of samples from children who reached a trial-defined endpoint 
(clinical, immunological or virological), and these children did demonstrate a 
significant median increase of 1 Log10(cells/day) thymic output between 96 and 248 
weeks (ANOVA p=0.02, Figure 5.9C). 
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Impact of CHER ART-strategies: Long-term  
The long-term impact of the CHER ART-strategies on thymic output was compared 
difference-from-expected log(thymic output) at 7-8 years of age in all 3 arms: ART-
Def, ART-40W and ART-96W (n=12, 21 and 11). ART-96W had higher than 
expected thymic output (mean 0.06 Log10(thymic output) higher than expected for 
age), SD 0.32) than ART-40W and ART-Def (p=0.08 and 0.04 respectively; Figure 
5.9D). In absolute numbers this is 6.24 x 107 naïve CD4 T-cells/day more for ART-
96W than healthy HIV-uninfected controls, 1.4 x107 more cells/day for ART-40W and 
3.85 x 107 less for ART-Def. By 7-8 years, ART-96W had less time on ART 
compared to ART-Def and ART-40W (ANOVA 0.02), and 5 children from ART-96W 
remained off ART. These 5 children had a higher mean thymic output than expected 
for age (0.13 Log10(thymic output higher than expected for age (SD 0.36)) compared 
to children from ART-96W still on ART (n=8, mean 0.008 Log10(thymic output) 
higher than expected for age, SD 0.32) however this was not statistically significant 
(p=0.5). Examining the longitudinal perspective of thymic output from enrolment until 
7-8 years of age in the combined early ART arms reveals sustained thymic output 
throughout at median 8 Log10(cells/day), (n=81 enrolment, 91 at week 96, 77 at 
week 248, 33 at week 360). 
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Trajectories of thymic output within individuals by CHER trial arm 
Where available, multiple measures of thymic output within individuals allow the 
opportunity to examine the dynamics over time on and off ART (Figure 5.10). In the 
12 children examined from ART-Def with multiple measures of thymic output, ART 
was commenced at mean of 26 weeks of the trial (range: 11.7-68.6 weeks). On 
examining the trajectory of thymic output 9/12 (75%, data not shown) of the children 
from ART-Def had low thymic output at the time of starting ART, and the regression 
curve of these results suggests thymic output then increases after initiation of ART. 
Although few data are available in ART-40W, thymic output appears to decline 
between 60-84 weeks after ART-interruption at 40 weeks, followed by an increase 
and plateau of thymic output corresponding to the mean ART-interruption of 55 
weeks (range: 0-208 weeks). In ART-96W, within individuals there appears to be a 
decline in thymic output in the first 12 weeks, however this is not particularly evident 
from the central regression line which suggests a stable thymic output throughout at 
approximately 8 Log10(cells/day) despite ART-interruption after 96 weeks. 
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Figure 5.10: Profiles of thymic output from individual children within each CHER trial 
arm from enrolment to trial end (248 weeks). 
 
ART-Def (n=12), ART-40W (n=7), ART-96W (n=27); no children who reached the primary 
endpoints in the trial were included in these trajectories to illustrate the range and pattern of 
thymic output in clinically stable HIV-infected children and the impact of the CHER ART 
strategies used. The y-axes represent thymic output in Log10 naïve CD4 T-cells per day. 
The red line depicts median regression throughout data available. Shaded pink areas are 
time on ART: for ART-Def mean time to initiating ART for these 12 children was 26 weeks; 
for ART-40W mean ART-interruption after 40 weeks of ART was 55 weeks for these 7 
children; and for ART-96W mean ART-interruption after 96 weeks of ART was 93 weeks for 
these 27 children (NB. 14 of these 27 children remained off ART until the trial end).  
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Trajectories of thymic output, viral load and CD4 count by CHER arm 
The relationship between thymic output, CD4 and viral load has been explored within 
arms using regression curves (Figure 5.11). Available viral load and CD4 data were 
only included from children with corresponding measures of thymic output at that 
time, and therefore is not representative of the entire cohort. In all arms, viral load is 
suppressed within a year and remains suppressed in ART-Def and ART-96W until 2 
years, however in ART-40W there is a viral resurgence coinciding with the period of 
time when ART was interrupted. CD4 count declines with age as expected, however 
the decline is more dramatic in ART-Def compared to ART-96W or ART-40W during 
the period where ART had not yet been initiated in ART-Def. ART-Def does appear 
to regain CD4 count to equal that of ART-96W by 2 years of age, whereas CD4 is 
lower in ART-40W, as expected as these children interrupted ART at week 40. Never 
the less, there were no significant differences in CD4 counts by 7-8 years between all 
arms (ANOVA, p=0.06).  
 
In ART-Def and ART-96W there appears to be evidence of declining thymic output in 
the first months of life, followed by an increase to around 8 Log10(cells/day) for all 
arms at 2 years of age. In both ART-Def and ART-96W, increasing thymic output 
occurs following viral load suppression and is also associated with a plateau in the 
CD4 count. Very few data were available for ART-40W in the first few months 
(Chapter 2, Table 2.1: Specimen numbers), so the lack of decline in this arm is 
unlikely to be reliable, especially since the ART-strategy was as that of ART-96W in 
the first year of life. Correspondingly, in ART-40W at ~1.5 years of age following 
ART-interruption, there is a surge in viral load corresponding to a trough in thymic 
output and CD4 count. 
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Thymic output and CD4 count 
Simple linear regression was used to further explore the relationship between CD4 
count and thymic output, and a significant regression equation was found for both 
CWC and CHER participants (all CHER participants were combined). Age-adjusted 
CD4 Z-score was calculated for each individual from either CWC or CHER against 
expected CD4 counts for healthy South African children using the CWC data-set 
(Statistical methods section 2.5: Thymic output). For CWC the parameters for linear 
regression are as follows: F(1,450)=58.8, p<0.0001 with R2=0.11 and for CHER: 
F(1,774)=188.7, p<0.0001 with R2=0.2. For CWC predicted CD4 Z-score is equal to 
8+0.22(thymic output in Log10(cells/day)), or for CHER 8+0.21(thymic output). This 
means that CD4 count Z-score increases by 0.22 for CWC or 0.21 for CHER 
children, for each increase of Log10 cells/day of thymic output (Figure 5.12). 
 
 
  
Figure 5.12: Relationship between thymic output and age-adjusted CD4 count Z-score. 
 
CWC (n=452 children) and CHER (n=776 samples from 293 children). Age-adjusted CD4 Z-
score was calculated for each individual from either CWC or CHER against expected CD4 
counts for healthy South African children using the CWC data-set. 
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5.2.3 Unstable HIV-infection and thymic output 
 
Thymic output in children who reached a CHER trial-defined endpoint 
The CHER trial primary endpoint was death or failure of first line ART, defined as 
CD4 <20%, HIV disease progression to CDC stage C or severe B, regimen-limiting 
toxicity or CD4% <20% (increased to <25% in 2006 in line with international 
guidelines) [68]. The relationship between thymic output and trial endpoints has been 
explored in using a case-control analysis approach. Children who reached the trial-
defined endpoint were defined as “cases” and included if stored specimens were 
available at both enrolment and up to a month prior to reaching the endpoint. 
“Controls” were children who did not meet an endpoint at any stage throughout the 
trial, adhered to their randomization arm and had stored specimens available at 
enrolment and age-matched to a “case” at the time of the “case’s” endpoint. Cases 
and controls were also matched by trial arm, gender, ethnicity and study site (PHRU 
or KIDCRU). Controls were selected randomly within matched subgroups. 
 
The case-control design at enrolment was used to assess whether measures of 
thymic output could be predictive of poor clinical outcome i.e. reaching one of the 
trial-defined endpoints. Although no significant difference was identified between 
each case-control pair, mean thymic output was lower in the cases of ART-Def and 
ART-40W at enrolment (Figure 5.13). Thymic output was next compared prior to or at 
the time of reaching the trial-defined endpoint between “cases” and “controls”. 
Although no difference was seen in the early ART arms, ART-Def had significantly 
lower thymic output prior to reaching a trial-defined endpoint compared to the control 
group (n=20, t-test p=0.02; Figure 5.13).  
 
Of the 52 children examined at enrolment who went on to reach trial-defined 
endpoints (i.e. the “cases”), the majority were due to death (n=26) or immunological 
failure defined as CD4 <20%/25% (n=17), however no significant relationship was 
demonstrated between thymic output at enrolment and going on to have 
immunological failure or die. Neither was a statistical relationship identified between 
thymic output at the time of reaching the trial-defined endpoint and type of endpoint 
in the 50 children examined.  
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Nevertheless, examining the trajectories of thymic output in children with more than 4 
individual measures of thymic output crudely revealed a pattern by which it appeared 
that thymic output was declining or at it’s lowest for that individual at the time of 
reaching the primary endpoint. This was true in 8/12 (66%) of ART-Def, 4/5 (80%) of 
ART-40W and 2/2 (100%) of the “cases” examined in ART-96W. Figure 5.14 
illustrates these findings in a selection of 4 individuals. Since “immunological failure” 
(CD4 <20%/25%) was one of the trial’s endpoints, reaching a trial-defined endpoint 
corresponds with low CD4 count in 3 of the 4 cases. In case 1 and 2, the children 
underwent scheduled ART-interruption at 40 weeks, thereafter thymic output and 
CD4 count diminish and the trial-defined endpoint is reached around 80 weeks. In 
case 3, the primary endpoint was reached before ART-interruption occurred but 
coincides with low thymic output and CD4 count. As per trial protocol ART was 
subsequently not interrupted and thymic output eventually gradually increases on 
continuous ART. In case 4, the primary endpoint also occurred before ART-
interruption with low thymic output although not low CD4 since this endpoint was 
reached by fulfilling clinical criteria (CDC severe B or C). However, ART was 
interrupted at 96 weeks and during ART interruption a fall in thymic output is evident. 
Figure 5.13: Case-control analysis of thymic output at enrolment and prior to reaching a 
trial-defined endpoint. 
Each child reaching a trial-defined endpoint (“case”, red) was age-matched to a “control” 
(gray) at the time of reaching the endpoint. Cases and controls were also matched by trial 
arm, gender, ethnicity and study site (PHRU or KIDCRU). Pairs of cases and controls at 
enrolment: ART-Def n=17, ART-40W n=20, ART-96W n=17. Pairs of cases and controls at the 
trial-defined endpoint: ART-Def n=20, ART-40W n=18, ART-96W n=12.  
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The rate and direction of change in thymic output within individuals between pairs of 
thymic output measures at enrolment and endpoint were examined. The children 
who reached endpoints in ART-Def (“cases”) demonstrated the greatest decline in 
thymic output that was significantly different compared to the age-matched controls 
from ART-Def (median decrease in “cases” -0.25 [IQR -0.41-0.03] 
Log10(cells/day/year) versus median increase in “controls” 0.13 [IQR -0.32-0.21], 
n=10 pairs of both cases and controls, t-test p=0.02). No significant difference was 
found in ART-40W (n=16 pairs), however in ART-96W a difference was seen in the 
change in thymic output over time between cases and controls, whereby the cases 
had more children who showed an increase in thymic output than in the controls, 
although median change was negligible in both groups (median change in “cases” -
0.03 [IQR -0.38-0.4] Log10(cells/day/year) versus median change in “controls” -0.08 
[IQR -0.67-0.02], n=12 pairs of both cases and controls, t-test p=0.04). 
 
  
Figure 5.14: Examples of 4 children who reached a CHER trial-defined endpoint. 
Individual trajectories of thymic output in Log10(cells/day) are marked in blue and CD4 count in 
cells/µl in green. The black dashed line indicates when the trial-defined endpoint was reached, 
and pink shaded area reflects time on ART. 
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The effect of an intercurrent infection on thymic output 
The effect of an intercurrent infection on thymic output was investigated by another 
case-control analysis examining the thymic output before and after an admission to 
hospital with pneumonia. The “pneumonia-cases” were defined by hospital admission 
for at least one night with an uncomplicated lower respiratory tract infection 
characterized by increased respiratory rate, chest recessions and oxygen 
requirement. Potential TB infections were excluded. “Pneumonia-cases” were 
matched to “controls” by gender, ethnicity, age, trial arm and trial site. “Pneumonia-
controls” were stable HIV-infected CHER participants who had an uncomplicated 
medical history, were not admitted to hospital for pneumonia or any other issue, and 
did not reach a trial-defined endpoint at any stage throughout the trial. 
Measurements of thymic output were performed from cryopreserved PBMCs stored 
from clinic reviews before and after the admission. Fourteen pairs of pneumonia 
case-controls with pre- and post-admission measures of thymic output were available 
for analysis. Both measures of thymic output in “pneumonia-cases” were lower than 
controls although with a trend towards significance in pre-pneumonia measures (T-
test p=0.09) and no difference in post-pneumonia (p=0.16, Figure 5.15). 
 
Figure 5.15: Thymic output before and after admission with pneumonia. 
 
Comparison of thymic output between “pneumonia-cases” (red) age-matched with well and 
stable CHER participants as “pneumonia-controls” (gray). Cases and controls were also 
matched by trial arm, gender, ethnicity and study site. Paired T-test pre-pneumonia p=0.09, 
post-pneumonia p=0.16, n=14 pairs of cases and controls. 
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5.3 Discussion 
 
5.3.1 Thymic output in healthy HIV-uninfected children 
The laboratory data from the CWC cohort were used to formulate a non-linear 
regression curve to delineate the change in thymic output during childhood. As was 
expected from the mathematical model, there was wide variability in thymic output 
values reinforcing the need to include large numbers to fully characterise the 
distribution. The laboratory data were similar to the model in demonstrating peak 
thymic output between 6-12 months of life followed by a decline until 2 years of age. 
However, thereafter our estimates appeared to deviate from the model’s estimations 
by maintaining a constant thymic output into late childhood where the model 
demonstrated a gradual decline until teenage years and adulthood.   
 
The reason for the discrepancies seen between the published model and our 
estimates of thymic output might be explained by a number of factors. The data used 
to form the model may have used different measurements for TRECs and Ki67 
labeling, and were from a small number of children from a different study population 
in the US (n=12) and Europe (n=25). Therefore a number of variables may have 
been introduced such as genetics, nutrition and exposure to environmental 
pathogens and allergens; and since the variability is so extensive a few individuals 
with extreme measures might easily influence the original model. Although numbers 
from the CWC were large, they were from many different participants and 
longitudinal follow-up of individual children may have been preferable in delineating 
the thymic output curve. 
 
A potential limitation of the thymic output model may result from the blood volume 
formula utilised to quantify the total number of naïve CD4 T-cells in the child’s 
circulating blood. There are few formulas available to estimate blood volume in 
children; the most comprehensive study was performed by Linderkamp et al in 1997 
[79] using a fixed ratio of plasma to red-cell volume (F-cell ratio) and weight to 
estimate blood volume and this approach has been used in estimating blood volume 
for thymic output in our study. Subsequent authors have suggested a fixed F-cell 
ratio is not plausible in children [176];  however better approaches to estimating 
blood volume are lacking. If available, a formula that reliably incorporated both 
weight and height may have been better since South African children could have 
stunted growth compared to their US or European counterparts used in the model.  
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Another limitation of the thymic output formula is that it is intrinsically constrained by 
an upper limit of 0.6 TRECs per naïve CD4 T-cell; however up to 2 TRECs per cell is 
biologically plausible if both alleles happen to have gene rearrangement [168]. The 
figure of “0.6” is derived from the average number of predicted cell divisions before a 
naïve CD4 T-cell leave the thymus. Although only 3 samples taken from the CWC 
had ≥0.6 TRECs per cell, these results had to be excluded since it would have 
produced an implausible value of negative thymic output. Thereby the robustness of 
the model is brought into question. 
 
Finally, a further limitation of the model is the possibility that Ki67 may not only reflect 
increased levels of proliferation from a homeostatic response to low cell numbers but 
may be elevated by immune activation or intercurrent infection [163, 177], and may 
remain elevated for days after completion of cell-division [178], and therefore could 
give an inappropriately high estimate of thymic output.  
 
A potential biological explanation exists for the lack of decline in thymic output after 2 
years of age compared to what was predicted by the mathematical model. In Chapter 
3, the CWC demonstrated a dramatic increase in the naïve/memory ratios of both 
CD4 and CD8 T-cells compared to industrialised countries, plausibly driven by 
environmental exposure to pathogens. Therefore the possibility of a feedback 
mechanism to the thymus is introduced, as increased antigen-stimulation converts 
naïve to memory CD4 and CD8 T-cells, the thymus may be mobilised to increase 
thymic export of naïve T-cells thereby maintaining a higher than expected thymic 
output, as seen by the CWC regression curve. In contrast, it is plausible that a more 
sterile environment lacking in antigen-stimulation, as occurs in the richer north, may 
play a role in reduced thymic output as seen in the published model. 
 
This feedback mechanism to the thymus is supported by the exploratory analyses of 
the CWC subgroups, as children with common childhood illnesses within the past 
month manifested a higher thymic output than expected for age. This could be 
explained by the release of IL7 during infection, which is also recognized to promote 
maturation of thymocytes and is a known modulator of T-cell homeostasis [179]. 
Similarly, the HIV-exposed uninfected children, albeit a very small sample, had 
higher thymic output, potentially due to antigen-stimulation from circulating maternal 
antigens within breast milk, or increased environmental exposure since poorer socio-
economic conditions have been associated with HIV-infected individuals [180].  
 
	   159 
Environmental pathogen exposure is unlikely to be the sole cause of the large 
variation in thymic output, and other factors have been implicated by the analysis of 
this study include gender differences, poor growth and method of feeding in the first 
6 months of life. Gender differences might be due to differences in height not being 
accounted for using the blood volume formula, or pre-puberty hormonal changes. 
Likewise variable growth hormones and nutrition may explain erratic thymic output in 
children with poor growth; and finally breast-feeding might augment the peak thymic 
output in infancy which corresponds with reports of increased thymic size and 
improved immune responses in breast-fed babies [181]. However, these are all 
limited analyses and any potential associations require further investigation. 
 
5.3.2 Thymic output in HIV-infected children on ART  
Thymic output was compared between HIV-uninfected CWC children and age-
matched HIV-infected children on ART from CHER (ART-96W). Although all 
measures of thymic output were derived from laboratory measures performed on 
cryopreserved PBMCs, CHER PBMCs had been stored in liquid nitrogen for up to 8 
years compared to 6-12 months for CWC specimens, and some CHER specimens 
had low yield of live cells on thawing. In these specimens, it was the dead cells that 
appeared to have a higher proportion of activation and proliferation markers which 
might be due to activated cells being more prone to death during freeze-thaw 
processing, or the fact that dead cells can generate artifacts as a result of 
nonspecific antibody binding and unwanted uptake of fluorescent probes. Never-the-
less, the fresh-frozen comparison described in Chapter 3 did not reveal a relationship 
between percentage of live cells and difference from the fresh measure of the 
immunophenotype of interest; therefore these samples were included in the analyses 
described in this chapter. 
 
The confidence intervals of the CWC and ART-96W regression curves largely 
overlap, implying no significant difference overall between the two groups of children 
and that early ART might maintain thymic output to that of a healthy child. However, 
the trajectory of the median curve from ART-96W is quite different from the CWC and 
provides valuable information to help understand the initial response of thymic output 
to HIV, and then to treatment with ART. Adjusted analyses in Table 5.2 shows that 
the thymic output of children in ART-96W differs most from the CWC children at 7, 
19, 67 and 140 weeks. At 7 weeks a higher thymic output in ART-96W might 
correspond with the thymus working hard to compensate for the loss of CD4 in the 
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early weeks of infection before ART had been initiated. There may be limited 
capacity for the thymus to maintain sufficient naïve CD4 T-cell output, since by 19 
weeks lower than expected thymic output is seen despite these infants having 
received 3 months of ART. However, by 67 weeks, the viral load should have then 
been suppressed for more than a year and ART appears to have preserved thymic 
output or even increased it over that expected for a healthy HIV-uninfected child. In 
ART-96W, ART was continued for 96 weeks until ART-interruption for a median of 34 
weeks in the children examined here, although it is a source of bias that there was a 
wide range ART-interruption duration with some children remaining off ART until the 
trial end. Nevertheless, thymic output falls during ART-interruption and is significantly 
different from expected for a healthy HIV-uninfected child at 140 weeks, 
subsequently rising gradually as children recommence ART.  
 
As demonstrated by the ART-96W regression curve and the individual trajectories, 
falling thymic output in the first 3 months of life may reflect the detrimental effect of 
vertically-acquired HIV on the developing thymus both in-utero and perinatally before 
commencing ART. Infection of recent thymic emigrants with HIV has been 
demonstrated [182], however it is not known how this influences thymic output or 
affects the longevity and function of recent thymic emigrants. One limitation of 
comparing measures of thymic output between HIV-uninfected and HIV-infected 
children using the mathematical model is that the formula relies upon the assumption 
that 2% of lymphocytes reside in the blood. This may be true of HIV-uninfected 
children and for clinically stable HIV-infected children on ART [183], however it could 
be much lower in untreated HIV-infection [184]. In view of this, the formula would 
thereby underestimate thymic output in ART-96W at 7 weeks of age and the 
difference compared to CWC is likely to be greater and therefore more significant.  
 
At 7-8 years of age ART-96W had better thymic output than ART-40W and ART-Def 
despite having received less cumulative ART overall. This is most likely to be due to 
the ART-strategy used; early-ART continued for 96 weeks rather than to only 40 
weeks, and could suggest that early ART for at least 2 years may sustain a good 
level of thymic output for longer. This is reinforced by the CD4 and thymic output 
data from the CWC and combined CHER arms which illustrated that absolute CD4 
counts were directly related to thymic output adjusted by age, i.e. as thymic output 
increases so does the CD4 count. This finding highlights the importance of 
preserving thymic output in children to optimize their potential for CD4 reconstitution 
and long-term immunological health. 
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5.3.3 Unstable HIV-infection and thymic output in CHER  
The endpoint case-control comparisons demonstrated a trend towards lower thymic 
output in the “cases” at enrolment and prior to reaching the trial-defined endpoint. 
Lower thymic output in the “cases” prior to the endpoint is reinforced by the 
observations in the individual trajectories of lower or falling thymic output at the time 
of the endpoint, thereby inferring that poor thymic output may be associated with HIV 
progression.  
 
ART-Def “cases” had significantly lower thymic output prior to the endpoint compared 
to ART-Def “controls”, whereas no significant difference was found between the 
“cases” and “controls” in the early-ART arms, suggesting that early ART may 
preserve thymic output. The paired measures of thymic output at 96 and 248 weeks 
in children that had reached an endpoint demonstrated the greatest increase in 
thymic output from all the available paired specimens. This is reflective of the 
findings that ART preserves and may even augment thymic output as seen in ART-
96W at 7-8 years compared to healthy controls, as reported elsewhere [66]. 
 
The pneumonia case-control analysis demonstrated lower thymic output before and 
after pneumonia compared to healthy CHER controls without pneumonia. This is 
consistent with the theory that lack of TCR diversity from poor thymic output 
predisposes individuals to opportunistic infections. Even despite adequate CD4 
counts, restricted TCR repertoires have been reported in HIV-infection [55] and may 
indicate that the CD4 T-cell pool has expanded from a limited number of clonotypes. 
Accelerated T-cell destruction in uncontrolled HIV is likely to restrict the TCR 
repertoire but T-cell generation dysfunction, such as impaired thymic output must 
also be present. 
 
A selection bias exists in the case-control analyses since not all specimens from 
those that died were available. The analyses are also constrained by the fact that 
insufficient numbers of samples were available to adequately compare the groups 
considering the wide variation of thymic output and the power calculations 
performed; this was particularly true of the pneumonia analysis, where the numbers 
within this comparison were too small to detect any difference between early and 
deferred ART. However in view of the nature of both these limitations any differences 
detected here are likely to be underestimated. 
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Thymic Output in Paediatric HIV Summary 
In summary, the CHER ART-strategies served most children fairly well in terms of 
preserving thymic output, however early ART for longer (i.e. ART-96W) appeared to 
sustain thymic output to that of a healthy child and be more beneficial long-term over 
deferred ART and shorter early ART. These data suggest thymic output temporarily 
increases as a consequence of untreated HIV-infection in the first months of life, 
plausibly due to a feedback mechanism from CD4 T-cell death plus antigen-
stimulated naïve to memory T-cell conversion. This increase is unsustainable and 
results in depleted thymic activity as reflected by subsequent falling thymic output in 
the first months of life until ART is initiated.  Augmented thymic output was 
demonstrated following ART-initiation either at enrolment, after interruption or as 
indicated in the deferred arm. Observations of low thymic output at the trial-defined 
endpoints, alongside the case-control and pneumonia analyses suggest low thymic 
output is associated with poor clinical outcome and may be due to limited 
functionality from a restricted TCR repertoire. 
 
Data from the previous chapter showed a declining CD4/CD8 ratio and increasing 
levels of CD8 and CD8 activation despite HIV RNA viral suppression and on-going 
ART. This could suggest immune activation persists and more needs to be done to 
restore immunological health to that of an HIV-uninfected child. The 
immunopathogenesis of HIV is largely due to accelerated destruction combined with 
impaired generation of CD4 T-cells; while ART successfully reduces CD4 T-cell 
destruction and timely ART-initiation may prevent impairment of thymic output, there 
is a dearth of adjunct strategies to repair thymic damage and optimise immunity. 
Detailed analyses are needed to unravel the association between thymic output and 
various immune parameters and thereafter ascertain clinical approaches to facilitate 
the function of organs that generate naïve T-cells, such as the bone marrow, thymus, 
and mucosal immune system.  
 
While these novel insights develop understanding of the influence of HIV and ART on 
the output of the thymus, further long-term studies are required to establish the 
relationship between thymic output and clinical health, and ultimately to advance 
ART-strategies to optimise the immunological health of HIV-infected children. 
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Chapter 6 
 
Naïve B-cell output in healthy and HIV-
infected children 
 
6.1 Background  
 
While thymic output may be a crucial component for T-cell immune reconstitution in 
HIV-infected children, little is known about the role of naïve B-cell output in B-cell 
immune recovery and preservation, including the association with thymic output. 
There is no recognized approach to quantifying naïve B-cell output, although Kappa-
deleting recombination excision circles (KRECs) are increasingly being used as a 
surrogate marker of bone-marrow output/activity. KRECs are stable double-stranded 
circular DNA structures, a product of variable (V), diversity (D), and joining (J) gene-
recombination (Figure 6.1 [87]) that occurs during B-cell development as precursor 
B-cells mature into functional naïve B-cells. These multiple rounds of gene 
rearrangements generate a diverse range of functional B-cell receptors [2] and 
therefore the ability to respond to a wide range of pathogens. 
 
KRECs are currently being used in some European countries and the USA for 
routine screening for primary immunodeficiencies characterized by the absence of T- 
or B-cells such as severe combined immunodeficiency (SCID), common variable 
immunodeficiency (CVID) and X-linked agammaglobulinaemia (XLA) [185]. There 
have been a small number of studies using quantification of KRECs to improve 
characterization of primary immunodeficiencies and monitor treatment such as 
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enzyme replacement therapy for SCID[2] and recovery from stem cell 
transplantation, however there is limited reference range data for KREC quantities in 
healthy children as a comparison. 
 
In HIV-infected adults, a correlation has been described between increased duration 
of untreated HIV-infection prior to commencing ART and reduced measures of 
KRECs [33], potentially reflecting suppressed bone marrow output. There are limited 
studies exploring B-cell dysfunction in HIV-infected children and no studies to date 
quantifying KRECs or estimating naïve B-cell output in this population.  
 
The effect of HIV on naïve B-cell output could possibly be associated with the 
variable rates and decline of protective antibody concentrations in HIV-infected 
children. Antigen-specific immunoglobulin G as low as 5% GMC at a median of 6 
years have been reported for measles [186], 43% at 1 year for Hib [187], 38% at 8 
months for tetanus [188], and 48% at 5 years for the pneumococcal conjugate 
vaccine [189]. A better understanding of the relationship between naïve B-cell output 
and antibody responses to routine vaccinations might help optimize primary and 
booster vaccination schedules in HIV-infected children. 
 
The absolute number of naive B-cells is theoretically regulated by four processes: 
output from the bone marrow, rate of survival in the periphery, loss of naive B-cells 
from naïve-to-memory switch after encountering antigen, and antigen-independent 
homeostatic proliferation. In view of this interplay, absolute measures of KRECs are 
Figure 6.1: Formation of kappa-deleting recombination excision circles (KRECs) [87]. 
 
KRECs are remnants of DNA that have been excised during gene rearrangement. They 
remain within the nucleus of one of the two daughter cells following cell division. 
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unlikely to provide a reliable estimate of naïve B-cell output, especially since KRECs, 
like TRECs, do not divide on proliferation of the cell in which they reside and they are 
consequently diluted upon cell division in the peripheral circulation. Therefore the 
thymic output formula [11, 82] has been adapted for this purpose combining 
quantification of KRECs with peripheral measures of naïve B-cells and rates of 
proliferation (Methods section 2.4.5). 
 
In this chapter, the normal ranges for measures of KRECs have been calculated and 
naïve B-cell output has been estimated in healthy South African children from birth to 
13 years. To help understand the clinical significance of naïve B-cell output, the 
differences between naïve B-cell output in HIV-infected and uninfected children have 
been examined, along with the relationship with a range of antibody responses to 
routine childhood vaccinations and whether the ART-strategies used by CHER had 
an impact upon naïve B-cell output. Using data from the previous chapter, the 
relationship between thymic output and naïve B-cell output in both healthy South 
African children and HIV-infected children from CHER has also been explored. 
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6.2 Results 
 
6.2.1 KRECs and naïve B-cell output in South African children  
KRECs were measured from 288 cryopreserved PBMCs from the children of the 
CWC aged from 2 weeks to 13 years. Since there are currently no existing reference 
ranges for KRECs or naïve B-cell output, Table 6.1 explores five different ways of 
representing the reference ranges of these data: 1) KRECs per PBMC, 2) KRECs 
per mililtre of blood, 3) KRECs per million B-cells (CD19+ lymphocytes), 4) KRECs 
per million naïve B-cells (CD19+IgD+CD27- lymphocytes), and 5) using the adapted 
thymic output formula to estimate naïve B-cell output from the bone-marrow in naïve 
B-cells cells/day. The first two formats are practical and easy to calculate using 
output from the DNA PCR and basic parameters of the blood sample itself. The 
following two require flowcytometric measures of B-cells and naïve B-cells to give an 
estimate of the probable KREC quantity within these cells. However, only the fifth 
format accounts for the peripheral proliferation of naïve B-cells (Ki67+ proportion of 
CD19+IgD+CD27- lymphocytes) and is therefore likely to be more accurate, 
especially in cases of HIV-infection. Figure 6.2 presents the distribution of three of 
these measurements with age.  
 
  
Figure 6.2: Possible representations of KREC data from healthy South African children. 
 
A) KRECs/ml blood. B) KRECs per million B-cells. C) KRECs per million naive B-cells. n=288. 
All y-axes limited to 3x106 to visualize data omitting 4, 1 and 2 data-points from each 
respective plot. 
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Table 6.1: Reference ranges for KRECs and naïve B-cell output from the CWC.  
 
Age-
group  
 
 
n 
KRECs per 
PBMC 
KRECs per 
mililtre of 
blood 
KRECs per 
million  
B-cells 
KRECs per 
million naïve  
B-cells 
Naïve B-cell 
output 
(cells/day) 
Median, [IQR], (5th–95th centiles) 
0 – 3 
months 
33 0.03 
[0.02-0.09] 
(0.01-0.32) 
3.5x105 
[2-7x105] 
(1.2x105 – 
1.7x106) 
2.2x105 
[1-4x105] 
(5.6x105 – 
1x106) 
2.1x105 
[1-4x105] 
(6x104 – 
7.9x105) 
3.2x108 
[1.9-8.3x108] 
(2.2x107 – 
1.6x109) 
3 – 6 
months 
33 0.05 
[0.02-0.09] 
(0.005-
0.21) 
3.9x105 
[1.7-6.9x105] 
(3.3x104 – 
1.7x106) 
2.1x105 
[1.1-3.8x105] 
(2.8x104 – 
1.1x106) 
2x105 
[1.1-3.7x105] 
(1.1x104 – 
5.5x105) 
7.4x108 
[2x108-
3.7x109] 
(2x107-1x1010) 
6 -12 
months 
50 0.04 
[0.02-0.06] 
(0.002-
0.12) 
3.4x105 
[1.7-8.5x105] 
(4x104 – 
1.6x106) 
1.6x105 
[1.2-3.3x105] 
(1.4x104 – 
9.6x105) 
1.7x105 
[1-2.3x105] 
(1.2x104 – 
4.7x105) 
6.6x108 
[1.5x108-
2.1x109] 
(2.6x107-
6.8x1010) 
1 -2 
years 
68 0.03 
[0.01-0.06] 
(0.003-
0.16) 
2.8x105 
[9.7x104-
6.4x105] 
(2.4x104-
1.6x106) 
1.4 x105 
[7.4x104- 
2.9x105] 
(1x104-
6.2x105) 
1.5 x105 
[7.2x104- 
3x105] 
(1.1x104-7x105) 
4x108 
[1x108-
2.3x109] 
(2.4x107-
1x1010) 
2 – 6 
years 
80 0.02 
[0.009-
0.04] 
(0.002-
0.15) 
1.1x105 
[6.1x104-
4.2x105] 
(1.5x104-
1.4x106) 
8.9x104 
[5.5x104-
3.1x105] 
(1.2x104-
1.1x106) 
1.2x105 
[7x104-2.7x105] 
(1.7x104-
9.3x106) 
1.4x108 
[4.9x107-
4.3x108] 
(3.8x106-
4.4x109) 
6-12 
years 
24 0.02 
[0.008-
0.03] 
(0.001-
0.05) 
9.7x104 
[4.1x104-
1.8x105] 
(9.9x103-
4.8x105) 
1.3x105 
[8.1x104-
3.4x105] 
(2.6x104-
5.2x105) 
1.9x105 
[9.2x104-
4.8x105] 
(4.2x104-
16.6x105) 
9x107 
[1.3x107-
1.7x108] 
(9.4x105-
6x108) 
 
Naïve B-cell output has been used in most of the analyses done in this chapter, since 
the formula compensates for the peripheral proliferation that dilutes KRECS, thereby 
providing an explicit quantity of naïve B-cells entering the circulation. The elements 
of the naïve B-cell output model: quantity of naïve B-cells, proliferation of naïve B-
cells and KRECs per PBMCs are represented in Figure 6.3 with the combined data 
plotted in a regression curve in Figure 6.4. The naïve B-cell output regression curve 
exhibits a steep increase and peak in the first year of life (median 8x108 naïve B-
cells/day), followed by a rapid decline to 6 years of age (median 7.2x107 naïve B-
cells/day) and subsequent relative plateau. The confidence interval of the median 
regression curve widens with increasing age due to less available data. 
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Figure 6.3: Elements of the naïve B-cell output model. 
 
Plot A: quantity of naïve B-cells (CD3-CD19+IgD+CD27-). Plot B: proliferation of naïve B-cells 
(CD3-CD19+IgD+CD27-Ki67+ as a percentage of all naïve B-cells). Plot C: KRECs per 
PBMC (NB. Plot C y-axis limited from 1.0 to 0.4 omitting 4 data-points to visualize the 
distribution). 
 
Figure 6.4: Naïve B-cell output regression curves across age from healthy South 
African children. 
A) Regression curve representing naïve B-cell output in cells per day. B) Logarithmic curve 
with 95% CIs surrounding the centrally fitted line and gray circles representing each data point 
(n=288). 
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6.2.2 Naïve B-cell output in HIV-infected children 
285 measures of naïve B-cell output were calculated from all 3 arms of the CHER 
trial from enrolment to CHER PLUS (7 weeks to 8 years of age). Measurements from 
ART-96W only were used for the purpose of exploring the effect of HIV and early 
ART on naïve B-cell output compared to healthy HIV-uninfected South African 
children from the CWC. Figure 6.5 illustrates children from ART-96W (n=139) had 
higher naïve B-cell output than their HIV-uninfected counterparts overall (Welch’s t-
test p<0.0001), particularly at 0-3 months of age (p<0.0001), 6-12 months (p=0.03) 
and 1-2 years (p=0.01). Figure 6.6 reinforces these differences with the data 
represented in the form of regression curves and Figure 6.7 demonstrates individual 
trajectories of naïve B-cell output that correspond to the overall regression curve.  
 
.   
 
Figure 6.5: Differences between naïve B-cell output in healthy HIV-uninfected children. 
 
CWC (gray) and ART-96W (blue). 0-3 months: CWC n=33 vs. ART-96W n=34 (Welch’s t-test 
p<0.0001); 3-6 months: 33 vs. 16 respectively (p=0.44); 6-12 months: 50 vs. 25 (p=0.03); 1-2 
years: 68 vs. 29 (p=0.01); 2-6 years: 80 vs. 7 (p=0.14); 6-12 years: 24 vs. 28 (p=0.40). ART-
96W initiated ART at median 7 weeks until 2 years, interrupting ART for a median 89 weeks in 
these children (median of 70 weeks overall for all of ART-96W). 
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Figure 6.6: Naïve B-cell output regression curves of HIV-uninfected children 
compared to HIV-infected children until 5 years of age. 
 
ART-96W is shown in red, n=111 samples in 70 individuals. ART-96W initiated ART at 
median 7 weeks until 2 years, interrupting ART for a median 89 (IQR 17-145) weeks in 
these 70 children. The central line is the best fit of the data and surrounding shaded areas 
are 95% CIs of the regression curve.  
Figure 6.7: Individual trajectories of 17 children from ART-96W with at least 3 
measures of naïve B-cell output from enrolment to 360 weeks follow-up. 
 
	   171 
Impact of CHER ART-strategies on naïve B-cell output:  
A) Deferred ART versus early ART 
There was no significant difference in naïve B-cell output between deferred (ART-
Def) and early ART (ART-96W) at all available paired time-points, although there 
was a trend towards lower naïve B-cell output in ART-Def in the first 4 weeks of the 
trial (Figure 6.8).  
 
B) ART-interruption in the second or third year of life 
ART-96W at 60 weeks had significantly higher naïve B-cell output over ART-40W 
(Welch’s t-test p=0.004, Figure 6.9). At 60 weeks ART-96W were receiving 
continuous ART, however ART-40W had interrupted ART at 40 weeks, although by 
60 weeks 71% of these samples were from children already back on ART. No further 
significant differences were seen at 96 weeks and 248 weeks, with 74% and 71% 
back on ART respectively in ART-40W, and 50% back on ART at 248 weeks in ART-
96W. There was no difference in naïve B-cell output between those on ART or still off 
ART at 248 weeks in ART-40W (n=15 vs. 6, p=0.3), however in ART-96W those off 
ART at 248 weeks had significantly higher naïve B-cell output (n=9 vs. 9, p=0.02). 
There were no significant differences identified when either ART-40W or ART-96W 
were compared with HIV-uninfected children from the CWC. 
Figure 6.8: Naïve B-cell output in Log10(cells/day) in deferred ART (ART-Def, red) 
versus early ART (ART-96W, blue). 
 
In these children ART-Def, in red, commenced ART at median 27 weeks of age and stayed on 
continuous ART. ART-96W, in blue, initiated ART at median 7 weeks until approximately 2 
years of age, then interrupting ART for a median of 89 (IQR 17-145) weeks. (Numbers in each 
age-group were: ART-Def n=10 vs. ART-96W n=18 at enrolment; then respectively 4 vs. 17 at 
4 weeks; 2 vs. 22 at 12 weeks; 26 vs. 19 at 40 weeks; 16 vs. 15 at 96 weeks; and n=9 vs. 10 
at 360 weeks). No significant difference was identified between the arms compared at each 
time-point. 
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C) Overall long-term effect of CHER strategies 
At 7-8 years of age there was no difference in naïve B-cell output detected between 
the 3 trial arms (ART-Def n=9, ART-40W n=14, ART-96W n=10, ANOVA p=0.52), 
and no difference compared to age-matched HIV-uninfected healthy children (n=23). 
 
  
Figure 6.9: The effect of ART-interruption on naïve B-cell output. 
Both ART-40W and ART-96W started ART at median 7 weeks, and either interrupted ART in 
the second year of life after 40 weeks of ART (ART-40W, green) or in the third year of life after 
96 weeks of ART (ART-96W, blue). Approximate age-matched healthy HIV-uninfected children 
are represented in gray for comparison. A significant difference was seen between the groups 
at 60 weeks (ANOVA p=0.006) but not subsequently. The number of children’s specimens 
examined were as follows: at 60 weeks ART-40W n=21 vs. ART-96W n=21 vs. CWC n=17; at 
96 weeks n=23 vs. 15 vs. 22; at 248 weeks n=21 vs. 18 vs. 14 respectively.  
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6.2.3 Naïve B-cell output and thymic output 
There is a trend towards a significant correlation between naïve B-cell output and 
thymic output in healthy children (CWC cohort, Pearson’s correlation p=0.07) and 
HIV infected children (all CHER arms combined, p=0.07) (Figure 6.10) although the 
spread of data is wide (R2=0.02 and 0.01) and therefore the relationship is unlikely to 
be linear and directly related. There were no differences in the relationship between 
naïve B-cell output and thymic output in each of the CHER arms. Six CWC and 3 
CHER children with both low naïve B-cell and thymic output were further 
investigated, however no association was identified with these combined low naïve 
cell outputs and any of the clinical or immunological data available. 
 
Examining the trajectories of thymic output and naïve B-cell output with age showed 
the peak thymic output corresponds to the peak naïve B-cell output in the first year of 
life in both CWC and ART-96W (Figure 6.11; NB. ART-96W was examined 
separately from the other arms of CHER so that the effect of the ART-strategies 
would not confound the overall impression). Both sets of children exhibit declining 
naïve B-cell output to 5-6 years of age while thymic output remains fairly constant. 
Following the trough of naïve B-cell output, both sets of children demonstrate a 
subsequent increase albeit greater in ART-96W. The median regression curve of 
ART-96W does not remain within the confidence interval calculated since there were 
no data between 5 and 6.5 years and only 10 data points between 6.5-8 years.  
Figure 6.10: Relationship between naïve B-cell output and thymic output in healthy HIV-
uninfected children and HIV-infected children from CHER. 
 
The CHER specimens included here are from the combination of arms: ART-Def, ART-40W 
and ART-96W, on and off ART (n=285); CWC specimens n=288. Detailed analysis within arms 
and by ART status did not reveal any further association between thymic output and naïve B-
cell output. 
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Naïve B-cell output and functional antibody responses 
The relationship between estimates of KRECs or naïve B-cell output was explored 
within individual CHER participants with a range of antibody responses measured 
after infant PCV7 and Hib vaccinations and again at 2 years of age (Methods section 
2.2). Pearson’s correlation was found to be significant with several serotypes in 
infancy and at 2 years of age, however on examining the data this relationship was 
skewed by one child with extremely high naive B-cell output (log 10.4 naive B-
cells/day) and corresponding extremely high antibody responses. Removing this one 
child from the analysis left nothing significant whatsoever. In addition, no relationship 
was detected between naïve B-cell output and quantity of HIV-specific antibody (anti-
gp120 IgG, methods described in section 2.4.6, results in Chapter 7) measured in 
CHER participants at 84 weeks of the trial, adjusted by age of ART-initiation (r=0.09, 
p=0.6). However, circulating B-cell count (CD19+ lymphocytes) and naïve B-cells 
(CD19+IgD+CD27- lymphocytes) were found to correlate with serum titres of 
antibodies against pneumococcal serotypes 4 and 18C (Pearson’s correlations were 
all p<0.004, r=0.5). 
  
Figure 6.11: Regression of thymic output and naïve B-cell output. 
 
Regression curves of thymic output (blue) and naïve B-cell output (red) in Log10(cells/day) 
with 95% confidence intervals of the line of best-fit. Healthy HIV-uninfected children (CWC, 
n=288) versus data from HIV-infected children on ART from 7 weeks of age until 96 weeks, 
restarting after a median of 38 (IQR 5-145) weeks ART-interruption (ART-96W, n=141 
samples from 83 children). 
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6.3 Discussion 
 
This chapter has been largely exploratory since little is known about normal KREC 
levels and the value of KREC measures in reflecting naïve B-cell output, in children 
and particularly in HIV-infected children.  
 
The measures of KRECs and naïve B-cell output obtained from healthy HIV-
uninfected children could form a reference dataset that might be useful in clinical 
practice for a number of paediatric conditions such as bone-marrow transplant, 
primary immunodeficiencies and potentially HIV-infection. Five different 
representations of the data have been proposed: KRECs/PBMC, KRECs/ml blood, 
KRECs/million B-cells, KRECs/million naïve B-cells and naïve B-cell output in 
cells/day. Although all measures reduce fairly rapidly after 2 years of age, the most 
biologically appropriate measure is probably the estimation of naïve B-cell output in 
cells/day. The naïve B-cell output formula accounts for the rate of naïve B-cell 
proliferation in the periphery, although the formula is limited since it assumes the 
mean KREC content of a naïve B-cell entering the peripheral circulation to be 0.6 as 
per the thymic output formula, and this is currently unknown and requires verification. 
However, each of the other representations do have their own value since because 
in the clinical setting it may not be practical to perform the intracellular 
immunophenotyping required to quantify Ki67 and thereby estimate naïve B-cell 
output. KRECs/ml of blood may somewhat overcome the bias of peripheral 
proliferation over using KRECs per unsorted PBMCs although would not be as 
accurate as naïve B-cell output. KRECs/million B-cells and KRECs/million naïve B-
cells also have their value as the measure is localised to the cell subsets of origin 
and gives an idea of the proportion of new circulating naïve B-cells. 
 
Not dissimilar to the predicted thymic output curve, the naïve B-cell output curve 
using KRECs and B-cell flowcytometry steeply increases from birth to peak around 1 
year of age, followed by a rapid decline until 6 years and a lower peak between 6 
and 12 years. The high naïve B-cell output coincides with the rapid development of 
the child’s immune system during the first year of life. The subsequent rapid decline 
in naïve B-cell output may reflect the physiological activity of the bone marrow or 
may also be influenced by the trafficking of naïve B-cells to the lymphoid organs. The 
second smaller peak may be related to growth and hormonal changes leading up to 
puberty, or could be an anomaly in view of the fact that there was comparatively less 
data during this age (n=24) and the confidence interval appears far wider here. 
  
	   176 
The analysis of this chapter suggested there might be a positive correlation between 
naïve B-cell output and thymic output, perhaps reflecting progenitor cell development 
in the bone marrow of both T- and B-cell precursors; however the distribution of data 
is broad and it is likely that a multitude of factors are involved. Interestingly, it 
appears that naïve B-cell output is less variable than thymic output overall, although 
it is not clear whether this is a true finding or attributable to the stability of laboratory 
measures of TRECs, KRECs and flowcytometry on cryopreserved cells. 
 
Naïve B-cell output may indirectly be increased with ART, as naïve B-cell output was 
overall significantly higher in HIV-infected children on ART compared to their 
uninfected counterparts for the first two years of life. This is reinforced by the decline 
of naïve B-cell output during ART-interruption after 96 weeks of ART, although 
further research is required to explore these important dynamics. 
 
The numbers between groups comparing different ART strategies used by CHER 
were not always optimal especially between ART-Def and ART-96W. There was a 
trend towards lower naïve B-cell output in ART-Def, suggesting that longer time 
before commencing ART is likely to be inferior to early ART at least until 2 years of 
age. However, despite delayed commencement of ART, individuals in ART-Def, on 
continuous ART appeared to sustain the trajectory of naïve B-cell output to those 
who interrupted ART after 96 weeks. This pattern was also seen with lower naïve B-
cell output in ART-40W at 60 weeks after they had interrupted for 20 weeks 
compared to ART-96W who had not yet interrupted, inferring that naïve B-cell output 
is being preserved by ART. The 3 different CHER strategies appear to have served 
the participants fairly in terms of preserving naïve B-cell output since by 5 and 7-8 
years of age no significant differences were detectable between the trial arms. 
 
In summary, this chapter has explored various representations of naïve B-cell output, 
the distribution in healthy HIV-uninfected children, the impact of the CHER ART-
strategies upon naïve B-cell output and relationship with functional antibody 
responses. These analyses suggest that HIV-infected children on ART have higher 
naïve B-cell output than their uninfected counterparts, that deferred ART and ART-
interruption are associated with lower naïve B-cell output compared to early or 
continuous ART, and that the relationship with thymic output or functional antibody 
responses are likely to be non-linear and multifactorial. However, any interpretation 
of these exploratory findings are tentative since there are numerous areas of further 
research required to validate these results, primarily to verify the assumptions made 
by the mathematical model. 
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Chapter 7 
 
HIV-antibody seronegativity with early 
antiretroviral therapy 
 
7.1 Background  
 
In the absence of breastfeeding and early ART, infants acquire HIV either in-utero or 
at delivery and develop HIV-antibody responses by mean age 7.4 months [190]. 
Measurement of HIV-antibody is not recommended for HIV diagnosis below 18 
months due to the persistence of maternal antibody [190, 191]; beyond 18 months 
HIV-antibody assays are used to diagnose and re-confirm HIV-infection. However, 
with early ART and effective viral suppression, there have been increasing case 
reports of infants not developing HIV-specific antibodies [47-51], probably due to 
reduced viral antigen exposure while maternal antibody is lost. Although rare, the 
decline of antibody titres has also been reported in HIV-infected children and adults 
on continuous ART initiated after infancy [192, 193].  
 
The incidence of seronegativity in HIV-infected children is not known, and the 
management implications are potentially important as absence of detectable HIV-
antibody could lead to misdiagnoses and inappropriate ART cessation. This is 
particularly relevant in many resource-limited settings where, for financial and 
logistical reasons, infants are started on ART following a single DNA PCR, and 
subsequent reconfirmation of HIV-status on ART using antibody tests then becomes 
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problematic. Since current ART guidelines recommend immediate ART for all HIV-
infected children under 5 years [44], it is important that the frequency and key 
predictors of seronegative status in HIV-infected children receiving early ART are 
understood, so that antibody results may be correctly interpreted, especially where 
HIV DNA or RNA tests are not readily available. In addition, neither the short nor 
long-term clinical, immunological or virological consequences of seronegativity in 
HIV-infected children treated early in infancy are known. This maybe particularly 
relevant during subsequent planned or unplanned ART interruption where 
pronounced viral rebound after discontinuation of ART has been reported in HIV-
infected seronegative children [49, 50]. 
Within a week of detectable HIV-viraemia in adults and children over 6 months of 
age, B-cell responses can be detected as antigen-antibody complexes [194] followed 
in days by circulating anti-gp41 antibodies and then anti-gp120 antibodies after 
several weeks [195]. These HIV binding antibodies are measured in standard 
diagnostic tests and, in contrast to neutralising antibodies, do not exert selective 
immune pressure on HIV [196]. Neutralising antibodies bind cell-free virus, 
preventing the virion from infecting host target cells, and thereby disrupting 
subsequent replication [195]. As HIV progresses the quantity of binding antibodies 
might infer the presence of neutralising antibodies [195]. B-cell depletion results in 
decline in both binding and neutralising antibodies, and a subsequent rise in plasma 
viral load rise [32], however in the context of ART initiated in early infancy HIV-
seronegativity does not reflect B-cell depletion since viraemia is typically controlled 
with effective ART, nor should it reflect viral eradication [192], instead it is likely to be 
simply due to lack of antigenic stimulation.  
 
This chapter describes the frequency of HIV-seronegativity by comparing antibody 
results taken from children who started early ART compared with deferred ART in the 
CHER trial. This work has been published in Lancet Infectious Diseases (Appendix 
XVII, [197]). The methods are described in section 2.4.6. 
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7.2 Results 
 
7.2.1 HIV-antibody in early versus deferred ART 
One hundred and nine plasma samples were available from 143 children randomised 
to ART-96W and 75 samples from 125 children in ART-Def. 34 ART-96W and 50 
ART-Def samples were not tested because: plasma not stored (10 vs. 11) or used for 
other reasons (1 vs. 10), children lost to follow-up (11 vs. 6), withdrew from study (1 
vs. 1) or died prior to trial week 84 (11 vs. 22). The following numbers of specimens 
were processed for each HIV antibody assay: anti-gp120 ELISA (109 ART-96W vs. 
75 ART-Def), automated serology (107 vs. 75), and rapid antibody test (101 vs. 74) 
due to volume of sample available.  
 
There were no significant differences between ART-96W and ART-Def children in 
gender, ethnicity, CD4 count/percentage or viral load at enrolment or week 84 (Table 
7.1). Most children in the CHER trial were formula-fed, with no difference between 
treatment groups (ART-Def 67 [89%] of 75; ART-96W 100 [92%] of 109). As per trial 
design, a significant difference exists in median age at ART initiation between ART-
96W and ART-Def, median 7 (7-8) weeks versus (23 (IQR 18-32) weeks 
respectively). Of all 184 children’s samples analysed, 94% had received at least 24 
weeks of ART by trial week 84. In ART-Def 67/75 (89%) had commenced ART by 
week 84. Of the 8 children who were not on ART, 4 started aged 3-5 years and 4 
remained off ART; all 8 were seropositive.   
 
Children in ART-96W were significantly more likely to be seronegative than ART-Def 
by the two commercial tests. 49 (46%) ART-96W versus 8 (11%) ART-Def were 
seronegative by automated serology (p<0.0001), and 54 (53%) versus 8 (11%) by 
rapid antibody test (p<0.0001, Table 7.2). Although most results were concordant 
between automated serology and the rapid test, 9 children in ART-96W with weakly 
reactive automated results had negative rapid tests. The 8 seronegative children 
from ART-Def started ART at median age 9.9 weeks (range 7.8-22.9), with median 
CD4 count 1521 cells/µl (range 939–2862) or CD4% 33 (31-43) and enrolment viral 
load at upper limit of detection (750,000 copies/ml).  
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Table 7.1: Characteristics of children whose plasma were analysed for HIV-antibody. 
*Difference in numbers of each group detailed in text. **Age of ART-initiation differed 
significantly between arms, as per CHER design.  
 ART-Def ART-96W 
 n (%) 
No. samples 75* (41) 109* (59) 
Gender male 33 (44) 48 (44) 
Ethnicity Black 
[Remaining mixed race] 
 
74 (99) 
 
105 (96) 
No. reached primary 
outcome in CHER trial  
18 (24) 
 
16 (15) 
 
 Median [IQR] 
CD4 at enrolment: 
- Absolute count (cells/µl) 
- Percentage 
2,039 
[1,587 – 2,861] 
34 [28 - 41] 
2,067 
[1,520 -2,743] 
35 [30 - 39] 
CD4 at 84 wks. 
- Abs count (cells/µl) 
- Percentage  
1,623 
[1,330 – 2,074] 
34.2 [31 – 40] 
1,641 
[1,247 – 2,065] 
36.9 [31.7 – 42.1] 
Log10 viral load at enrolment 5.88 
[5.68-5.88] 
5.88 
[5.72-5.88] 
Percentage with viral load 
<400 copies/ml at 84 wks. 
60 (80%) 91 (83.5%) 
Log10 viral load at 84 wks of 
trial in unsuppressed 
4.71 
[3.78-5.16] 
4.17 
[4.01-4.79] 
Age of starting ART 
(weeks)** 
22.9 
[18.2 – 31.2] 
7.3 
[6.8 – 8.3] 
 
Table 7.2: Comparison of automated serology (“Serology”) and rapid antibody test 
(“Rapid”) between ART-Def versus ART-96W at CHER trial week 84.  
 ART-Def 
n (%) 
ART-96W 
n (%) 
 
 Serology Rapid Serology Rapid p-value 
Total processed 75 74 107 101  
 
<0.0001* 
Reactive 62 (83) 64 (86) 38 (36) 41 (41) 
Weakly reactive 5 (7) 2 (3) 20 (19) 6 (6) 
Non-reactive 8 (11) 8 (11) 49 (46) 54 (53) 
Insufficient 0 1 2 8 
Sensitivity 89.3% 89.1% 54% 56.5%  
*Chi-square test for difference between CHER arms is p<0.0001 for both routine antibody test 
methods (serology and rapid antibody tests). Sensitivity of these antibody tests was 
calculated based on known HIV-infection in all CHER participants, diagnosed by HIV DNA 
PCR and confirmed with a RNA viral load >1000 copies/ml in all children at enrolment. A 
weakly reactive test will yield a weak line present in the test area and follow-up testing is 
recommended to confirm an initial weakly reactive result. 
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Total IgG levels were similar in both ART-96W and ART-Def (median 25,993 µg/µl 
[IQR 17,779-44,241] versus 25,530µg/µl [IQR 15,568-40,391], p=0.28). However, the 
quantitative anti-gp120 ELISA showed significant differences between ART-96W 
(median 230 µg/µl [IQR 133–13,129]) and ART-Def (6,870 µg/µl [IQR 1,706–
53,645]), p=0.04, Figure 7.1). In all children, higher anti-gp120 IgG were strongly 
associated with seropositivity by automated serology with median 162µg/µl [IQR 102-
223] in seronegative versus 9,984 µg/µl [630-70,469] in seropositive children, 
p<0.0001. The 8 children from ART-Def who were not on ART by week 84 
demonstrated very high anti-gp120 IgG (median 336,687 µg/µl). No anti-gp120 IgG 
was detected in any of the 18 HIV-uninfected controls, whereas all samples from the 
184 CHER participants had detectable anti-gp120 IgG.  
 
By automated serology, starting ART between 12-24 weeks old had 13.7-fold higher 
odds for seropositivity at trial week 84, compared to starting ART aged 0-12 weeks 
(95% CI: 3.1–60.2, p=0.001). All 33 children starting ART after 24 weeks old were 
seropositive at week 84. Figure 7.2A presents frequency of HIV antibody 
seropositivity by automated serology at week 84 according to age at ART initation. 
The significant association between age at ART initiation and seropositivity also 
holds when the analysis is restricted to ART-96W only. 
Figure 7.1: Distribution of HIV-specific antibody between deferred and early ART. 
  
Distribution of anti-gp120 antibody by ELISA between ART-Def (n=75) and ART-96W 
(n=109) at CHER trial week 84 (p=0.04). Anti-gp120 IgG was detectable in all children. 
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Logistic regression analysis demonstrates a strong association between serostatus 
and age of ART initiation (OR 1.24 95% CI 1.12-1.38), which reflects a 24% increase 
in the odds of seropositivity for every week before ART is initiated (Figure 7.2B. The 
effect of viral load (estimated by area-under-the-curve viral load until week 84) is also 
Figure 7.2: Frequency and probability of HIV antibody seropositivity. 
 
Figure 7.2A: Frequency of HIV antibody seropositivity by automated serology at 84 weeks of the 
CHER trial (~2 years of age) according to age of ART initation. The bar chart demonstrates the 
percentage of children who were seropositive at 2 years depending on whether commencing 
ART at 0-12, 12-24 or after 24 weeks of age (Blue = seronegative, Red = seropositive; here, a 
weakly reactive serology was interpreted as seropositive).  
Figure 7.2B: Estimated probability of HIV seropositivity at ~2 years of age derived from a logistic 
regression model fitting antibody response on age at ART initiation as linear in a logit scale. 
Here, the red data represents where weakly reactive serology was interpreted as seropositive, 
and the black data represents weakly reactive serology being seronegative; the circles 
represent the proportion of seropositivity in equally-sized groups for age at ART initiation; 
individual data-points are represented by the red or black dots at 0.0 (seronegative) or 1.0 
(seropositive) on the probability y-axis. The inset table gives the odds or odds ratio and 95% 
confidence intervals of the two logistic regression models. 
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significant with OR 1.67 (95% CI 1.19-2.33), increasing the odds of seropositivity by 
67% for every 100 copies of HIV RNA per militre blood. When the effect of viral load 
on seropositivity is adjusted for age of ART initiation, and vice-versa, both remain 
significant with age of ART initiation decreasing to OR 1.14 (95% CI 1.0-1.32), and 
viral load OR 1.59 (95% CI 1.1-2.3) (Table 7.3). CD4 count, and CD4 percentage 
when adjusted for viral load did not affect the odds of seropositivity. P-values for the 
null hypothesis that age at ART initiation doesn’t affect the log-odds are highly 
significant in both models, where weakly reactive was interpreted as positive or 
negative (p<0.0001). In addition, older age at ART initiation was also associated with 
increased anti-gp120 IgG (Spearman’s rank correlation p=0.002, coefficient=0.35).  
 
Table 7.3: Univariate and adjusted logistic regression of serostatus against ART 
initiation age, viral load and CD4%. 
 Univariate analysis Adjusted analysis 
 OR 95% CI p-value OR 95% CI p-value 
ART initiation age 1.24 1.1-1.4 <0.0001 1.15 1.0-1.3 0.06 
AUC viral load 1.67 1.2-2.3 0.003 1.59 1.1-2.3 0.02 
CD4% 1.0 0.9-1.0 0.04 1.0 0.9-1.1 0.71 
 
 
7.2.2 HIV-antibody and HIV RNA viral load 
In all children, cumulative log-viral load from study enrolment until week 84 correlated 
with anti-gp120 IgG levels (Spearman’s rank correlation p<0.0001, coefficient=0.54) 
(Figure 7.3). Children with high viral exposure had high HIV-specific antibodies; 
however children with less cumulative viral exposure (i.e. <7.8 log) showed greater 
variation in HIV-specific antibody levels.  
 
Neither serostatus nor quantity of anti-gp120 IgG appeared to correlate with 
subsequent time spent off ART after stopping at week 96 in ART-96W (median 54.9 
weeks off ART in these 109 children [IQR 12.7 – 140], Spearman’s rank correlation 
both p>0.26, coefficient=0.11). All 71/109 (65%) children who had viral load available 
during ART-interruption exhibited HIV viral rebound during interruption. However, 
examining the viral loads revealed a contrasting pattern of HIV RNA resurgence by 
serostatus during interruption (Figure 7.4). Although not statistically significant, 
seronegative children have a median 0.44-log higher HIV viral rebound than 
seropositive children at first viral load during ART-interruption; and subsequently 
seronegative children began to suppress their viral load by the second measurement, 
whereas seropositive children demonstrated an increasing viral load.  
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Figure 7.3: Relationship between quantitative anti-gp120 IgG and cumulative viral 
load from enrolment until trial week 84. Cumulative viral load was summarized by area 
under the time-versus-log(viral load) curve from randomization to week 84. Spearman’s 
rank correlation p<0.0001, coefficient=0.54. 
 
Figure 7.4: HIV RNA viral load resurgence after ART-interruption by serostatus. 
 
A) First viral load after ART-interruption (median 8, IQR 8–20 weeks from interruption, n=72, 
t-test p=0.36). B) Second viral load after ART-interruption (median 20, IQR 20–34 weeks from 
interruption, n=54, t-test p=0.49). C) Change in viral load during ART-interruption from first to 
second available viral load, quantified in change of HIV RNA copies/ml per day (n=54, t-
test=0.28).  
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7.3 Discussion 
 
We have shown that nearly half of children starting ART in the first 12 weeks of life 
are seronegative for antibodies to HIV using commercial assays at approximately 2 
years of age, compared with only 6% of infants starting ART aged 12-24 weeks and 
none starting ART thereafter. Furthermore, concentrations of antibodies to HIV 
gp120 were significantly correlated with HIV viral loads suggesting an important role 
of antigenic stimulation in antibody production.  
 
Although HIV-seronegativity has been previously described [47-50], this is the first 
study to formally compare HIV antibody values taken at the same age from children 
who started early ART compared with deferred ART in a randomised trial. A key 
implication of our results is that in children with early diagnosis and treatment before 
6 months, a negative antibody test is a frequent occurrence, particularly among those 
starting before 12 weeks. All ART-96W children experienced HIV-RNA rebound 
following ART interruption at week 96; thus, a negative antibody assay does not 
indicate absence of HIV. 
 
For numerous reasons it may be necessary to reconfirm HIV-status in children on 
ART from early infancy. The accessibility, accuracy and false positive rates of HIV 
proviral DNA PCR in some resource-limited countries are far from ideal, especially 
with older assays [198], and children are started on ART without confirmation of HIV 
status [199]. There are anecdotal reports that caregivers not infrequently doubt the 
initial diagnosis and request confirmation from healthcare practitioners, or purchase 
over-the-counter rapid antibody tests, which are increasingly available. When faced 
with a negative HIV-antibody result it may be difficult to convince families to continue 
therapy, which may ultimately be to the detriment of the child.  
 
In view of the limitations of present commercial antibody tests in this setting, WHO 
stresses the importance of repeating HIV DNA PCR in children just before ART is 
initiated, but not waiting for the results before ART is started. If discordant with the 
initial DNA PCR, a third tie-breaker DNA PCR would guide any decision about 
stopping ART. Where confirmation of status is requested in a child started on ART 
before 6 months old, DNA PCR should be repeated and HIV-antibody tests should 
not be used. If the DNA PCR result is negative and families insist on stopping ART, 
interruption should be undertaken with staggered stopping for non-nucleoside 
reverse-transcriptase inhibitors [200], and might be followed with antibody testing. 
Preliminary data from quantitative DNA PCR analysis in CHER show that even 
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children with negative DNA PCR after early ART have viral resurgence after stopping 
ART [51, 201]. 
 
In view of increased focus on early treatment strategies to limit reservoir size [202], 
more sensitive simple diagnostic tests are needed. Our data confirm previous studies 
showing that rapid HIV antibody tests are less sensitive than automated serology 
[203]. Considering all CHER participants tested had detectable anti-gp120 IgG, 
clinical tests using these envelope antigens might improve diagnostic accuracy 
alongside proviral DNA assays and be cheaper than viral load testing. 
 
Analysis demonstrated that age of ART initiation and viral load are strong predictors 
of serostatus, and adjusted analyses demonstrate that they both have independent 
contributions. The association between cumulative plasma HIV RNA and anti-gp120 
IgG levels suggest that antibody production is related to HIV antigen-stimulation. 
Whether persistence of anti-gp120 IgG represents slow decay or is a response to low 
levels of HIV replication, requires serial measurements alongside comprehensive 
analysis of cell-associated HIV DNA and RNA. Detecting low-level replication despite 
sustained virological control could support investigating potential novel targets for 
eradication strategies. 
 
There was no correlation between levels of anti-gp120 IgG and duration of time 
tolerated off ART in ART-96W; however studies using quantitative measurements of 
DNA PCR alongside more detailed mathematical analysis of CD4 and viral load 
trajectories throughout ART-interruption in CHER are underway. 
 
We cannot extrapolate our results to all children starting ART over 24 weeks old 
since the number of children starting ART after 6 months in CHER was small and 
they were likely to be symptomatic. Other limitations include the fact that children 
from ART-Def had fewer samples than ART-96W, due mainly to higher numbers of 
deaths. However, this difference might, if anything, increase the proportion of early 
treated children being seronegative. We also cannot comment about HIV-antibody 
status among breastfeeding children starting ART, as most children in CHER were 
formula-fed.  
 
Due to the study design of CHER, the effect of age of ART-initiation is 
indistinguishable from duration of ART until trial week 84. However, in adults loss of 
antibody is not reported unless the individual was either receiving pharmacological 
immunosuppression or initiated ART rapidly after primary infection [204], therefore 
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this suggests that age of ART-initiation plays an important role in the suppression of 
HIV-antibody.  
 
In addition to age and timing of ART-initiation, HIV-antibody status and quantity is 
likely to depend on timing of transmission, maternal virus inoculum size and strength 
of immunological responses. Although routine antibody tests to confirm HIV-status 
cannot be recommended in this population, the strong relationship between 
cumulative viral load and anti-gp120 IgG levels, support a possible role for antibody 
quantification to assess extent of virological control or reservoir size [205]. These 
assays might also be used to improve clinical management since high HIV-antibody 
quantity or seropositivity after early-ART could be a marker of poor adherence, 
inappropriate dose, drug absorbance/metabolism issues, or a combination of these 
factors. 
 
In conclusion, this study demonstrates that almost half of the children starting ART 
within 12 weeks of birth and 6% of those starting at 12-24 weeks were seronegative 
by 2 years of age. Therefore, clinical results from automated serology and rapid 
antibody assays cannot be used as evidence for HIV-infection among these children. 
WHO is planning to update early infant diagnostic guidelines in 2015 (Penazatto M, 
WHO Paediatric HIV Department, personal communication) and should take account 
of our findings. Clear guidance is needed for children of caregivers seeking HIV-
status confirmation of their children, along with monitoring strategies for children who 
interrupt ART because the caregiver questions the original diagnosis of HIV. 
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Chapter 8 
 
HIV proviral DNA and early antiretroviral 
therapy 
 
8.1 Background  
 
The introduction of antiretroviral therapy (ART) early in life has effectively reduced 
morbidity and mortality [45, 68] and optimised CD4 cell reconstitution [206]. Although 
HIV virological suppression is achievable in most children, HIV remains latent and 
integrated within the host genome in subpopulations of infected cells [207]. This 
reservoir, commonly estimated by quantitative measures of HIV proviral DNA [208, 
209], is found in many cell types including CD34 stem cells, central nervous system 
(CNS) macrophages, astrocytes and dendritic cells [210-212]; however CD4 memory 
cells are considered a critical reservoir due to their longevity, homeostatic cell 
division and potential for reactivation on antigen encounter [213].  
 
In the context of sustained virological suppression, there may be two or three phases 
in decay of proviral DNA reflecting the different half-lives of various cell populations 
[62]. Although HIV proviral DNA decay kinetics appear to vary over time and between 
individuals [50, 214], in a study of 14 children aged 3-14 years the reservoir was 
found to decay with a median half-life of 5 months over the first 1-9 months of ART, 
decreasing to a half-life of 30 months thereafter [214]. HIV eradication on stable 
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continuous ART might therefore only be possible after more than a decade of ART. 
Adult studies have reported reduced latent reservoirs in patients commencing ART in 
the early course of infection compared to the chronic phase [215-217]. Similarly, 
paediatric studies are increasingly demonstrating the same importance of early ART-
initiation in reducing reservoir formation [202, 218, 219]. Numbers in these studies 
however are small and data is largely descriptive since patients are typically from 
resource-rich settings and have heterogeneous ART histories and demographics.  
 
There is increasing interest in viral reservoirs since reports of functional cures in 
adults treated soon after infection [204]. Functional cure is defined as lack of 
detectable virus in the blood with a functional immune system without the need for 
ART, even though HIV can still be detectable within cells with sensitive assays. The 
case report of the “Mississippi Baby” has focused attention on early ART followed by 
interruption in children. This infant was given ART from 31 hours of age and rapidly 
suppressed plasma HIV-RNA to below detectable limits. The mother discontinued 
ART 15-18 months of age and when retested at 23 months of age, the infant was 
well with undetectable plasma HIV-RNA on conventional testing. The infant 
maintained virological suppression for more than 2 years before viral resurgence 
[220, 221] and detailed studies revealed only traces of proviral DNA while off ART. 
Novel approaches to obtaining a functional cure are being pursued, including 
depletion of T-cell subsets known to have integrated HIV DNA, elimination of the 
latent reservoir through activation and clearance mechanisms, and processes that 
interfere with memory CD4 T-cell homeostasis [213, 222, 223]. As these are not 
presently considered viable options for either adults or children, early ART initiation 
remains the therapeutic focus [224]. 
 
Current WHO policy recommends ART for all HIV-infected infants up to 5 years of 
age regardless of CD4 percentage, viral load or CDC staging[44]. In the absence of 
robust clinical trial evidence to support these recommendations, European guidelines 
advise ART for all infants under 1 year and to treat children aged up to 3 years old if 
CDC stage B/C, CD4%<25% (or <1000 cells/ul) or viral load >105 copies/ml [225]. In 
children who have already survived the first year of life, initiation of ART before their 
CD4 count drops below the threshold recommended level by the WHO [226, 227] 
has been linked, using mathematical modeling techniques, to improved long-term 
CD4 outcome [206]. The same may be true for the decay of the proviral DNA 
reservoir [202], since reservoir size has been associated with time to first 
undetectable viral load while on ART [218], reinforcing the aim of rapid suppression 
of plasma viraemia after commencing ART in any child. In addition to early ART, 
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there may be other factors that could enhance reduction of levels of HIV proviral 
DNA such as maintaining stable CD4 counts [228] and reducing immune 
activation[229-231], therapeutic vaccinations [232] and treating co-infections such as 
cytomegalovirus (CMV) or Epstein Barr Virus (EBV) [233, 234]. 
 
It is not known whether the duration of initial therapy is critical in reducing the 
reservoir nor whether ART-interruption within early childhood years might be 
detrimental to reservoir clearance, or even functional for the developing immune 
system [50] by inducing development of HIV-specific antibody responses. ART 
interruption has its benefits of convenience, reduced costs and potential reduction in 
rates of drug-toxicity, side effects and resistance. Although adult studies such as the 
SMART trial have demonstrated significantly higher risk of disease progression with 
structured ART interruption [235], there is less evidence to show the same is true for 
ART-interruption in children. Studies in adult patients who started ART very early in 
their primary infection have shown safety and low disease progression [204, 236, 
237]. Although not encouraged, ART-interruption in children has not been associated 
with adverse clinical, immunological or virological consequences [68, 238, 239] and 
may be an acceptable option for certain situations such as where adherence is an 
insurmountable issue.  
 
Formation and stability of the HIV reservoir in the presence of ART is not well 
understood [240-242], particularly whether its persistence is primarily due to 
longevity of latently infected cells or to low-level replication [243-245]. Further 
knowledge in these areas could be valuable in establishing practical approaches 
towards functional cure in children from high disease-burdened settings. Even in the 
absence of a functional cure, the long-term impact of different ART-strategies on 
reservoir size is now of considerable interest with potential to inform future strategies 
on ART management in childhood. 
 
In this chapter, specimens have been used from CHER to describe the differences in 
the peripheral HIV proviral DNA between early and deferred ART, and where 
possible compare continuous and interrupted ART. The effect of ART-interruption, 
the pattern of decline of HIV proviral DNA in patients on continuous ART and any 
predictive factors that may influence the magnitude of decline have been explored 
such as serostatus, quantitative HIV-antibody, baseline CMV DNA, and 
neurocognitive outcome.  
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8.2 Results 
 
8.2.1 HIV proviral DNA in early versus deferred ART 
Between weeks 40 and 96, proviral DNA in ART-96W decreased from median 420 
[IQR 190-640] to 270 [IQR 80-510] HIV proviral DNA copies per 106 PBMCs (Figure 
8.1A). By week 96 3/73 (4%) children had no detectable HIV proviral DNA. Estimates 
of the peripheral HIV-reservoir from quantification of HIV proviral DNA were 
compared between ART-Def and ART-96W at 96 weeks on trial. Weeks spent on 
ART by trial week 96 was significantly less in ART-Def (median 81 [IQR 70.3–85.9]) 
versus ART-96W (96 [IQR 96-96] weeks, p<0.0001), and there was significantly 
more HIV proviral DNA in ART-Def (median 1000 [IQR 480–2020]) compared to 
ART-96W (270 [80–510] copies of provirus per 106 PBMCs, p<0.0001, Figure 8.1B). 
HIV proviral DNA is higher in those starting ART at an older age (p<0.0001, Figure 
8.1C) and lower in those with a longer duration of continuous HIV RNA suppression 
below 400 copies/mm3 (p<0.0001, Figure 8.1D).  
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Figure 8.1: HIV proviral DNA at week 96 of the CHER trial. 
 
Plot A: HIV proviral DNA from ART-96W at trial week 40 (n=9) and 96 (n=73), no difference in 
levels of proviral DNA (p=0.7). Plot B: HIV proviral DNA in ART-Def (n=45, median 1000 [IQR 
420-2020]) versus ART-96W (n=73, median 270 [IQR 80-510]) at trial week 96 (p<0.0001). Plot 
C: HIV proviral DNA at trial week 96 by age of starting ART (n=118, correlation coefficient = 0.4, 
p<0.0001). Plot D: HIV proviral DNA at trial week 96 by weeks of continuous HIV RNA 
suppression below 400 copies per mm3 (n=118, correlation coefficient = -0.4, p<0.0001). Y-axes 
represent HIV proviral DNA (Log10 copies per 106 PBMCs). 
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8.2.2 ART-interruption and HIV proviral DNA 
Time off ART during interruption was unrelated to levels of HIV proviral DNA at 96 
weeks in ART-96W (p=0.7). We examined change in proviral DNA between 96 and 
248 weeks of the trial. In 17 paired samples from ART-96W who underwent ART-
interruption for a median 45.1 weeks [IQR 34.4–80.4] there was an overall trend 
towards increasing proviral DNA (median +250 [IQR +1530 to +6860] copies of 
provirus per 106 PBMCs, t-test p=0.07, Figure 8.2A).  In contrast, in 41 paired 
samples from ART-Def on continuous ART, there was no significant change in 
proviral DNA (median decrease 140 [IQR -1190 to +900] copies of provirus per 106 
PBMCs, t-test p=0.6).  
 
The effect of time off ART in the first (ART-Def, n=75), second (ART-40W, n=56) or 
third (ART-96W, n=44) year of life was assessed by comparing HIV proviral DNA 
between the three different treatment strategies at 248 weeks. In the children who 
fulfilled the selection criteria at 248 weeks (≥24 weeks of ART and two consecutive 
undetectable plasma HIV RNA ≥3 months apart), there was no significant difference 
between the three arms in total time spent on ART from enrolment until 248 weeks  
(median 229 [IQR 215-235] weeks for ART-Def, 226 [203-244] for ART-40W, 224 
[183-248] for ART-96W; ANOVA p=0.5). Similarly, there was no significant difference 
at 248 weeks between the 3 arms in HIV proviral DNA (median 950 [IQR 240-2950] 
copies of provirus per 106 PBMCs for ART-Def, 1250 [260-3870] for ART-40W, 690 
[200-4080] for ART-96W; ANOVA p=0.5, Figure 8.2B). In univariate analyses, HIV 
proviral DNA decreased with time on ART (p<0.0001, Figure 8.2C) and weeks of 
continuous HIV RNA suppression below 400 copies/mm3 (p<0.0001, Figure 8.2D). 
Greater duration of ART received by 248 weeks was significantly associated with 
lower levels of proviral DNA, however it is clear from the plots that some children had 
low levels of provirus despite a relatively short duration of ART or weeks of 
continuous HIV RNA suppression and others had high proviral DNA, despite longer 
time on ART.  
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Figure 8.2: HIV proviral DNA at week 248 of the CHER trial. 
 
Plot A: Change in HIV proviral DNA from trial week 96 to 248 by CHER trial arm, comparing 
continuous ART (ART-Def, n=41 children who had samples stored from both weeks 96 and 
248) with interrupted ART (ART-96W, n=17 children with samples from both weeks 96 and 
248, median interruption 45.1 [IQR 34.4 – 80.4] weeks). Welch’s t-test for difference in 
provirus from 96 to 248 weeks between ART-Def and ART-96W p=0.07. Plot B: HIV proviral 
DNA in ART-Def (n=75), ART-40W (n=56) and ART-96W (n=44) at 96 weeks of trial 
(ANOVA p=0.5). Plot C: HIV proviral DNA at trial week 248 by duration of ART received by 
248 weeks (n=175, correlation coefficient = -0.35, p<0.0001). Plot D: HIV proviral DNA at 
trial week 248 by weeks of continuous HIV RNA suppression below 400 copies per mm3 
(n=175, correlation coefficient = -0.24, p<0.0001). Plot A y-axis represents change in 
quantity of HIV proviral DNA represented in copies of provirus per 106 PBMCs and has been 
shortened to better visualize the data distribution from -17000 to -10000 removing one data-
point from ART-Def, and from 28000 to 20000 removing 2 data-points from ART-96W. Plots 
B-D y-axes represent quantity of HIV proviral DNA  (Log10 copies per 106 PBMCs). 
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8.2.3 Determinants of HIV proviral DNA  
Fifteen children from ART-Def on continuous ART each had 3-5 measures of HIV 
proviral DNA available between 84 and 252 trial weeks (Figure 8.3). As a group, HIV 
proviral DNA declined over the 156 weeks examined. However, one child had a peak 
at 156 weeks and six children had increasing provirus towards 252 weeks.  These six 
children were all HIV-seropositive at 84 weeks and one child had evidence of a “viral 
break-through” to 4.8log, which subsequently suppressed. The child with the highest 
proviral peak had high levels of CD8 T-cell activation (CD8+HLADR+ 85-67%) but 
much lower CD4+ T cell activation (CD4+HLADR+ 13-10%). There was also high 
proliferation in both CD4 and CD8 memory T-cells (40% and 50% respectively) and 
low naïve CD4 T-cells (8-12% of all lymphocytes). In contrast, the child with the 
lowest reservoir demonstrated comparatively lower levels of activation 
(CD8+HLADR+ 36%, CD4+HLADR+ 5%), low proliferation in memory T-cells 
(CD4+Ki67+ 11%, CD8+Ki67+ 17%), and high naïve CD4 T-cells (42%). 
 
Of all 334 HIV proviral DNA measurements, 60 values in 47 children were ≤100 
copies per 106 PBMCs, with 31 of these children having 36 measures ≤50 copies per 
106 PBMCs including five children with undetectable proviral DNA. These 
undetectable measures occurred at 96 or 248 weeks of the trial, following at least 96 
weeks of continuous ART (further detail shown in Figure 8.4 and Table 8.1). At 96 
weeks 23/73 (31.5%) children from ART-96W had HIV proviral DNA <100 copies per 
106 PBMCs and 3 (4%) had undetectable provirus. The only predictor of HIV proviral 
Figure 8.3: Pattern of HIV proviral DNA change in 15 children from ART-Def on 
continuous ART. 
The y-axis represents quantity of HIV proviral DNA copies of provirus per 106 PBMCs and has 
been shortened to better visualize the data distribution from 1.9x104 to 1.0x104. 
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DNA <100 copies per 106 PBMCs at 96 weeks in children who received early ART for 
96 weeks (ART-96W) was high enrolment CD4 count (p=0.03). However, predictors 
of undetectable provirus at 96 weeks were: longer duration of HIV RNA suppression 
(p<0.0001) and lower levels of anti-gp120 IgG (p=0.02). Negative serostatus for HIV-
antibody was not predictive (p=0.7). 
 
 
 
  
Figure 8.4: Profiles of the 5 children with an undetectable HIV proviral DNA 
measurement at any time during the CHER trial.  
 
Blue = CD4 count (cells/µl), Red = Log10 HIV RNA viral load, green-dashed line = ART-
interruption at 96 weeks; black-dashed line = restart ART after ART-interruption, black 
diamond = undetectable HIV proviral DNA, red diamond = <50 copies HIV proviral DNA. 
Children 1-4 started ART aged 6-7 weeks and interrupted ART after 96 weeks. Child 5 
started at 14 weeks of age and did not interrupt ART. 
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Table 8.1: Characteristics of children with undetectable HIV proviral DNA (copies per 106 
PBMCs). Naïve CD4 T-cells (CD3+CD4+CD45RA+ of all CD4 T-cells) and proliferation of 
memory CD4 T-cells (CD3+CD4+CD45RA-Ki67+ of all memory CD4 T-cells) were taken from 
various time-points from enrolment to trial end. 
 Child 1 Child 2 Child 3 Child 4 Child 5 
CHER arm ART-96W ART-96W ART-96W ART-96W ART-Def 
HIV proviral 
DNA* and 
trial week (w) 
<10 at 96w <10 at 96w <10 at 96w <10 at 248w 17 at 96w 
<10 at 204w 
<10 at 248w 
<10 at 252w 
Enrolment 
Age (weeks)  5.9 6.6 7.4 7.0 8.3 
Viral load 
(Log cp/ml) 
5.7 5.6 4.6 >5.9 >5.9 
HIV DNA 
PCR  
Positive Positive Positive Positive Positive 
CMW DNA 
PCR 
Negative Negative Negative Negative Negative 
During the trial 
Age starting 
ART (weeks) 
5.9 6.6 7.4 7.0 13.9 
Serology at 
trial week 84 
Negative Positive Positive Negative Positive 
HIV Viral 
load (cp/ml) 
<400  
until 96w 
<400 with a 
viral blip to 
4.6log at 48w 
<400  
until 96w 
<400  
until 248w 
<400  
until 252w 
Range of 
CD4 counts 
(cells/ul) 
1903-4028 593-4272 716-1888 773-4497 742-2621 
Naïve CD4 
T-cells 
(median %) 
78.6 
(5 values) 
74 
(6 values) 
52.2 
(2 values) 
91.2 
(6 values) 
80  
(1 value) 
Memory CD4 
proliferation 
(median %) 
17.2 
(5 values) 
13.2 
(6 values) 
13.5 
(2 values) 
22.2 
(6 values) 
11.2  
(1 value) 
ART interruption 
Duration 
(weeks) 
Remained off ART until end of trial  
(minimum 152 weeks) 
56.7 N/A 
Plasma HIV 
viral rebound  
Steep 
rebound to 
5.5log then 
stabilized to 
3.3log 
Lower initial 
rebound to 
4.3log then 
remained 
4log 
Lower initial 
rebound to 
4.4log then 
fluctuation 
4.4 – 5.3log 
Steep 
rebound to 
5.8log then 
dropped to 
4.6log 
N/A 
 
 
HIV serostatus and HIV proviral DNA  
A trend between seronegative status at 84 weeks and lower levels of proviral DNA at 
96 weeks was found in ART-Def (n=39, T-test p=0.08) although not in ART-96W 
(n=68, p=0.92). Quantitative anti-gp120 IgG did not correlate with levels of proviral 
DNA (correlation coefficient=0.04, p=0.66) in either group. In ART-96W, 33/68 
(48.5%) were seronegative at 84 weeks, of which 1/33 (3%) had undetectable 
provirus and 12/33 (36.4%) had <10 copies of provirus per 106 PBMCs at 96 weeks. 
Two of the three children who had undetectable provirus at 96 weeks were 
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seropositive; therefore it was not possible to propose a minimum proviral load that 
might be suggestive of seronegative status. However, the predictive capacity of 
seronegative status at 84 weeks in estimating proviral DNA in children started on 
ART at <12 weeks of age (ART-96W, n=68) was as follows: sensitivity of 90.9% and 
specificity of 8.6% for <100 copies of provirus per 106 PBMCs, with decreasing 
sensitivity and increasing specificity to 36.4% and 77.1% respectively for <10 copies.  
 
Cytomegalovirus and HIV proviral DNA 
A positive CMV DNA-status at CHER enrolment did not correspond to high or low 
levels of HIV proviral DNA reservoir at 96 weeks (median 450 [IQR 100-1000] in 
CMV-negative versus 380 [IQR 200-610] copies per 106 PBMCs in CMV-positive, 
p=0.6), in ART-Def and ART-96W separately and combined (n=97). However, 
although numbers were small, high quantitative CMV viral load (>150 copies/ml) was 
significantly associated with high levels of HIV proviral DNA at 96 weeks (n=12, 
correlation coefficient = 0.67, p=0.02, R2=0.45). All children with undetectable HIV 
proviral DNA at any time during the CHER trial were noted to have undetectable 
CMV DNA PCR at enrolment (Table 8.1). 
 
 
  
Figure 8.5: Cytomegalovirus viral load and HIV proviral DNA at 96 weeks of CHER.  
 
High levels of CMV at enrolment of CHER were significantly associated with higher HIV 
proviral DNA (n=12, correlation coefficient = 0.67, p=0.02, R2=0.45). Y-axis represents 
quantity of HIV proviral DNA  (Log10 copies per 106 PBMCs). 
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8.2.4 Neurocognitive state and HIV proviral DNA 
HIV proviral DNA quantification from 96 and 248 weeks of the trial (n=29 and 65) 
were examined to explore whether peripheral measures of HIV proviral DNA might 
reflect HIV-associated CNS disease and impact upon neurocognitive performance 
(Tables 8.2 and 8.3).  
 
Table 8.2: Characteristics of the CHER participants that had a Griffith’s assessment 
and HIV proviral DNA quantification at trial week 248 (n=65). *Statistical significance in 
age of ART-initiation as per CHER trial design. 
 ART-Def ART-40W ART-96W  
No. 23 25 17  
Male  39% 44% 53%  
 Median [IQR] (range) p-value 
CD4%  38.2 
[36 – 44.2] 
36.8 
[31.5–39.5] 
34.2 
[31.3–41.5] 
0.07 
CD4 count  1176 
[947-1473] 
1157 
[1036-1308] 
1087 
[894-1426] 
0.76 
Continuous viral 
suppression (weeks) 
168 
[120 - 204] 
151 
[84 - 173] 
180 
[140 - 212] 
0.20 
ART start age 
(weeks) 
33.7  
[20.4-40.7] 
7.7 
[7.3 – 9.3] 
7.7 
[7 – 9.1] 
<0.0001* 
 
Time off ART 
(weeks) 
33.7  
[20.4–40.7] 
36.9  
[18.9–59.3] 
21.7 
[7.6–43.6] 
0.10  
Total ART (weeks) 223 
[216 - 234] 
226 
[207 - 245] 
244 
[221 - 255] 
0.14 
Proviral DNA 
 (copies/105 cells) 
36 
[21 – 103] 
(4 – 2,346) 
49 
[18 - 101] 
(3 – 385) 
26 
[16 - 46] 
(0 – 402) 
0.11 (3 arms) 
0.16 (Def vs 40W) 
0.09 (Def vs 96W) 
0.16 (40W vs 96W) 
 Griffith’s scores – Median [IQR] p-value 
Age at Griffith’s 
(weeks) 
264 
[261 – 268] 
260 
[260 - 264] 
262 
[258 - 267] 
0.06 
Locomotor (%) 73 
[67 – 81.5] 
70 
[64 - 76] 
72 
[66 - 78] 
0.37 
Personal and social 
(%) 
68 
[66 – 74] 
66 
[62 - 70] 
66 
[62 - 66] 
0.19 
Language (%) 56 
[51 – 64] 
54 
[48 - 58] 
56 
[50 - 60] 
0.61 
Eye-hand 
coordination (%) 
56 
[50 – 57] 
52 
[44 - 56] 
52 
[48 - 58] 
0.11 
Performance (%) 58 
[51 – 58] 
50 
[46 - 56] 
50 
[48 - 54] 
0.46 
General Griffiths (%) 60 
[57 - 64] 
57 
[53 - 60] 
57 
[54 - 61] 
0.10 
Visual Motor 
integration (VMI)  
91 
[84 - 95] 
89 
[85 - 93] 
89 
[81 - 91] 
0.62 
Visual standard 76 
[63 - 89] 
78 
[74 - 89] 
74 
[63 - 84] 
0.59 
Motor standard 96 
[86 - 100] 
92 
[87 - 96] 
97 
[92 - 100] 
0.81 
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The only significant finding was that levels of HIV proviral DNA at 96 weeks were 
correlated with motor standard score (correlation coefficient = -0.4, p-value=0.03, 
R2=0.12), i.e. higher levels of HIV proviral DNA at 96 weeks were associated with a 
poor motor standard (fine-motor coordination). However by 248 weeks this 
association was no longer present. 
 
Table 8.3: Correlation of Griffith’s assessment variables with levels of HIV proviral DNA 
at 96 and 248 weeks of the CHER trial. Pearson’s correlation coefficient (r). *Indicates 
statistical significance at <0.05. 
 
Neurocognitive variable  
HIV proviral DNA  
at 96 weeks (n=29) 
HIV proviral DNA  
at 248 weeks (n=65) 
r p-value r p-value 
Locomotor quotient -0.22 0.25 -0.09 0.49 
Language quotient -0.09 0.65 0.18 0.16 
Personal and social 0.29 0.12 0.03 0.78 
Eye-hand coordination -0.05 0.77 -0.0005 0.99 
Performance -0.008 0.97 -0.12 0.34 
General Griffiths -0.12 0.54 -0.04 0.74 
VMI standard -0.20 0.31 -0.04 0.76 
Visual standard -0.21 0.29 -0.09 0.47 
Motor standard -0.4 0.03* -0.08 0.54 
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8.3 Discussion 
 
HIV proviral DNA was lower at 96 trial weeks in children receiving early ART for 96 
weeks compared to deferred ART until clinically or immunologically indicated. Earlier 
age of ART-initiation and longer duration of continuous HIV RNA suppression were 
significantly associated with lower levels of HIV proviral DNA, thus supporting the 
results from smaller studies [202, 218, 219]. However, there was no difference in HIV 
proviral DNA levels between the three ART-strategies of the CHER trial at 248 
weeks. This suggests that the benefit gained from early ART is lost by interrupting 
ART, or alternatively, the disadvantage of starting ART later might be offset by 
continuous ART.  
 
There is an inherent selection bias in this study since more children died in ART-Def, 
meaning that children who died contributed fewer reservoir results. Clinically unwell 
children may have been less likely to have an aliquot of PBMCs or plasma stored. 
However, these biases might underestimate the associations seen above as unwell 
children may be more likely to have uncontrolled HIV viraemia and presumably more 
integrated HIV proviral DNA. The effect of duration of HIV infection and age of ART 
initiation on HIV proviral DNA levels cannot be distinguished, since these two 
variables are intrinsically related. 
 
While early ART and sustained viral suppression are clearly important determinants 
of the viral reservoir, we observed different patterns of virological dynamics within 
individuals. As both Figures 8.1 and 8.2 illustrate, a few children have low proviral 
reservoirs despite relatively short durations of HIV RNA suppression, and some have 
high reservoirs despite long-term ART. When examining the trajectories of HIV 
proviral DNA in the children on continuous ART, it is clear that some have a variable 
course despite apparent sustained virological suppression. This has been described 
previously [214] and could be explained by interval viral load testing not capturing 
“viral blips”. It may also be due to homeostatic proliferation in the absence of viral 
reactivation [246], or by low-level antigen-driven stimulation, T-cell activation and 
subsequent proliferation of HIV-infected memory CD4+ T-cells that harbor latent 
integrated HIV [213].  
 
High CMV viral loads at CHER enrolment were associated with high levels of HIV 
proviral DNA at 96 weeks, as seen in a adult study [233], while all children with 
undetectable HIV proviral DNA were CMV DNA negative at enrolment. High levels of 
T-cell activation and proliferation were also observed in individuals with high HIV 
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proviral DNA. This raises the possibility that immune activation, potentially due to co-
infections such as CMV, may contribute to the formation and accumulation of the 
latent reservoir. High naïve CD4 T-cells were observed in individuals with low levels 
of HIV proviral DNA perhaps reflecting good thymic output. Although little can be 
concluded from these observations, there appears to be a complex interplay between 
virological and immunological dynamics and levels of HIV proviral DNA, likely to be 
influenced by ART adherence, co-infections, timing of HIV-transmission and initial 
maternal viral burden.  
 
High levels of HIV proviral DNA at 96 weeks were shown to be associated with 
significantly lower standards or fine-motor coordination using the Griffith’s 
assessment. This association disappeared by 248 weeks suggesting that the deficit 
could resolve with time, or that it might not be a true finding. Further analysis to 
explore this association is needed since multiple statistical comparisons were done in 
this analysis and the association might have therefore occurred due to chance rather 
than biological plausibility. 
 
Predictors of low or undetectable provirus included longer duration of HIV RNA 
suppression, high CD4 count at enrolment, lower quantity of HIV-specific antibody 
but not negative serostatus. The lack of absolute correlation between serostatus or 
antibody quantity and proviral DNA levels imply that the dynamics of reservoir 
decline may not be solely reliant on adequate viral suppression, as observed 
previously[205], although it could suggest that interval viral load testing might not be 
a reliable way of indicating continuous viral control.  
 
Five individuals had one or more measures of undetectable HIV proviral DNA, of 
whom three underwent ART-interruption and remained off ART by end of trial. One 
child interrupted ART for 56 weeks and the fifth child did not interrupt as she was 
randomised to ART-Def. All children who interrupted ART exhibited HIV RNA 
rebound during interruption, inferring that undetectable provirus, at least at the level 
of detection for this study, cannot indicate cure. The measurement of HIV proviral 
DNA alone, or with HIV-antibody status, is not sufficient to predict the outcome of 
children who stop ART. Improvements in the sensitivity of viral DNA detection, 
combined with assays that ascertain levels of replicative virus may be more 
informative, however such assays require large volumes of blood, which is a barrier 
in young children. Further work is required to understand the complex relationship 
between HIV viral dynamics and immune function to help identify children who may 
be functionally cured or amenable to novel treatment modalities.  
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In summary, this study demonstrates reduced levels of HIV proviral DNA in children 
started on early ART. Levels of HIV proviral DNA are strongly associated with earlier 
ART-initiation and longer continuous virological suppression, however HIV proviral 
DNA levels prior to ART-interruption do not predict time tolerated off ART. ART-
interruption appears to replenish the reservoir to that of a child starting ART later i.e. 
>12 weeks of age. Pre-ART events such as reduced naïve CD4 T-cells, co-infections 
and immune activation may be import determinants of HIV proviral DNA levels and 
provide potential targets for adjunctive reservoir reduction strategies. These findings 
provide valuable insights into the development and dynamics of the HIV reservoir 
and support early ART with sustained virological suppression to limit levels of HIV 
proviral DNA in children. 
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Chapter 9 
 
Conclusions 
 
The CHER trial demonstrated a hugely significant benefit of early ART on morbidity 
and mortality of paediatric HIV and has had a fundamental impact upon treatment 
guidelines and survival worldwide. While the clinical outcome is indisputable, the 
immunological and virological mechanisms by which this survival advantage occurs 
are not well understood and have been the focus of this thesis. More detailed 
knowledge of these dynamics has the potential to contribute towards improving 
strategies to further reduce morbidity and mortality, establish more convenient and 
cost-effective care, optimise immunological health and strengthen approaches 
towards functional cure in certain individuals. 
 
The prerequisite to enhanced understanding of these immunological and virological 
mechanisms is a detailed knowledge of the paediatric immunology of a comparative 
HIV-uninfected population. The Child Wellness Clinic was created for this purpose 
and has established a set of local haematological and immunological reference 
intervals for the South African paediatric population. The comparison of these 
immunological data with 3 similar studies from the US and Europe reinforced the 
need for population-specific reference intervals. However, the main finding of these 
comparisons was the increased naïve to memory T-cell ratio in early childhood, 
presumably due to increased environmental pathogen exposure as reflected in the 
elevated activation markers and levels of natural killer cells compared to their US and 
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European counterparts. While providing insight into the developing paediatric 
immune system within an African context, the long-term health implications of these 
findings certainly require further study.  
 
The immunological and virological laboratory analysis performed during this 
fellowship used cryopreserved PBMCs and plasma from the CHER trial and the 
CWC cohort. This presented the opportunity to explore the effect of cryopreservation 
on immunological markers by comparing a large number of specimens that were 
processed by both fresh whole blood assay and using cryopreserved PBMCs. The 
preliminary work comparing fresh and cryopreserved PBMCs revealed no significant 
differences in a range of cell-surface markers, however numerous statistically 
significant differences were found when comparing a fresh whole blood assay with 
cryopreserved PBMCs. Although not all statistically significant differences were likely 
to be clinically relevant, this analysis suggested methodological differences play a 
prominent role and caution should be applied when comparing studies with differing 
technical procedures, and in studies using cryopreserved specimens unless 
appropriate controls are used. In the remaining analysis done in this thesis, 
immunological results from cryopreserved specimens were only compared to other 
cryopreserved specimens from relevant control groups. 
 
The measures of thymic output obtained from the cryopreserved specimens of the 
CWC cohort were used to formulate a non-linear regression curve to delineate the 
change in thymic output during childhood. Although the shape of the curve clearly 
differed to that anticipated by the mathematical model, there are numerous reasons 
why this might be including a potential feedback mechanism to the thymus from 
increased naïve to memory T-cell conversion as demonstrated by the CWC 
immunological analysis. 
 
The CD4 and age-adjusted thymic output analysis from both the healthy children 
from the CWC and the combination of CHER arms illustrated that higher absolute 
CD4 counts were significantly associated increased thymic output, highlighting the 
importance of preserving thymic output in children to optimise their potential for CD4 
reconstitution and long-term immunological health. These findings were reinforced 
and further explored by the analysis of the impact on thymic output of the different 
ART-strategies used by the CHER trial. 
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Immunological changes in HIV-infected children with or without ART 
Overall the ART-strategies of early ART for 96 weeks (ART-96W), followed by ART-
interruption until clinical/immunological deterioration, appeared to preserve thymic 
output in the early childhood years to that of a healthy HIV-uninfected child. The 
ART-strategy of ART-96W appeared to be more beneficial long-term over deferred 
ART followed by continuous ART (ART-Def), and early ART continued for 40 weeks 
with subsequent ART-interruption (ART-40W). Examining the individual thymic 
output trajectories and combined regression curve of ART-96W shows thymic output 
to be high in the first few months of life. This may be a consequence of the initial 
effects of untreated HIV-infection, bringing the thymic output peak earlier than 
expected in the first year of life, hypothetically due to a feedback mechanism from 
CD4 T-cell death plus antigen-stimulated naïve to memory T-cell conversion. High 
levels of thymic output may be unsustainable and result in depleted thymic output 
even though ART is initiated around that time. Thereafter, the benefits of ART in 
suppressing HIV RNA and reducing associated CD4 T-cell death are seen with a 
corresponding increase in thymic output. This pattern is replicated by the trajectories 
and analysis exploring ART-interruption and the effect of deferred ART, alongside 
observations of low thymic output at the trial-defined endpoints, and in cases of 
pneumonia. The association between low thymic output and poor clinical outcome, 
such as acquiring pneumonia, may be due to limited functionality of circulating naïve 
T-cells from a restricted TCR repertoire however this inference requires verification. 
 
Despite on-going ART, the immunophenotype comparisons between HIV-uninfected 
and HIV-infected children suggest immune activation persists and more needs to be 
done to restore immunological health to that of an HIV-uninfected child. It may be 
that HIV RNA viral load is inadequately suppressed, and viral load testing strategies, 
if available, are not sensitive enough or do not capture transient increases in plasma 
viral load. This requires more detailed scrutiny, however it has not been possible in 
this thesis since the viral load data from CHER was incomplete at time of analysis. 
Some caution should be applied to these findings since the analyses were done on 
cryopreserved PBMCs, and although all comparisons done were between 
cryopreserved specimens, the cryopreservation-thawing process might have 
influenced the differences detected.  
 
The immunopathogenesis of HIV is largely due to accelerated destruction combined 
with impaired regeneration of CD4 T-cells. While ART successfully reduces CD4 T-
cell destruction and timely ART-initiation may prevent impairment of thymic output, 
there is a dearth of adjunct strategies to repair thymic damage and optimise 
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immunity. In addition to the relationship seen between CD4 count and thymic output, 
it is possible that several other immunological markers such as activation, 
proliferation or naïve/memory ratio may also be associated with thymic output, and 
plausibly involved in a feedback mechanism to the thymus, as has been seen with T-
regulatory cells [247]. However, further complex analyses are needed to unravel 
these associations and thereafter ascertain clinical approaches to facilitate the 
function of organs that generate naïve T-cells, such as the bone marrow, thymus, 
and mucosal immune system.  
 
The naïve B-cell and thymic output analyses revealed similar peaks in output within 
the first year of life in both sets of children from the CWC and ART-96W. The 
magnitude of the naïve B-cell peak was far higher and sustained for longer in ART-
96W compared to the healthy HIV-uninfected controls, yet during this time thymic 
output appeared to be falling as a consequence of untreated HIV. These results 
could infer the intrinsic effect of uncontrolled HIV on the bone marrow; or 
alternatively, might suggest that a feedback mechanism could exist during times of 
immunological pressure on the thymus to thus stimulate the bone marrow to increase 
early lymphocyte progenitors and maintain thymic output. While intriguing results, 
further research is needed to validate these results and explore the mechanisms 
involved. 
 
Quantity of HIV-specific antibody was not found to be directly related to naïve B-cell 
output but instead highly correlated with cumulative viral load exposure and therefore 
more likely to be due to HIV antigen-stimulation than any B-cell deficit or dysfunction. 
Although all children tested in the antibody substudy had detectable anti-gp120 IgG, 
almost half children starting ART within 12 weeks of birth and 6% of those starting at 
12-24 weeks were seronegative by automated serology or rapid antibody tests at 
approximately 2 years of age. In view of these findings, commercial antibody tests 
should not be used to confirm HIV status among children already diagnosed and 
started on ART at less than 6 months of age. This has clinical implications since the 
confirmation of diagnoses are required for several reasons particularly for children 
started on ART with presumptive diagnoses in resource-limited settings and false 
negative serology may result in inappropriate cessation of ART. 
 
A further implication of the seronegative status is the growing attention on 
approaches towards achieving functional cure in HIV-infected children. HIV proviral 
DNA is the current gold standard for diagnosis, however reduced levels of HIV 
proviral DNA were demonstrated in children started on early ART in this study. Lower 
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levels of proviral DNA were found to be strongly associated with earlier ART-initiation 
and longer continuous virological suppression. However, HIV proviral DNA quantity 
did not predict time tolerated off ART and ART-interruption appeared to replenish the 
reservoir. Pre-ART events such as reduced naïve CD4 T-cells, co-infections and 
immune activation may be import determinants of levels of proviral DNA and provide 
potential targets for adjunctive therapy in reservoir reduction strategies. These 
findings provide valuable insights into the development and dynamics of HIV proviral 
DNA and lend support to the early use of ART with sustained virological suppression 
to limit the viral reservoir in children.  
 
Limitations and future studies 
Alongside an enhanced knowledge of the immunological dynamics of healthy 
children in a disease-burdened setting, these novel insights develop the 
understanding of the influence of HIV and ART on thymic and naïve B-cell output, 
antibody status, proviral DNA reservoirs and a range of immunological parameters. A 
vast amount of data has been generated during this fellowship, however the analysis 
so far has been largely descriptive. The CHER trial was a randomized controlled trial, 
however there were numerous potential biases such as missing samples since more 
children died in ART-Def, multiple confounding factors involved in ART interruption 
analysis, incomplete viral load data, and that only virally suppressed children could 
be used for proviral DNA analysis. While the current analysis of the antibody and 
proviral DNA studies may be directly applicable to clinical guidelines, there is great 
potential for more complex combined analyses using sophisticated statistical 
techniques and mathematical modeling that are beyond the scope of this thesis but 
that I intend to pursue with the assistance of colleagues in the future. 
 
Further long-term studies are needed to establish the relationship between thymic 
and naïve B-cell output with clinical health. Decline in naïve T-cell output has been 
associated with reduced T-cell diversity and thereby increased susceptibility to 
infection, autoimmune disease and cancer [5]. Longitudinal analysis of individuals 
would more accurately characterise the trajectories of thymic and naïve B-cell output. 
A valuable longitudinal study would be one that quantifies thymic and naïve B-cell 
output with T-cell and B-cell receptor diversity alongside the clinical and 
immunological condition of the child as they progress throughout childhood, aiming to 
determine what is the range of optimal thymic and naïve B-cell output required for 
good clinical health. It would be necessary to identify crucial factors associated with 
establishing and maintaining thymic and naïve B-cell output such as nutrition, 
genetics, and exposure to a range of environmental pathogens.  
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Laboratory studies in animals might further explore the feedback mechanism 
postulated whereby peripheral destruction of CD4 T-cells or naïve-to-memory T-cell 
conversion hypothetically results in increased output of naïve CD4 T-cells from the 
thymus, and potentially drives increased output of early lymphocyte progenitors from 
the bone marrow. Proof that this mechanism exists, and whether it changes with age, 
may be clinically important and might even inform strategies on ART-interruption i.e. 
if higher thymic output in early childhood years was related to long-term improved 
clinical health, therapeutic mechanisms to increase thymic output might be indicated 
such as the use of IL7; alternatively if the mechanism is age-dependent and 
diminishes with age it is plausible that limited ART-interruption might only be feasible 
in earlier years when the mechanism exists. 
 
A follow-up study of the CHER trial is underway and over the next five years I will 
continue to measure the participants’ thymic output, immunological profile, serostatus 
and HIV-specific antibody. This will give a greater longitudinal perspective on the 
effect on thymic output of early and deferred ART, and the impact of ART 
interruptions in the second or third year of life. The immunological data generated 
with be analysed with data from clinical events, neurocognitive function, and detailed 
virology including infectious virus recovery assays, proviral DNA and viral loads. 
 
Summary 
The initial aim of my fellowship was to describe the influence of HIV and ART on 
thymic output in infants and children. As the fellowship progressed, opportunities 
arose to utilise the infrastructure of my study to explore other relevant aspects of the 
immunology and virology of HIV-infected children. I established a healthy child clinic 
to acquire blood specimens to use as HIV-uninfected controls, and alongside the 
specimens available from the randomised controlled CHER trial I had access to a 
large invaluable biological resource. I have learnt and built upon existing laboratory 
methods, and have successfully created a rich source of immunological data, 
including normal heamatological and immunological reference intervals for South 
African children. I have then collaborated with colleagues with skills in mathematical 
modeling to explore and analyse these data. Therefore the studies of this thesis 
include immunological profiles of healthy HIV-uninfected and HIV-infected children, 
the effect of cryopreservation on immunological markers, the effect of early ART on 
serostatus, the impact of CHER ART-strategies on levels of HIV proviral DNA, and 
the influence of HIV and ART on thymic output and also naïve B-cell output. These 
studies are largely descriptive and infer much potential for further investigation, 
however it is hoped that future work might build upon these findings to further the 
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knowledge of the child’s developing immune system and its response to infection or 
immunodeficiency, and that this understanding might contribute to advancing ART-
strategies to optimise the immunological health of HIV-infected children. 
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APPENDIX I: Child Wellness Clinic poster and flyers 
 
Child Wellness Clinic 
Wesbank Health Centre 
You and your baby are invited to attend the “Infant Wellness Clinic” every 
Tuesday and Wednesday from August 2012 onwards. We would like to ask 
you if you would agree to take part in a research study to investigate the 
immune system in well infants. 
 
  
 
At the “Infant Wellness Clinic” your child will have the following: 
- Clinical review and medical examination 
- Height and weight measured 
- Have one blood test  
- Given nutritional supplements  
- Given a “Road to Health” booklet if you do not have one already 
- Reimbursement for your time and travel 
 
Your child may take part in the study if he/she is healthy and less than the age 
of 5 years. If your child is currently unwell or has not had all his/her routine 
vaccinations, he/she may not be able to take part, however, we will treat 
him/her if he/she is unwell and administer their missing vaccinations if 
possible. 
 
The blood taken will be tested for the number of red and white blood cells, 
HIV-antibody and to measure the production of immune cells. For more 
detailed information please come along to Wesbank clinic health centre or you 
can contact me, Dr Helen Payne, on hpayne@sun.ac.za or 0833 633 057.  
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APPENDIX II: Child Wellness Clinic patient information / consent form  
 
PATIENT INFORMATION LEAFLET AND INFORMED CONSENT FORM  
 
Centre: Children’s Infectious Diseases Clinical Research Unit, Tygerberg Children’s Hospital 
Study number: M12/01/005 
Sponsored by: The Wellcome Trust 
Principal Investigator: Dr Helen Payne  
 
TITLE OF THE STUDY:  THYMIC OUTPUT IN INFANTS AND YOUNG CHILDREN 
 
This information is provided to help you decide whether to take part in this clinical research study. 
Please read this form carefully and ask the study doctor or the study staff to explain any words or 
procedures you do not understand. 
 
Dear parent or guardian, 
 
Hello, my name is Helen Payne and I am a children’s doctor and research fellow at Tygerberg 
Hospital. I would like to invite your child to take part in a research project. If your child is healthy then 
he/she can participate in the trial. I am looking for children who are NOT infected with HIV to take 
part in this study. 
 
The study will help us, as doctors, understand more about the way in which HIV affects the immune 
system of babies and young children. A better understanding will mean we will be able to improve 
the care we give to babies and children with HIV to help them have a healthier life. 
 
The following sheets explain the project in more detail and are for you to keep. When you have read 
it, or someone has read it to you, I or one of my colleagues will be pleased to answer any questions 
you have. If you are happy to take part then you will need to sign the consent form when you attend 
the “Infant Wellness Clinic”. No information from the study will reveal your or your child’s identity, 
and you can withdraw from the study at any time. 
 
I thank you in advance for your time and help.  
Yours sincerely,   
 
Dr Helen Payne 
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WHAT IS THE STUDY AND WHY ARE WE DOING IT? 
Although your child may not have HIV, HIV infection in children is still a major problem in South 
Africa. Although treatment with medicines against HIV (HAART) has saved many lives, there are 
still important questions we do not know the answers to. We know we should start HAART as soon 
as possible after birth in children who are HIV-infected; however, we do not know exactly how long 
we should continue HAART and when it is safe to have a treatment break. We hope the results of 
this study will provide information that will help to answer these questions. This information could 
be important for HIV management worldwide. 
HIV weakens the immune system and makes children vulnerable to serious infections. The 
immune system is controlled by a gland called the thymus. However it is not understood how the 
thymus reacts to HIV-infection or treatment. In this study we will investigate how HIV and HAART 
affect this gland and the production of immune cells (what is called thymic output).  
 
WHY ARE YOU ASKING MY CHILD TO TAKE PART? 
In this study we need a group of babies and children who do NOT have HIV to compare with 
children who do have HIV. It will also help us define what are normal immune cells (cells which 
fight infection) in this age group because this is something that is not currently known. 
 
WHAT WILL HAPPEN AT THE “CHILD WELLNESS CLINIC”? 
At the “Child Wellness Clinic” you will be asked to give us your address and phone number (if 
possible). Your child will have the following: 
- Clinical review and medical examination 
- Height and weight measured 
- Vaccination review and catch-up if needed 
- Have one blood test  
- Given nutritional supplements 
- Review and update of your “Road to Health” booklet 
- You will be reimbursed for your time and travel 
 
CAN MY CHILD DEFINITELY TAKE PART? 
Your child may take part in the study if he/she is healthy and is not unwell at the time. If your child is 
unwell or severely malnourished, she/he will be treated at the health center or referred to hospital if 
necessary. If your child has not had his/her vaccinations according to the national schedule, we may 
offer to give his/her vaccines if appropriate or arrange another time to do so. If this is the case, 
he/she will not be able to take part in the study but may attend the clinic for clinical review, 
examination, height and weight measurement and supplements.  
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WHAT ARE THE BLOOD TESTS FOR? 
Your child will have one blood test (2-3 mls or 1 teaspoon of blood). This will be used to: 
1) Check the level of red and white blood cells (a full blood count) 
2) Test for HIV 
3) To measure the cells of your baby’s immune system and thymic output 
 
HOW WILL I KNOW THE BLOOD TEST RESULTS? 
You will need to wait 20-30 minutes until the result is available. You may become worried or anxious 
while waiting for the results of your child’s HIV test. You will have counseling sessions with a trained 
counselor to help you with any feelings or questions you may have. 
 
WHAT IF MY BABY’S BLOOD TEST IS HIV-POSITIVE? 
If the blood taken has tested positive for HIV-antibody, it usually means the baby’s mother has HIV. 
We will perform a second test on the blood (called HIV proviral DNA), which will tell us whether your 
baby has HIV, or not. If you, or both you and your baby, have HIV we will refer you to the local family 
HIV clinic where you will be assessed for starting treatment (HAART). 
 
WHAT ABOUT CONFIDENTIALITY? 
Information about your HIV status, your child’s HIV status, your child’s care in the clinic and his/her 
blood test results will be stored in locked cabinets. All medical information collected during the study 
will be treated as confidential. Any information that is used for research or publication purposes will 
be kept confidential and will not have your or your child’s name recorded on it. The Health Research 
Ethics Committee may check that these records are kept correctly. 
YOUR CHILD’S PARTICIPATION IS VOLUNTARY 
Your child’s participation is voluntary. You can refuse to consent to this study and even if you sign 
the consent form, you can withdraw your consent at any time. Approximately 500 children will take 
part in this study. 
 
WHAT ARE THE RISKS TO MY CHILD? 
There are no serious risks to your child from this study. During the collection of blood samples, your 
child may experience light-headedness, pain, bleeding and/or bruising at the site on the arm where 
blood is taken. Blood clots may form and infections may occur, but this is unusual. Fainting may 
occur during or shortly after having blood drawn.   
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WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
Thank you for taking the time to consider this study. If at any time you have any questions during the 
study, please do not hesitate to contact myself (Helen Payne) or any of my colleagues. 
 
CONTACT DETAILS: 
Children’s Infectious Diseases Clinical Research Unit 
Ward J8, Tygerberg Children’s Hospital 
University of Stellenbosch 
Francie van Zijl Avenue 
Parow, 7505, Cape Town, South Africa 
hpayne@sun.ac.za 
Tel: 0833 633 057 
 
If you would like any information regarding your child’s rights as a research participant, or have 
complaints regarding this research study, you may contact: 
 
The Chairperson 
Human Research Ethics Committee                  
University of Stellenbosch                             
Tel:  021 938 9075 
 
This independent committee has been established to help protect the rights of research participants 
and gave written approval for the study protocol. 
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THYMIC OUTPUT STUDY: INFORMED CONSENT SIGNATURE PAGE 
 
Name of participant: ______________________________________________________________  
Study registration number: _____________________Date of Birth:__________________________ 
 
To parents/legal guardians, please TICK the box if the answer to the question is YES: 
 
1) Have you read or has someone read to you the information sheet about this study? 
 
2) Have you had an opportunity to ask questions and discuss this study, and are you happy with the 
answers to all your questions?   
 
3) Do you understand that you are free to withdraw your child from this study at any time? 
 
4) Do you agree to let your child take part in this study?    
 
5) Do you consent to the use of your child’s blood to measure thymic output (production of cells to 
help fight infection)? 
 
6) Do you consent to the use of your child’s blood for a full blood count and to test for HIV? 
 
7) If the HIV test is positive, do you consent to you and your child being referred to the local  
family HIV services? 
 
8) Do you consent to the use of your child’s medical notes alongside these tests?  
 
9) Do you understand that the information produced from these tests in this study will be 
anonymous, and not reveal the identity of you or your child?  
 
Name of Parent/Legal guardian _____________________Signature__________ Date ______ 
 
Name of Witness (if applicable)_____________________Signature ___________Date ______ 
 
Person obtaining consent: I am satisfied that the parent/legal guardian understands what the study 
is about and that his/her questions have been answered. 
 
Name _____________________ Signature________________________ Date ____________ 
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APPENDIX III: Structure and Activities of the Child Wellness Clinic 
 
 
• Introduction and overview of what will happen in the clinic 
• Basic details: Name, date of birth, address, phone number, next of kin 
• Consent: in native language, written information will be provided. A copy 
of the consent form will be given to the parent/guardian, and one will be 
kept onsite at the clinic. Please see Appendix I. 
• Medical history: antenatal details, neonatal, family and social history, 
and history of medical problems including any current complaint. 
• Review of the “Road to Health” booklet: review of record keeping, 
previous problems and growth. 
• Anthropometry: weight, height, head circumference (added to the “Road 
to Health” booklet). 
• Review of vaccinations: from “Road to Health” booklet and make 
arrangements for vaccinations if not up-to-date. 
• Physical examination: routine infant examination performed by a 
paediatrician (Helen Payne, the principal investigator of this study) 
• Management: address any arising health issues and health education 
• Phlebotomy: A 5ml sample of blood would be taken from each child for 
full blood count, HIV rapid antibody test and a sample for assessment of 
normal parameters of immune cells (T-cell and B-cell markers). A dried 
blood spot for HIV DNA PCR would also be taken should any positive 
HIV-antibody tests arise, and if so, the child and mother would be 
referred to the Wesbank family HIV service. 
• Waiting for results: The parent/guardian and infant would be asked to 
wait in the waiting area (estimated 20 minutes) for the results of the HIV-
antibody test 
• Discussion of results: of HIV-antibody test and referral if necessary to 
the local family HIV service 
• Provision: of nutritional supplements and travel reimbursement 
• Summary: of clinic and thanks, and reminder to return in one week for 
FBC results and review. 
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APPENDIX IV: Proforma for the Child Wellness Clinic 
 
Name:  CWC No:  
Next of kin:  Date:  
Maternal facility No:  DOB:  Infant facility No:   
Address:  DOB:  
Phone No:  Ethnicity: B / C / W 
Consented? Y / N Sex: M / F 
 
HISTORY: 
Antenatal: 
Neonatal: 
Medical Hx: 
Current problems? 
 
 
 
 
Family Hx: 
Social Hx: 
Feeding Hx: 
 
 
 
GROWTH: (plot on “Road to Health” booklet) 
 Height / length: Weight: Head circumference: Growing well 
Measure:    Not growing well 
Plotted z-score:    Severe Malnutrition 
  
Antenatal screening HIV negative in records? YES / NO; Verbal negative? Y / N 
Normal pregnancy? YES / NO 
Born on time? YES / NO   If early, how early? 
If mum positive, clinic DNA PCR records confirm baby negative? YES / NO / NA 
Baby stayed in hospital after birth / during 1st month of life? YES / NO 
In first 6mths - Exclusive breast-feeding / only 
formula / mixed / solids introduced early? 
Hospital admissions? YES / NO   
Medications? YES / NO 
Unwell in last month? YES / NO 
Any problems with alcohol, drugs, violence in the family? YES / NO 
Cough? YES / NO 
Fever? YES / NO 
Diarrhoea? YES / NO 
Vomiting? YES / NO 
Skin rash? YES / NO 
Any concerns/ worries? YES / NO 
TB contacts at home? YES / NO 
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REVIEW VACCINATIONS (tick if already given): 
Birth BCG  OPV        
6 weeks PCV  OPV  DTaP- 
IPV/HIb 
 Hep B  RV  
10 weeks     DTaP- 
IPV/HIb 
 Hep B    
14 weeks PCV    DTaP- 
IPV/HIb 
 Hep B  RV  
9 months PCV  Measles        
18 months   Measles  DTaP- 
IPV/HIb 
     
Comment / action required? 
Date of last vaccination (and which if not consistent with the above): 
 
EXAMINATION: 
 
 
BLOOD TESTS TAKEN (tick if performed): 
Test: FBC  HIV antibody  Thymic output  
 
MANAGEMENT: 
 
  
 
 
INCENTIVE: 
   
Nutritional supplements: ….. x Yabatwana (porridge); …. x Imunut (peanut butter) 
Travel reimbursement: R50 Shoprite voucher – YES / NO 
 
 
  
  
Normal vital signs? YES / NO 
Heart sounds normal? YES / NO 
Breath sounds normal? YES / NO 
Abdomen normal? YES / NO 
Skin rashes? YES / NO 
Lymphadenopathy? YES / NO 
Result: 
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APPENDIX V: Coded Information recorded from Child Wellness Clinic 
 
  
Column headings: 
       CWC.No Child wellness clinic number (chronological in order of attendance) 
 Initials Child’s initials as used on FBC request form 
   Mat Facility No Maternal facility number to identify mother from NHLS datawarehouse 
Mat.DOB Maternal date of birth 
     Infant Facility No Infant facility number  
     DOB Date of birth 
     Sample.date Date of sample 
     Ethnicity Black, Coloured, Asian, White (B, C, A or W) 
   Sex Male or Female (M or F) 
     Dec.age Decimal age at the time of sample being taken 
   Age.wks Age in decimal weeks at the time of sample being taken 
  Age.cat Age category  
Mat.stat Maternal HIV status checked in notes and verbally (0=negative, 1=positive) 
NHLS.data NHLS confirmed maternal serostatus at child's birth (0=negative, 1=positive) 
Baby.pcr Infant's HIV proviral DNA PCR result (0=negative, 1=positive) 
Ant.event Antenatal event requiring admission to hospital (0=no, 1=yes) 
  Ant.info Free text on reason for hospital admission (NAP = not applicable) 
  Neo.event Neonatal event requiring admission to hospital (0=no, 1=yes) 
  Neo.info Free text on reason for hospital admission (NAP = not applicable) 
  Med.hx Past medical event requiring admission to hospital (0=no, 1=yes) 
  Med.hx info Free text on reason for hospital admission (NAP = not applicable) 
  Recent.ill.mth Recent infection within last month (0=no, 1-yes) 
   Unwell Current illness limiting participation in study (0=no, 1=yes) 
  Fam.hx Single parent or family support (0=support, 1=single parent and no support) 
Soc.hx Social problems at home: drugs, excess alcohol, violence? (0=no, 1=yes) 
Feed Type of feed during first 6mths? (0=breast feed, 1=bottle, 2=mixed) 
 Length Length in centimetres 
     Wt Weight in kilograms 
     HC Head circumference in centimetres 
    Nut.stat Nutritional status (0=growing well, 1=not growing well, 2=malnourished) 
z.score.wt How many standard deviations from median/mean? (0=median, 1, 2 or 3) 
 Im.utd Are the immunisations up to date? (0=yes, 1=no, V=verbal report) 
 Baby.ab Baby's HIV antibody status (0=negative, 1=positive) 
   BARC No BARC bar code number on blood samples 
   Hb Haemoglobin in g/dL 
     Hct Haematocrit in L/L 
     Plts Platelets per 10^9/L 
     Wbc White blood cells per 10^9/L 
    Nt Neutrophils per 10^9/L 
     Lym Lymphocytes per per 10^9/L 
    Mono Monocytes per 10^9/L 
     Comment Comment on the blood test results 
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APPENDIX VI: Ethical and regulatory approvals 
 
The following approvals were obtained: 
• HREC Stellenbosch University 
• HREC Witwatersrand University 
• City of Cape Town, Department of Health 
• Tygerberg Hospital Management 
 
HREC Stellenbosch University: 
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HREC Witwatersrand University: 
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City of Cape Town, Department of Health: 
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Tygerberg Hospital Management: 
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APPENDIX VII: Ethical approval for CHER PLUS thymic output substudy 
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APPENDIX VIII: Information / consent form for thymic output in CHER PLUS 
 
CHER PLUS PATIENT INFORMATION LEAFLET AND INFORMED CONSENT FORM: 
ADDITIONAL BLOOD TO BE TAKEN AT THE ROUTINE YEARLY BLOOD DRAW 
Centre: Children’s Infectious Diseases Clinical Research Unit, Tygerberg Hospital 
HREC study number: M11/10/042 
Principal Investigator of CHER PLUS: Dr Barbara Laughton 
Investigator to do thymic output analysis: Dr Helen Payne  
Sponsored by: The Wellcome Trust 
 
TITLE OF THE STUDY:  THYMIC OUTPUT IN CHER PLUS 
 
This information is provided to help you decide whether to take part in this clinical research 
study. Please read this form carefully and ask the study doctor or the study staff to explain any 
words or procedures you do not understand. 
 
Dear parent or guardian, 
Hello, my name is Helen Payne and I am a children’s doctor and research fellow at Tygerberg 
Hospital. I am working with the CHER PLUS team and would like to invite your child to take 
part in a research project that will help us understand more about the way in which HIV affects 
the immune system of children. A better understanding will mean we, as doctors, will be able 
to improve the care we give to your children and help them have a healthier life. 
 
Your child will not need any more blood tests than usual. I am only asking for your consent to 
take 2mls (less than half a teaspoon) extra blood at your child’s routine yearly blood test. It will 
not mean an extra needle and 2mls more of blood will not make a difference to your child’s 
body at all. 
 
The following sheets explain the project in more detail and are for you to keep. When you have 
read it, or someone has read it to you, I or one of my colleagues, will be pleased to answer 
any questions you have. If you are happy to take part in the study then all you need to do is 
sign the consent form. No information from the study will reveal your or your child’s identity, 
and you can withdraw from the study at any time. 
 
I thank you in advance for your time and help.  
Yours sincerely, 
  Dr Helen Payne 
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WHAT IS THE STUDY AND WHY ARE WE DOING IT? 
HIV infection in children is still a major problem in South Africa. Although treatment with 
medicines against HIV (HAART) has saved many lives, there are still important questions we 
do not know the answers to. We know we should start HAART as soon as possible after birth 
in children who are HIV-infected; however, we do not know exactly how long we should 
continue HAART and when it is safe to have a treatment break. The results this study intends 
to produce may provide information that will help us answer these questions. This information 
could be important for HIV management worldwide. 
WHY WILL THIS BE USEFUL? 
HIV weakens the immune system and makes children vulnerable to serious infections. The 
immune system is controlled by a gland called the thymus. However it is not understood how 
the thymus reacts to HIV-infection or treatment. In this study we will investigate how HIV and 
HAART affect this gland and the production of immune cells (called thymic output).  
 
WHAT DOES MY CHILD HAVE TO DO IF I AGREE TO THIS STUDY? 
Your child does not have to do anything at all. During CHER PLUS, your child will have a 
yearly routine blood test and at the time of this blood test we would like to draw an extra 2mls 
of blood. This would not mean an additional needle and 2mls of blood would not make a 
difference to your child’s body at all. I will use this blood to measure the production of immune 
cells from the thymus (thymic output). 
 
YOUR CHILD’S PARTICIPATION IS VOLUNTARY 
You can refuse to consent for the extra 2mls of your child’s blood for this study. Even if you 
agree, you can withdraw consent at any time. If you decide not to take part, this will not affect 
the standard of care your child receives. Approximately 100 children as part of CHER PLUS 
will be asked to participate in this study. 
 
WHAT ABOUT CONFIDENTIALITY? 
Information about your HIV status, your child’s HIV status, your child’s care in the clinic and 
his/her blood test results will be stored in locked cabinets. All information collected during the 
study will be treated as confidential. There will be no difference from the way your medical 
information is used than it has been so far with the CHER trial and CHER PLUS. All 
information that is used for research or publication purposes will be kept confidential and will 
not have your or your child’s name recorded on it. The Health Research Ethics Committee 
may check that these records are kept correctly. 
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WHAT ARE THE RISKS TO MY CHILD?  
There are no serious risks to your child from this study. During the collection of blood samples, 
your child may experience light-headedness, pain, bleeding and/or bruising at the site on the 
arm where blood is taken. Blood clots may form and infections may occur, but this is unusual. 
Fainting may occur during or shortly after having blood drawn. 
 
WHAT ARE THE COSTS TO ME? AND WILL I RECEIVE ANY PAYMENT FOR MY CHILD’S 
PARTICIPATION?  
There is no cost to you for the tests. You will not receive any additional payment for your 
child’s participation in the study. 
 
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS?  
Thank you for taking the time to consider this study. If at any time you have any questions 
during the study, please do not hesitate to contact myself (Helen Payne) or any of my 
colleagues. 
 
CONTACT DETAILS: 
Children’s Infectious Diseases Clinical Research Unit (KID-CRU) 
Ward J8, University of Stellenbosch, Tygerberg Children’s Hospital 
Francie van Zijl Avenue, Parow,  
7505, Cape Town 
hpayne@sun.ac.za 
Tel: 0833 633 057 
 
If you would like any information regarding your child’s rights as a research participant, or have 
complaints regarding this research study, you may contact: 
 
The Chairperson 
Health Research Ethics Committee 
University of Stellenbosch                             
Tel:  (021) 938-9075 
 
This independent committee has been established to help protect the rights of research 
participants and it gave written approval for the study protocol. 
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CHER PLUS THYMIC OUTPUT STUDY: INFORMED CONSENT SIGNATURE PAGE 
 
Name of participant: ___________________________________________________ 
Date of Birth:____________________________ CHER participant number:_____________ 
 
To parents/legal guardians, please TICK the box to answer YES or NO: 
                                       YES  NO  
1) Have you read or has someone read to you the information sheet about this study? 
 
2) Have you had an opportunity to ask questions and discuss this study, and are  
you happy with the answers to all your questions?   
 
3) Do you know that you are free to withdraw your child from this study at any time? 
 
4) Do you agree to let your child take part in this study?    
 
5) Do you consent to the use of your child’s blood to measure thymic output  
(the production of immune cells to help fight infection)? 
 
6) Do you consent to the use of your child’s medical notes alongside these tests?    
 
7) Do you understand that the information produced from these tests in this study  
will be anonymous, and not reveal the identity of you or your child?  
 
Parent/Legal guardian:  
________________________          ___________________          ___________     
                 Name                                                      Signature                                      Date                      Time 
 
Witness (if applicable): 
________________________          ___________________         ___________     
                 Name                                                      Signature                                       Date                      Time 
 
Person obtaining consent: I am satisfied that the parent/legal guardian understands  
what the study is about and that his/her questions have been answered. 
________________________          ___________________         ___________    
                  Name                                                      Signature                                       Date                      Time 
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APPENDIX IX: Standard operating procedure for PBMC isolation  
 
Preparation: 
1) Heat waterbath to 37°C. 
2) Warm RPMI and 2 x 50ml falcons of RPMI with 2% FCS in waterbath for at 
least 10 mins. 
3) Set up hood. 
4) Check initials, DOB, IWC number of samples and place in ascending order in 
blue rack. Blood quantity will be between 1-2mls each. 
5) Take 2 x 15ml tube per sample and label according to IWC number (one tube 
will be for lymphoprep, one for aspiration of PBMCs). 
6) Fill 15ml vial with 3ml lymphoprep. 
 
PBMC Isolation procedure: 
1) Add 1ml RPMI to each EDTA tube of blood. 
2) Using 1ml pipettes gently layer blood onto lymphoprep. 
3) Note on the counting log an estimate of the volume of blood per sample. 
4) Centrifuge at 2200rpm (4 acceleration, 0 deceleration) for 25 minutes. 
5) First remove plasma layer to 2-3mm above layer of PBMCs and place in 
1.5ml sterile eppendorf.  
6) Aspirate layer of PBMCs and all lymphoprep to 2-3mm layer above RBCs. 
7) Add 5ml RPMI with 2% FCS to each aliquot of PBMCs. 
8) Please note whether PBMCs have >50% RBCs – these samples will need to 
be lysed. 
9) Centrifuge 1500rpm (9 acceleration, 9 deceleration) for 10 mins. 
10) Refill 50ml falcon with RPMI and 2% FCS and place in waterbath. 
11)  While spinning: 
 Prepare cryovials and labels. Please label as follows: 
e.g.   HP IWC182 
14-11-12 
 PBMC  
Or… HP IWC182 
 14-11-12 
 FFP 
12)  Discard RPMI mix and add 5ml further RPMI with 5% FCS  
13)  Centrifuge 1500rpm (9 up, 9 down) for 10 mins. 
14) While spinning: 
a. Prepare counting wells with 10ul trypan blue and haemocytometers. 
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b. Prepare freezing media: 90% FCS and 10% DMSO. Keep wrapped in 
foil and in the fridge. Discard any leftover freezing media. 
15)  Note: IF sample had >50% RBCs do not mix with RPMI/FCS – mix with 2ml 
FACS Lyse and leave in the dark for 10 mins while the remaining samples 
are being centrifuged. After these 10 mins, add 10ml RMPI with FCS to falcon 
and centrifuge for 5mins. 
16)  Discard RPMI mix and add 5ml further RPMI with 5% FCS 
17)  Mix well with 1ml pipette. 
18)  Then add 10ul of cell-mix to trypan blue – mixing well, then apply to 
haemocytometer. 
19)  Centrifuge again at 1500rpm for 5 minutes. 
20)  Count all cells in 25 large squares – note on counting log. 
21)  Multiply cell count _____ by 5.2ml x 2 x 10,000 to get total number of cells. 
22)  Calculate freezing media required to freeze each sample at a concentration 
of 1 x 10^7 per ml, rounded to the nearest 100ul. 
23)  Discard RPMI mix. 
24)  Aspirate remaining RPMI and discard. 
25)  Mix required quantity of freezing media with cell pellet and add to cryovial. 
26)  Place in Mr Frosty in -80°C freezer. Please ensure that isopropranol is at the 
level of 250ml (if lower, top up). Change Mr Frosty after every fifth use. 
27)  Place plasma in plasma freezer box at -80°C. 
28)  Remove samples frozen in Mr Frosty after 24-48hrs and place in liquid 
nitrogen. Defrost Mr Frosty ready for next session. 
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APPENDIX X: Standard operating procedure for measuring thymic output  
 
 
 
 
Thymic Output SOP: 
 
Isolation of naïve CD4 T-cells  
and flowcytometry cell-preparation  
 
October 2013 
 
 
CONTENTS: 
1. Abbreviations 
2. Background of this approach of measuring thymic output 
3. Overview of procedure 
4. Schedules, worksheets and specimen records 
5. Reagents, consumables, storage and equipment 
6. Samples: 
a. Storage and location 
b. Health risk and necessary precautions 
7. Procedure 
a. Thawing PBMCs 
b. Aliquot PBMCs 
c. Parallel procedures: 
i. Naïve CD4 T-cell isolation 
ii. Intracellular-staining for flowcytometry 
d. DNA extraction 
8. Training 
APPENDICES: 
A) MACS/FACS worksheet 
B) Example: specimen details, storage location and identification codes 
C) DNA extraction worksheet 
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1) Abbreviations 
CHER   Children with Early antiretroviral therapy trial 
cRPMI   Complete RPMI media (with 2% FCS) 
FACS Fluorescence activated cell-sorting (but used to indicate 
standard flowcytometry in this text) 
FACS buffer  Buffer used to prepare flowcytometry specimens 
FCS   Fetal calf serum 
FOXP3 buffers Fixative and permeabilisation buffers 
CWC   Child Wellness Clinic (healthy controls) 
LD   Live-dead viability dye for flowcytometry 
MACS   Miltenyi biotec magnetic beads isolation procedure 
PBMC   Peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
TRECs  T-cell receptor excision circles 
 
 
2) Background of this approach to measuring thymic output 
The major limitation of many surrogate markers used for estimating thymic output is 
that these single measures (usually taken from peripheral blood) do not take into 
account rates of peripheral T-cell division and death. Thereby these single measures 
cannot be reliable due to the dilution effect of cell-division - something which is 
especially relevant in HIV-infected individuals in whom increased rates of cell division 
and CD4 T-cell death is well recognized. 
 
TRECs (T-cell receptor excision circles) are one of these surrogate markers of 
thymic output. TRECs are episomal DNA that exist within a recent thymic emigrant 
and indicate that gene rearrangement within the thymus has occurred. The do not 
divide during mitosis and therefore they become rapidly diluted in the peripheral 
blood in conditions of increased cell proliferation. 
 
This SOP describes the procedure to estimate thymic output that attempts to 
overcome this limitation by combining rates of proliferation of naïve CD4 T-cells and 
TRECs from purified naïve CD4 T-cells. These measures are combined in a 
mathematical model that also takes into account total blood volume and peripheral 
naïve CD4 T-cell count. Proliferation of naïve CD4 T-cells is measured by 
flowcytometry (delineated by the markers CD3+CD4+CD45RA+Ki67+). Naïve CD4 
T-cells are purified by magnetic bead isolation and DNA PCR is used to quantify 
TRECs. 
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3) Overview of procedure 
Morning (~5hrs) 
1. Thawing cryopreserved PBMCs. 
2. Dividing the PBMCs into three aliquots:  
a. Aliquot to be used for DNA extraction (leave for afternoon) 
b. To be used for magnetic bead isolation of naïve CD4 T-cells 
c. To be used for flowcytometry 
3. To save time aliquot (b) and (c) are processed as two separate 
procedures in parallel, i.e. during the incubation phases of the magnetic 
bead isolation, fluorochrome-conjugated antibodies are prepared and 
mixed with PBMCs etc.  
(When finished, I will collect and run the prepared PBMCs on the canto) 
Afternoon (~2hrs) 
4. DNA extraction: 
a. PBMCs from the morning 
b. Purified naïve CD4 T-cells from magnetic bead isolation 
5. Nanodrop the 24 specimens of extracted DNA (if time) 
 
 
4) Schedules, worksheets and specimen records 
Between the three of you there should be 50-60 days work and I can offer to pay 
R900 per day (7 hours work for 12 samples); and I will pay you for the days of 
training as well. I hope this will be okay. If it is acceptable to you, I will pay you at the 
end of each month for the number of days you have done.  
 
I have printed out a calendar that I will keep on my desk so you may put your name 
down for the days that you would like to do. So we may all plan our working weeks, I 
would like ask if you could put your name down for the days you would like to do by 
the Friday of the week before (but of course you can mark you name down as far in 
advance as you wish). When you mark your name down you can collect a pack of 2 
worksheets and list of specimens required (as per appendices). 
 
Appendix A is a worksheet that should be used on a daily basis. It contains an 
overview of the procedure and table to record the cell count and aliquot details, plus 
space to comment on anything unusual about the specimen. Appendix B is an 
example of a list of 12 samples that you will receive each day including specimen 
identification details, storage location and identification codes. Appendix C is the 
worksheet required for DNA extraction.  
 
Please return the 3-page pack to my desk after the experiment is finished, thank you. 
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5) Reagents, consumables, storage and equipment 
Consumable Supplier Cat no. Location Comments 
THAWING PBMCS:         
cRPMI 
 
 
Sigma-Aldrich 
 
 
R4130-10L 
 
 
Fridge 
 
 
1L dH2O, 16.9g 
RPMI, 
2% FCS 
Fetal bovine serum 
 PAA laboratories 
A15-101 
 
Immunofreezer 
4, tray 3 
50ml aliquot  
in fridge 
MACS ISOLATION:         
Naïve CD4+ T-cell 
isolation Kit II 
Miltenyi Biotec 
 
130094131 
 
Fridge 
   
LS columns (and pre-
separation filters) Miltenyi Biotec 130042401 My cupboard   
MACS BUFFER 
 
Made in lab 
 
NA 
 
Fridge 
 
1L PBS, 2mls 
EDTA, 5g BSA 
FLOWCYTOMETRY:         
Ki67 PE  BD Pharmingen 556027 Fridge   
CD4 PERCP  Invitrogen MHCD0431 Fridge   
CD3 FITC  Insight Biotech 300306 Fridge   
CD45RA FITC  Invitrogen 
MHCD45RA
01 Fridge   
CD3 PE  Invitrogen CD0304 Fridge   
FoxP3 Fix/Perm  eBioscience 00-5521-00 Fridge   
Permeabilising buffer  eBioscience 00-8333-56 Fridge   
Fixable Viability Dye 
eFluor 660 
eBioscience 
 
65086418 
 
Upright -80 
(~LN room)   
CD19 PERCP  C. Bioscience 302228 Fridge   
CD56 PE-Cy7  Insight Biotech 304628 Fridge   
CD8 BV510 Biolegend 301048 Fridge   
IGD BV510 BioLegend 302824 Fridge   
CD27 BV421 BioLegend 348219 Fridge   
PBS (from tablets) MP Biomedicals  92810307 My cupboard   
FACS BUFFER 
 
 
Made in lab 
 
 
NA 
 
 
My cupboard 
 
 
1L PBS, 1g 
BSA, 20mls 1% 
Na-azide 
DNA EXTRACTION:         
QiAmp mini kit Qiagen 51304 My cupboard   
Dulbecco PBS liquid Invitrogen 14190094 My cupboard   
EQUIPMENT:         
Quadromacs magnet Miltenyi Biotech NA My cupboard   
Pipettes and racks Mixed NA My cupboard   
FACS tubes and caps Lasec 352054 My cupboard  
Ice-packs Mixed NA Freezer 4   
Blue cool box Big Jim NA Gates TC  
Sterile eppendorfs Mixed NA Above fridge  
Tips, tubes, gloves Mixed NA General stock   
* Please inform me if anything is running out and I will make/find more.  
*All antibodies are mouse anti-human. 
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6) Samples: 
Thymic output will be measured from HIV-infected children on and off ART (CHER 
specimens) and HIV-uninfected healthy children (CWC specimens). 
 
a. Storage and location 
i. CHER: All CHER specimens are stored in the Immunology 
liquid nitrogen tank in column 3 in boxes 1 to 10 in descending 
order. 
ii. CWC: CWC specimens are stored in the Immunology liquid 
nitrogen tank in column 4 in slots 7, 8 and 9 (in descending 
order). 
• Slot 7: Box CWC2 = specimens no. 54 to 178 
• Slot 8: Box CWC3 = specimens no. 179 to 252 
• Slot 9: Box CWC4 = specimens no. 253 to 333 
NB. CWC specimens 334 to 487 are in liquid nitrogen 
storage in Virology. I will transfer them to slots 7, 8 and 
9 when space becomes available. 
 
b. Health risk and necessary precautions 
i. Liquid nitrogen: Please take usual precautions with retrieving 
the samples from liquid nitrogen (lab coat, LN2 gloves, shoe-
covers and protective eye-shield). 
ii. Caps for CHER specimens until cells are fixed: Please 
keep caps on top of the FACS tubes containing CHER 
specimens when outside of the laminar flow cabinet especially 
during vortex and centrifugation until the cells are fixed with 
FOXP3 fixation buffer (step 15). 
iii. Spillage procedures: In the event of a spillage of CHER 
specimens (live HIV-infected cells), clean contaminated 
equipment thoroughly with virkon and dispose in sealed 
rubbish bags. If contact with skin puncture or mucous 
membranes, immediately rinse with water then seek medical 
attention.  
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7) Procedure 
 
Thawing cryopreserved PBMCs: 
 
1) Switch on waterbath at 37°C. Label 12 x 15ml falcon tubes: 1 to 12, then 
Aliquot 3ml FCS and 2ml cRPMI into each. Plus place one 15ml falcon 
containing 7mls FCS to warm in the waterbath for washing cryovials to 
retrieve any leftover cells. 
2) Warm aliquots of FCS/RPMI and 2 x 50ml falcon tubes of cRPMI in 
waterbath for 15mins while setting everything up. 
SET-UP: 
• Tip boxes (10µl, 20µl, 200µl, 1ml) 
• Pipettes and multi-dispenser (tray of multi-dispenser tips) 
• 96-well plate for counting, trypan blue, hand-held counter 
• 4 type of racks: 50ml, 12ml, FACS tube and eppendorf racks 
• Sponge floatation device for thawing specimens 
• 1L jug for discarded fluids with 10mls Virkon 
• Put QuadroMACS magnet in small freezer compartment 
• Magnet stand and rack 
• 4 x 50ml falcon tubes of MACS Buffer in freezer compartment 
• 24 FACS tubes (with caps if processing CHER specimens, no need 
for caps with CWC specimens). Label FACS tubes: 1A, 2A, 3A etc. 
until 12A; 1B, 2B, 3B etc. until 12B. Please use green pen for Panel A 
and blue pen for Panel B. In some cases there will only be panel A – 
therefore only 12 FACS tubes required 
• 24 sterile eppendorfs. Label: 1P, 2P, 3P etc. until 12P; 1R, 2R, 3R, 
etc. until 12R. Please use black pen for “P” for PBMCs and blue pen 
for “R” for naïve CD4 T-cells (from CD45RA abbreviated to RAs). 
Likewise, when no Panel B there will only be 12 eppendorfs labelled 
1R to 12R (no 1P to 12P needed). 
• 12 x 15ml falcon tubes. Labelled 1F, 2F, 3F etc. until 12F. “F” is for 
flowcytometry. 
• 12 x MACS columns (± pre-separation filters for any samples with less 
than 2x10^6 PBMCs). 
• 1L bottles of PBS and FACS buffer as will need refills 
• Place ice packs (in drawer 3 immunofreezer 4) in blue cool box. 
• Check fridge temperature is >4°C – if not please adjust accordingly as 
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antibody-staining may be inhibited if fridge is too cold. 
 
3) Retrieve aliquot of viability stain from upright -80 freezer (keep wrapped in 
foil as light-sensitive), and retrieve specimens from liquid nitrogen tanks 
(please use usual precautions including use of tweezers to remove 
specimens from the box).   
a. Please check id details on each specimen 6-digit identification 
number, date of specimen and sample id number match specimen 
sheet given (as per example in Appendix B).  
b. If no cell count is recorded on specimen sheet provided, it is likely 
to be hand written on the vial, if this is the case please record this 
pre-frozen cell count in the space provided.  
c. Keep specimens in cool box with ice-packs while identifying other 
specimens.  
d. Finally, when all samples are retrieved from liquid nitrogen, add 
specimens to sponge floatation device in ascending order and 
place in waterbath to thaw.  
4) Please observe thawing process carefully – this may take as little as 30 
seconds only. While thawing quickly remove warmed FCS from 
waterbath, place in rack in ascending order and remove lids. As soon as 
the aliquot has thawed pipette sample into the 15ml falcon tube with 
warmed FCS and gently resuspend 5-times. Add 0.5ml warmed FCS to 
each empty cryovial to retrieve any leftover cells and pipette into their 
respective falcon tubes. 
5) First centrifugation at 1500rpm for 5min at room temperature. 
a. While spinning prepare mastermixes for Panels A and B (as per 
quantities indicated on specimen sheet (see example in Appendix 
B). Please have the light off in the hood when working with 
fluorochrome-conjugated antibodies, and please mix with a pipette 
and do not vortex. NB. Viability stain (LD) and Ki67PE do not go 
into the mastermix, this is added separately.  
b. When spinning complete discard supernatant supernatant. 
c. Using multi-dispenser add 4ml warmed cRPMI to each cell discard 
supernatant and resuspend solution with 1ml pipette. NB: when 
using the multi-dispenser, always discharge 1ml first as the first 
dispensing is not always accurate. 
6) Second centrifugation at 1500rpm for 5min at room temperature. 
a. While spinning prepare slides for counting, place 10µl trypan blue 
in 12 wells of the 96-well counting plate, refill multi-dispenser with 
50ml warmed cRPMI. 
b. When spinning complete discard supernatant supernatant  
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c. Using multi-dispenser add 4ml warmed cRPMI to each cell discard 
supernatant and resuspend solution with 1ml pipette. 
d. Take 10ul sample solution and mix 10-times with trypan blue then 
apply to haemocytometer. 
e. Count all live and dead PBMCs – and place the number counted in 
the first 2 columns of the table on the worksheet (Appendix A). 
f. Multiply the number of live PBMCs by 84,000 to get the number of 
live PBMCs in whole sample (see example below). This figure is 
derived by 2 x 4.2 x 10,000, which reflects a 2-fold dilution with 
trypan blue, 4.2mls of cRPMI and the magnification of the 
haematocytomter. 4.2mls is used because after the centrifuged 
sampled is has it's supernatant discarded, approximately 200µl of 
liquid remains in the bottom of the falcon tube. 
ID Live PBMC Dead cells Total live 
1 48 2 4.0x10^6 
2 76 24 6.4x10^6 
 
g. Finally, refill the 50ml falcon tubes with cRPMI and return to fridge. 
 
Dividing the PBMCs into three aliquots:  
a. Aliquot to be used for DNA extraction (leave for afternoon) 
b. To be used for magnetic bead isolation of naïve CD4 T-cells 
c. To be used for flowcytometry 
 
7) Divide PBMCs into 3 aliquots as per guide below and indicate in table on 
worksheet the quantities (see example).  
- FACS aliquot should be placed in falcon tubes labeled 1F to 12F. 
- PBMC DNA aliquot should be placed in eppendorfs labeled 1P to 12P. 
Put PBMC DNA aliquot aside for DNA extraction in the afternoon.  
- MACS aliquot is the remaining solution in the original tubes labeled 1-12. 
 
• If total number of thawed live cells >4x10^6 – 300µl for FACS, 600µl for 
PBMC DNA and remaining for MACS 
• If total number of thawed live cells <4x10^6 - use 300µl for FACS and 
remaining for MACS (no aliquot for DNA extraction of PBMCs) 
• If total number of thawed live cells <2x10^6 – as above, plus use pre-
separation filters to maximise yield (or if samples appear  clumpy) 
• If <1x10^6 use for FACS only (no MACS) 
 
ID Live PBMC Dead cells Total PBMC µl Comment 
1 48 2 4x10^6 NA  
2 76 24 6.4x10^6 600  
3 20 38 1.7x10^6 NA Filter used 
NB. Not all CHER samples will require an aliquot of PBMCs for DNA 
extraction. – this will be indicated on all worksheets collected daily 
(Appendices A, B and C), i.e. the mastermixes and DNA extraction sheet 
will be adjusted accordingly. 
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MACS naïve CD4 T-cell isolation / Flowcytometry preparation 
 
To save time aliquot (b) and (c) are processed as two separate 
procedures in parallel, i.e. during the incubation phases of the magnetic 
bead isolation, fluorochrome-conjugated antibodies are prepared and 
mixed with PBMCs etc. In the detailed instructions below the intracellular-
staining for flowcytometry steps are written in underlined italics and the 
MACS isolation steps are written in normal script. 
8) Centrifuge both MACS and flowcytometry (FACS) aliquots at 1500rpm for 
5min at room temperature. 
• MACS aliquot wash in existing cRPMI. 
• FACS aliquot wash with 1ml PBS. After spinning, discard supernatant and 
place aside. 
9) Mix MACS buffer and antibody cocktail: 
a. Aspirate MACS supernatant completely 
b. Add 40µl MACS buffer per 10^7 cells and resuspend well. 
c. Add 10µl naïve CD4 T-cell biotin-antibody cocktail per 10^7 cells. 
Mix really well. 
d. Incubate for 30mins in the dark in the fridge. Please note time 
incubation will be complete on the worksheet. 
10) Add 1ml PBS to FACS aliquots, centrifuge at 1500rpm for 5min at room 
temperature 
a. Meanwhile, aliquot 10µl of mastermix A to 12 FACS tubes for 
Panel A (labeled 1A to 12A). 
b. Then, aliquot 12µl of mastermix B to 12 FACS tubes for Panel B 
(labeled 1B to 12B). 
c. NB. Please check specimen details sheet (as per Appendix B) to 
confirm quantity for mastermixes and aliquots as the panel will 
change slightly with some of the CHER specimens (i.e. there may 
not always be two panels). 
d. Please have the light off in the hood when working with 
fluorochrome-conjugated antibodies. 
e. When spinning finished, discard supernatant PBS 
f. Add 0.5µl viability dye to each PBMC discard supernatant 
g. Add 100µl PBS to resuspend each PBMC discard supernatant 
(100µl only is sufficient as some PBS will remain in the tip of the 
falcon tube after discarding supernatant). If only doing Panel A – 
no need to add any PBS here. 
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h. Add 100µl to each respective FACS tube i.e. from falcon tube 1F 
add 100µl of resuspended PBMCs to FACS tube 1A and 1B. 
i. **Apply FACS tube caps if working with CHER specimens. 
j. Vortex for 5 seconds each 
e. Incubate for 30mins in the dark in the fridge. Please ensure fridge 
temperature is >4°C and note time incubation will be complete on 
the worksheet. 
 
11)  When MACS antibody-cocktail incubation complete, add 2ml MACS 
buffer with multi-dispenser and centrifuge at 1500rpm for 5min at 4°C. 
Rinse multi-dispenser with distilled H2O. 
• Meanwhile, prepare fixation and permeabilisation buffers. 
o Fix/Perm:  for 24 tubes mix 625µl fixative-concentrate with 1875µl 
of diluent (1 in 4 dilution). 
o Perm/Wash: for 24 tubes mix 2.5ml permeabilisation-concentrate 
with 22.5ml distilled H2O (1 in 10 dilution). 
o Store in fridge until required. 
o NB. These buffers must be made fresh daily.  
o NB. If Panel B excluded, please only make half the quantities 
above. 
12)  When MACS aliquots finishes spinning: 
a. Aspirate MACS supernatant completely 
b. Add 80µl MACS buffer per 10^7 cells and resuspend well 
c. Add 20µl anti-biotin microbeads per 10^7 cells, mix really well. 
d. Incubate for 30mins in the dark in the fridge. Please note time 
incubation will be complete on the worksheet. 
13) When FACS aliquots incubation complete, add 3ml FACS buffer per 
FACS tube using multi-dispenser, and centrifuge at 1500rpm for 5min at 
room temperature. Rinse multi-dispenser with distilled H2O. 
a. Discard supernatant FACS tubes 
b. Add 100µl Fix/Perm per tube (use 100µl multi-dispenser) 
c. Vortex (with caps on) 
d. Incubate at room temperature for 15mins in the dark (cover 
completely with foil) 
14)  When MACS microbeads incubation complete, add 2ml MACS buffer 
with multi-dispenser and centrifuge at 1500rpm for 5min at 4°C.  
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a. Label 12 x 15ml falcon tubes 1M, 2M, 3M etc. to 12M 
b. Retrieve QuadroMACS magnet from freezer shelf and attach to 
stand. Care not to trap fingers, as magnetic force can be strong. 
c. Apply 4 columns to the magnet with place tubes 1M to 4M beneath 
in rack. If a pre-separation filter is required, it is placed above the 
columns before rinsing. 
d. Rinse columns with 3ml cold MACS buffer. 
e. When buffer has run through, discard eluted buffer but retain 
falcon tubes. 
f. When centrifugation complete, discard supernatant from all 12 
tubes. 
g. Add 3ml MACS buffer to each tube using multi-dispenser.  
h. Place tubes labeled 5 to 12 in the fridge as only 4 samples can be 
processed at once. 
i. Using 1ml pipette, resuspend sample and apply to top of column 
(first 3mls). Care that bubbles are not created or applied to the 
column as it can obstruct the elution. 
j. Add 3ml MACS buffer to the empty tubes to “mop up” any leftover 
cells (for the second 3mls).  
k. When the column is dry following the first 3mls, apply the second 
3mls. NB. If using pre-separation filter for clumpiness, please use 
inside of syringe to massage the filter after the first 3mls and after 
the second 3mls. 
l. Likewise, when the column is dry following the second 3mls, apply 
3mls MACS buffer from multi-dispenser directly to the column 
(third 3mls). 
m. Finally, when the column is dry following the third 3mls, apply 3mls 
MACS buffer from multi-dispenser directly to the column (fourth 
3mls). 
n. The falcon tubes (1M to 4M) beneath the columns should then 
contain 12mls of diluted but purified naïve CD4 T-cells. 
o. Centrifuge these purified cells at 1500rpm for 10mins at 4°C. 
p. Remove the next set of 4 falcon tubes (5 to 8; or 9 to 12) from the 
fridge and recommence the process above from “i“ to “o”. 
q. Finally refill MACS buffer 50ml aliquots when empty and keep in 
freezer compartment until the end of the experiment. 
15)  Meanwhile, when the FACS fixation incubation stage is complete:  
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a. Add 0.5ml Perm/Wash per each FACS tube (use multi-dispenser) 
b. Centrifuge at 1500rpm for 5mins at room temperature 
c. While spinning prepare Ki67-mix: 24µl Ki67PE with 1200µl 
Perm/Wash for 24 tubes (please half both quantities if only using 
Panel A). 
d. When centrifugation is finished, discard supernatant supernatant, 
then add 50µl of KI67-mix per FACS tube 
e. Vortex (FACS caps no longer necessary as cells are now fixed) 
f. Incubate for 30mins in the dark in the fridge 
16)  While MACS purified cells are spinning, prepare to count the cells:  
a. Haematocytometer ready and 10ul of trypan blue per counting well 
of 96-well plate.  
b. When spinning complete discard supernatant supernatant  
c. Add 800ul of PBS to each falcon tube. 
d. Resuspend solution with 1ml pipette and apply to eppendorfs 
labeled 1R to 12R. 
e. Take 10ul sample solution, from 1R to 12R, and mix 10-times with 
trypan blue then apply to haemocytometer. 
f. Count all naïve CD4 T-cells – and place the number counted in the 
first “RAs ct” column of the table on the worksheet. 
g. Multiply the number of cells by 20,000 to get the number of naïve 
CD4 T-cells (see example below). This figure is derived by 2 x 1 x 
10,000, which reflects a 2-fold dilution with trypan blue, 1ml of 
PBS and the magnification of the haematocytomter. 1ml is used 
because after the sample is centrifuged and supernatant is 
discarded, approximately 200ul of liquid remains in the bottom of 
the falcon tube. 
ID Live 
PBMC 
Dead 
cells 
Total FACS 
µl 
PBMC 
µl 
RAs 
ct 
RA Total  Comment 
1 48 2 4x10^6 420 NA 15 3x10^5  
2 76 24 6.4x10^6 300 600 33 6.6x10^5  
 
17)  When FACS Ki67-incubation is complete: 
a. Add 0.5ml Perm/Wash per FACS tube 
b. Centrifuge at 1500rpm for 5mins at 4°C 
c. Discard supernatant 
d. Add 200µl FACS buffer per tube 
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e. Place in fridge – I will collect and run the PBMCs on the canto 
18)  Finally, when all 12 samples have had the naïve CD4 T-cell fraction 
isolated and counted – place the 12 eppendorfs labeled 1R to 12R along 
with the PBMC DNA aliquots labeled 1P to 12P. Leave at room 
temperature for 1-2 hours until DNA extraction. Please return any remains 
of viability stain aliquot to the -80 freezer. Please wash the multi-
dispenser tips with distilled water and then spray with ethanol at the end 
of each day. 
 
DNA extraction: 
a. PBMCs from the morning 
b. Purified naïve CD4 T-cells from magnetic bead isolation 
 
19) Heat hot-block to 56°C.  
20)  Move eppendorf-centrifuge into Gates TC room. Centrifuge all specimens 
1R-12R and 1P-12P at 4,000rpm for 4mins. While spinning set-up hood: 
SET-UP: 
• Tip boxes (20µl, 200µl, 1ml) 
• Pipettors 
• 2 type of racks: 50ml and eppendorf racks x 5 
• 24 mini-spin columns (or however many extractions required) 
• 24 sterile eppendorfs (or however many extractions required) 
• Box of Qiagen DNA extraction kit (Qiagen protease, >95% ethanol, 
buffers AL, AW1, AW2 and AE) 
• Dulbecco’s Phosphate Buffered Saline 
• Label printer 
 
21)  Discard supernatant. 
22)  Add 1ml Dulbecco’s PBS and resuspend by vortex for 15 seconds. 
Please use PBS from 50ml aliquots rather than from the original 500ml 
bottle. Also for DNA extraction please do not use the multi-dispenser as 
traces of salts can have inhibiting effects on PCR. 
23)  Centrifuge at 4,000rpm for 4min; afterwards discard supernatant 
supernatant. 
24)  Add 20µl Qiagen protease (protease digestion), mix 10-times. 
25)  Add 100µl Dulbecco’s PBS and 200µl buffer AL (lyse buffer). 
26)  Vortex for 15 seconds 
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27)  Incubated at 56°C on the hot-block for 10mins 
• Meanwhile open mini-spin columns and label 1R-12R and 1P-12P (or 
as per the day’s experiment) 
• Note PBMC or naïve CD4 T-cell count on the table on the DNA 
extraction worksheet (Appendix C). Naïve CD4 T-cell count can be 
taken straight from final column of table in MACS/FACS worksheet. To 
calculate PBMC number = 0.14 x total no. PBMCs (i.e. 0.14 = 0.6/4.2 
= 600ul of 4.2mls of PBMCs were put aside in step 7). 
• Then calculate the required elution volume: samples with <1x10^6 
cells will be eluted in 50µl of AE buffer, and samples with >1x10^6 
cells will be eluted in 80µl of AE buffer. 
Sample code Sample type Cell count Elution volume 
1P PBMC 9x10^5 50µl 
2P PBMC 1.3x10^6 80µl 
 
28)  When incubation complete, briefly centrifuge tubes to remove drops from 
the lid. 
29)  Add 200µl ethanol to each sample 
30)  Mix by pulse-vortex for 15 seconds 
31)  Briefly centrifuge tubes again – also to remove drops from the lid. 
32)  Apply contents to QIAmp mini spin columns. ***Please check specimen 
ID matched the ID written on the spin columns*** 
33)  Centrifuge at 8000rpm for 1min. 
34)  Reapply filtrate to column and spin again at 8,000rpm for 1min. 
• While spinning, arrange 3 rows of collection tubes (i.e. 3 tubes per 
sample) in eppendorf racks. 
35)  Transfer column onto new collection tube, add 500µl buffer AW1 to each 
column, and spin again at 8,000rpm for 1min. Discard old collection tubes 
and filtrate. 
36)  Transfer column onto new collection tube, add 500µl buffer AW2 to each 
column, and spin again at 14,000rpm for 3min. Discard old collection 
tubes and filtrate. 
37)  Transfer column onto new collection tube and spin again at 14,000rpm 
for 1min. Discard old collection tubes and filtrate. Note – here another 
buffer is not added, the extra spin step helps to remove contaminants that 
might inhibit PCR. 
38)  Transfer column onto sterile eppendorf and discard filtrate and tube.  
39)  Add 50µl buffer AE to all columns and incubate at room temperature for 
5min. 
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• While incubating, print required number of labels in this format. Please 
refer to the specimen location list for the sample label code: 
o Sample ID/label code  e.g. HP-CWC062 
o Date    e.g. 04.10.13 
o Sample type   e.g. PBMC DNA; or RA DNA 
 
40)  Centrifuge at 8,000rpm for 1min.  
41)  Add further 30µl Buffer AE to samples with >1x10^6 cells. For those 
samples with <1x10^6 reapply the 50µl of eluate to column – followed by 
1min incubation 
42)  Centrifuge at 8,000rpm for 1min.  
43)  Discard columns and apply labels.  
44)  Nanodrop as per instructions in next section (if time). 
45)  Then store at -20°C for PCR analysis. Can leave samples in green 
eppendorf rack and place directly in freezer (Immuno Freezer 3, 5th 
drawer). 
NB. When tidying up – please place waste fluid in a waste bottle under 
sink in Gates TC room. When waste fluid bottle is full, dispose with 
experiment waste bag in red biohazard rubbish container.  
NB. If working with 24 specimens, DNA extraction will be split into two 
groups of samples and perform each step alternately i.e. while one group 
of samples are spinning, prepare the others with buffers etc. If you do this, 
it is easier to keep colour-coded samples in separate groups. 
 
 
Nanodrop the 24 specimens of extracted DNA (if time) 
 
On the days when there are around 24 specimens to extract DNA, you 
may not have time to do measure these samples on the Nanodrop as well 
– so just let me know if this is the case and I will do it. However, on the 
days when there are only 12 specimens there should be enough time. 
 
46)  Log into the computer your usual MED_BIOCHEM login details. Select 
the Nanodrop (ND-1000) icon, then “nucleic acid” analysis. 
47)  Use aliquots of 1.2µl for both nuclease-free water and extracted DNA.  
48)  Use 1.2µl of nuclease-free water to initiate the nanodrop, and then blank 
once with 1.2µl AE buffer before beginning. 
49)  Place 1.2µl of sample on the nanodrop and click on “measure”. 
50)  In between samples, use 1.2µl of AE buffer to blank. 
51)  After each sample and each blank, wipe the nanodrop with tissue paper. 
52)  Please note ng/ul, 260/280 and 260/230 ratios in the spaces provided on 
the worksheet. Record to 1 decimal place. 
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53)  Repeat the nanodrop with 1.5µl once only if the sample readings are 
widely out of normal range. 
54)  When complete, store extracted DNA at -20°C for PCR analysis. Can 
leave samples in green eppendorf rack and place directly in freezer 
(Immuno Freezer 3, 5th drawer). 
 
8) Training 
I would suggest 3 days of training (or more if you prefer): one day observing the 
procedure, and two days performing the technique under observation (starting with 4 
samples/day, increasing to 8 and then 12 when ready). On the final day the purity of 
the naïve CD4 T-cells isolation will be checked (ideally >95%). 
 
 
SOP APPENDICES: 
A) MACS/FACS worksheet 
B) Example of specimen details, storage location and identification codes 
C) DNA extraction worksheet 
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SOP APPENDIX A:  
H Payne: Thymic output in paediatric HIV 
MACS/FACS, worksheet no:…….. Date of procedure:……………….... Performed 
by:……………………… 
 
1) Aliquot 3ml FCS and 2ml RPMI into 12x 15ml falcon tubes 
2) Warm FCS and cRPMI in waterbath for 15mins at 37°C while setting everything up 
3) Retrieve specimens (keep in cool box with ice-packs while identifying) then place in 
waterbath 
4) As soon as thawed pipette into 15ml falcon tube with warmed FCS 
5) Centrifuge 1500rpm for 5min, Discard supernatant, add 4ml cRPMI  (Prepare mastermixes 
A and B) 
6) Centrifuge 1500rpm for 5min, Resuspend in 4ml cRPMI (prepare for counting & tubes for 
division) 
7) Count and divide cells (place PBMC aliquot aside for the afternoon) 
 
ID Live PBMC Dead cells Total live PBMC? RAs ct RA Total  Comment 
1        
2        
3        
4        
5        
6        
7        
8        
9        
10        
11        
12        
 
 
MACS Isolation: 
 
Flowcytometry Preparation: 
Wash in existing cRPMI, 1500rpm, 5min Wash with 1ml PBS: 1500rpm, 5min, discard 
supernatant 
Aspirate supernatant, add 40µl MACS buffer up 
to 107 PBMCs + Antibody cocktail 10µl; MIX 
WELL  
INCUBATE (30min in dark/fridge).  
 
 Wash with 1ml PBS: 1500rpm, 5min, discard 
supernatant 
- Aliquot 10µl mastermix A per FACS tube 
- Aliquot 12µl mastermix B per FACS tube 
Add LD stain to tubes (0.5µl of LD stain per 
tube) 
Resuspend with 100µl PBS, then add to FACS 
tubes 
Vortex; INCUBATE (30min in dark/fridge).  
WASH with 2ml MACS buffer, 1500rpm, 5min Prepare FOXP3 buffers: 
- Fix/Perm = 625µl fix-conc + 1875µl diluent 
- Perm/Wash = 2.5ml perm-conc + 22.5ml H2O 
Discard supernatant, add 80µl MACS buffer 
+ 20µl Anti-Biotin Microbeads; MIX REALLY 
WELL 
INCUBATE (30min in dark/fridge).  
 
 
 
 
 
 
Wash with 3ml FACS buffer 1500rpm, 5min, 
discard supernatant 
Add Fix/Perm: 100µl Fix/Perm per tube, 
Time incubation complete:______ 
Time incubation complete:______ 
Time incubation complete:______ 
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 Vortex 
INCUBATE (15min room temp/dark).  
 
WASH 2mls MACS buffer, 1500rpm, 5min, 
discard supernatant 
MACS MATRIX COLUMN:  
Rinse with 3ml cold MACS Buffer, discard 
Resuspend sample in 3ml MACS buffer, apply 
to column and repeat 
Apply 2 x 3ml MACS buffer to columns,  
WASH for 10mins, 1500rpm, discard 
supernatant, resuspend in 800µl PBS, transfer 
to eppendorf, COUNT 
WASH - 0.5ml Perm/Wash, 1500rpm, 5min, 
discard supernatant 
Prepare 24µl Ki67PE + 1200µl Perm/Wash 
Add 50ul per FACS tube, vortex 
INCUBATE (30min in dark/fridge).  
 
 
Wash with Perm/Wash, 1800rpm, 5min, discard 
supernatant 
Add 200µl FACS buffer per tube, place in fridge 
 
1 
  
                                                
1 If total no. thawed cells >4x10^6 – 300ul for FACS, 600ul for PBMC discard 
supernatant and remaining for MACS 
If <4x10^6 cells, use 300ul for FACS and remaining for MACS (no PBMCs) 
 **If <2x10^6 = Use pre-separation filters**, If <1x10^6 PBMCs for FACS only 
Time incubation complete:______ 
Time incubation complete:______ 
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H Payne: Thymic output in paediatric HIV 
Sample identification, sheet no:…….. Date of procedure:……… Performed by:…………. 
	  
SOP APPENDIX C: DNA Extraction  
1) Set up hood, heat hot-block to 56°C 
2) Spin 4,000rpm 4mins, discard supernatant supernatant 
3) Add 1ml PBS, vortex 10 seconds: spin samples 4,000rpm, 4min, discard supernatant 
4) Add 20µl QIAGEN Protease, mix well 
5) Add 100µl PBS 
6) Add 200µl Buffer AL  
7) Mix by pulse-vortex for 15secs 
8) Incubate at 56°C for 10mins (meanwhile calculate elution volumes and label spin 
columns) 
9) Briefly centrifuge to remove drops from lid 
10) Add 200µl ethanol  
11) Mix by pulse-vortex for 15secs 
12) Briefly centrifuge again to remove drops from lid 
13) Apply contents to QIAmp Mini spin column in a 2ml collection tube  
14) Spin 8,000rpm for 1min 
15) Reapply filtrate to column; Spin 8,000rpm for 1min 
16) Discard filtrate and tube; new tube, add 500µl AW1; Spin 8,000rpm for 1min 
17) Discard filtrate and tube; new tube, add 500µl AW2; Spin 14,000rpm for 3mins (print 
labels) 
18) Discard filtrate and tube; new tube, spin 14,000rpm for 1min  
19) Discard filtrate and tube, place column in microcentrifuge tube 
20) Add 50µl Buffer AE to column, incubate for 5mins at room temperature, 1min spin 
8,000rpm 
21) Add further 30µl Buffer AE to samples >1x10^6 cells; if <1x10^6 reapply 50µl of eluate to 
column, 1min incubation, Spin 8,000rpm for 1min 
22) Discard columns and apply labels 
23) Nanodrop (blank with AE buffer)  
24) store at -20°C until PCR analysis (Immuno Freezer 4, 5th drawer) 
 
Sample 
code 
Sample 
type 
Cell count Elution 
volume 
Ng/µl 260/280 
ratio 
260/230 
ratio 
Comment 
1P PBMC       
2P PBMC       
3P PBMC       
4P PBMC       
5P PBMC       
6P PBMC       
7P PBMC       
8P PBMC       
9P PBMC       
10P PBMC       
11P PBMC       
12P PBMC       
        
1R Naïve CD4       
2R Naïve CD4       
3R Naïve CD4       
4R Naïve CD4       
5R Naïve CD4       
6R Naïve CD4       
7R Naïve CD4       
8R Naïve CD4       
9R Naïve CD4       
10R Naïve CD4       
11R Naïve CD4       
12R Naïve CD4       
  273 
APPENDIX XI: Standard operating procedure for TREC and KREC Quantification  
 
Reagents and consumables: 
• PCR grade Water – Sigma, Part No. W4502 1 Litre Bottle.  
• 100 x TRIS-EDTA (TE) buffer – Sigma, Part No. T-9285 100ML bottle.  
• Patient Naïve T- cells (stored at -20°C) 
• Standards (stored at -20°C) 
• FAST optical 96-well reaction plate 
• Micro Amp adhesive film 
• Azowipes – VWR International. Part No. 222/01 55/02.  
• 1.5mL autoclaved snap top micro centrifuge tubes.  
• Pipette tips (autoclaved). 
MASTER-MIX (measures given for each well required): 
All primers and probes should be stored at -20°C in the dark, diluted as indicated 
by the manufacturer then separated into aliquots: 
o TREC F Primer (45 µM)  - 0.5µl  
o TREC R Primer (45 µM) – 0.5µl  
o TREC FAM-TAMRA Probe (10µM) – 0.5µl  
o KREC F Primer (45 µM) – 0.5µl 
o KREC R Primer (45 µM) – 0.5µl 
o KREC HEX-TAMRA Probe (10µM) – 0.5µl 
o TRAC F Primer (45 µM) – 0.5µl 
o TRAC R Primer (45 µM) – 0.5µl 
o TRAC FAM-TAMRA Probe (10µM) – 0.5µl  
o Sterile water – 4.5 or 6µl (kept at room temperature) 
o Taqman FAST UMM polymerase (2x) : 12.5µl (stored at 4°C) 
For DNA extraction using the mini-kit: 
o Buffers AE, AW1, AW2, AL 
o QIAGEN Protease  
o Ethanol 96-100% 
o PBS 
o 2ml collection tubes 
o QIAamp Mini spin columns 
 
Equipment:  Taqman PCR machine PTC 100, program 7500 
 
Sample requirement and storage:  Cell pellets from separated T cell fractions and 
stored at -20°C. Cell pellets are stable for DNA extraction for 12 mths at -80°C.  
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Methods 
A: DNA Extraction (Appendix X: Thymic Output SOP) 
B: Preparing the Taqman plate 
C: Running the Taqman plate 
D: Notes on analysis 
E: Making the standard curve 
 
B: Preparing the Taqman plate 
1) Defrost samples from -20°C in room temperature. Each sample requires 35µl of 
extracted DNA. Remove standards out of freezer. 
2) Label Taqman plate/chart to reflect the 96 well plate: 
a. 3 of each of the 5 standards for TRECs/KRECs and 2 x (1x106), 3 x 5 for 
for TRACs standards and 2 x (1x106) – therefore 34 wells for standards 
b. 6 of each sample – maximum 10 samples per plate (60 wells) 
c. 2 blanks 
3) Calculate quantities of probes/primers needed for the mastermixes. Always 
calculate total requirements for two extra wells. 
4) Prepare the Mastermixes in PCR clean room. Multiply by number of wells. Ensure 
enough is made for each of the wells – a total of 20µl of the Mastermix and 5µl of 
standard solution or 5µl of patient DNA will go into each well (excluding the blank 
wells which will have 5µl sterile water). Therefore each well will contain 20µl of 
solution.  
 
MASTER-MIX for TRECs/KRECs: 
Reagent Conc Volume/well Volume for x+2 extra wells 
TREC F Primer 45µM 0.5µl  
TREC R Primer 45µM 0.5µl  
TREC FAM-TAMRA Probe 10µM 0.5µl  
KREC F Primer 45µM 0.5µl  
KREC R Primer 45µM 0.5µl  
KREC HEX-TAMRA Probe 10µM 0.5µl  
Water - 4.5µl  
Taqman UMM 2x 12.5µl  
 
MASTER-MIX for TRACs: 
Reagent Conc Volume/well Volume for x+2 extra wells 
TRAC F Primer 45µM 0.5µl  
TRAC R Primer 45µM 0.5µl  
TRAC FAM-TAMRA Probe 10µM 0.5µl  
Water - 6µl  
Taqman UMM 2x 12.5µl  
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5) Vortex Mastermixes for 15 seconds 
6) Apply 20µl of TRECs/KRECs Mastermix to the 1st 48 wells (base of each well). 
7) Apply 20µl of TRACs Mastermix to the next 48 wells (bottom half) 
8) Take to DNA prep room with samples and standards 
9) Remove standards from fridge – 5 standards. The 6th will need to be made fresh 
each time. 
Tube 1 106 copies/5µl 
Tube 2 105 copies/5µl 
Tube 3 104 copies/5µl 
Tube 4 103 copies/5µl 
Tube 5 100 copies/5µl 
Tube 6 Empty 
 
10) Prepare Tube 6: take 3µl of tube 5 and add to 27µl sterile water = 10 copies/5µl 
11) Vortex Standards or pipette mix 
12) Pipette 5µl of standard solution into each of the standard wells – see worksheet 
(i.e. 2x106, 3x105, 3x104, 3x103, 3x102, 3x10 = 17 wells for top half of tray 
TRECs/KRECs… and 17 wells for bottom half: TRACs).  
13) Pipette 5µl of sterile water to the two blank wells. 
14) Add 5µl of each extracted DNA sample to the specimen wells – 3 per 
TRECs/KRECs half of the plate and 3 each per the TRACs half. Therefore max 
10 samples. 
15) Attach the microAmp adhesive film to the plate and score with a Micro Amp 
adhesive film applicator 
16) Cover with foil and keep in fridge if any delays. 
17) Check wells for air-bubbles. If any present, VERY gently tap underneath. 
NB. Ideally also have a “run control” with each run. 
 
C: Running the Taqman plate 
1) Spin the plate at 3500rpm for 1min (or 4680rpm if any air bubbles). 
2) Set up computer 
a. 7500 software, login as guest-user 
b. Place plate in PCR machine 
c. Select template kept under file name “Helen” 
d. Plate set-up: TRECs/KRECs and TRACs standards already set, as are 
blanks. Add number of patient samples (max. 10) 
e. Number each well in triplets in both halves of the plate (tick the patient 
sample box then highlight the wells) 
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f. Highlight all patient wells and tick the box for TRECs/KRECs or TRACs – 
depending on side of plate. 
g. Select “S” for standards, “N” for blanks and “U” for samples 
h. Set cycles to 45-50 (it measures from 22-50 cycles) 
i. Check threshold of 0.03  
j. Save plate under date and code for samples 
k. Start Run… –will take approximately 2hrs 
l. At end of run click OK at the prompt and save 
 
D:  Notes on analysis 
-­‐ Set threshold at 0.03 or closest per each TREC, KREC or TRAC analysis that 
matches the ideal ct mean 
-­‐ Set cycles at 3-points lower (ie. If 20 cycles, set at 17) 
-­‐ Save raw data in separate file 
-­‐ Review the standard curves for slope, intercept and R2 values (eyeball which 
points, if any, may need to be omitted) 
Slope Range must be within -3.1-3.6 (ideally 3.3) 
Intercept Should be consistent but range could be 36-41 
R2 >0.97 
Ct value Should typically fall within +2 points of the average range 
 
-­‐ Check each triplet of standards and complete the table (amplifications, omissions, 
ct mean etc). Check samples triplets (if any 1 deviates – re-run sample) 
-­‐ Omit wells and reanalyse (only up to 3 data points can be removed from stds) 
-­‐ Check standard curve meets requirements 
-­‐ Then, record results from samples 
-­‐ Save analysed data and separate file - export to excel 
-­‐ Blanks should have no peaks 
-­‐ All standards should have peaks at spaced intervals  
-­‐ Each sample should have a TRAC peak but may/may not have a TREC/KREC 
peak depending on the clinical condition 
-­‐ Expected Reference Range: 
Newborn-3yrs CD3+ T cells >100,000 
3yrs-10yrs CD3+ T cells 30,000-70,000 
10yrs-16yrs CD3+ T cells 20,000-60,000 
Adult Negligible TREC levels 
-­‐ Expected Reference Range: 10-1000ng/µl DNA concentration 
-­‐ Expect 0.044 TRECs/cell  (from TRECs/No. cells from TRAC) 
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E: Making the standard curve  
 Stock = 2 x 106/µl (107/5µl) This should be enough for 60 runs 
Standard 1 1 x 106/5µl 150µl stock + 1350µl buffer 
Standard 2 1 x 105/5µl 200µl of 1 + 1800µl buffer 
Standard 3 1 x 104/5µl 200µl of 2 + 1800µl buffer 
Standard 4 1 x 103/5µl 200µl of 3 + 1800µl buffer 
Standard 5 1 x 102/5µl 200µl of 4 + 1800µl buffer 
Standard 6 10/µl Make fresh every time 
 
Quantity Mean Ct TRECs Mean Ct KRECs Mean Ct TRACs 
10 35.46 35.17 35.13 
100 32.15 31.79 31.90 
1,000 28.83 28.83 28.50 
10,000 25.43 25.10 25.23 
100,000 22.02 21.70 21.82 
1,000,000 18.21 18.25 18.20 
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APPENDIX XII: Standard operating procedure for quantitative anti-gp120 antibody 
ELISA 
 
Concept: 
Two ELISAs plates run together – one will measure gp120-specific IgG and the other 
will measure total IgG. Therefore the output may be described as a ratio of gp120-
specific IgG per total IgG. It will also be possible to estimate the child’s total IgG.  
 
Reagents Required: 
• Anti-Human IgG (Fc Specific) Antibody Produced in Goat, Affinity Isolated 
Antibody, Buffered Aqueous Solution (for coating the plate) 
• Goat anti-Human, IgA+G+M (H+L), Biotin (detection antibody) 
• Anti-Biotin-Peroxidase Antibody Produced in Goat, Affinity Isolated Antibody, 
Buffered Aqueous Solution (capture antibody) 
• IgG from Human Serum, Reagent Grade, >95% (for the IgG standard curve) 
• Goat Serum, Donor Herd, USA Origin, Sterile- Filtered, Suitable for Cell Culture 
(for blocking agent/solution for IgG ELISA) 
• Tween® 20, viscous liquid (for various buffer solutions) 
• Plate Immuno F96 MaxiSorp (Cert) Polystyrene  
• Carbonate-bicarbonate (for plate) Sigma: C3041-50 CAP 
• Plate Sealer, EASYsealTM, Transparent 
• Sulphuric acid (1.0 molar) – for stopping agent 
• Non-fat dry milk (Elite) – for buffers 
 Preparations of buffers / agents: 
• Carb-bicarbonate: Break one tablet into 100ml distilled water. Keep at 4°C for 
one month. 
• PBS/Tw20: 1 litre PBS with 500µl Tween20 (for 2 plates). Make fresh each 
time. 
• Blocking agent for IgG plate: 5% goat serum, 5% milk, 0.05% Tween20 and 
PBS. Make fresh each time. Make 30mls per IgG plate e.g. 30ml PBS, 1.5ml 
goat serum, 1.5g milk powder, and 15µl Tween20. 
• Dilution buffer: PBS, 5% milk, 0.05% Tween20. Make fresh each time. Make 
50mls per gp120 plate e.g. 50ml PBS, 2.5g milk powder, 25µl Tween20. 
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Preparation of the plates: 
 
IgG Plate Gp120 plate 
1) Make IgG coating buffer: add anti-
human IgG to carb-bicarbonate to make 
a solution of 4ug/ml. 11µl of anti-h IgG 
and 6ml carb-bicarbonate.  
1) Prepare gp120 coating buffer: 8µl of 
5mg/ml gp120 in 10mls of Carb-
Bicarbonate buffer. 
2) Coat plate with anti-human IgG in 
coating buffer, 50µl per well. 
2) Coat plate with gp120 coating buffer, 
50µl per well. 
3) Incubate overnight at 4°C or for one hour at 37°C. 
4) Wash x 4 in PBS/Tw20 solution. 
5) Block with 200µl blocking agent. 5) Block with 100µl dilution buffer. 
6) Incubate 1hr at 37°C. 
7) Calculate sample dilution series and prepare standard curve and samples in 
separate sample plate. NB, for IgG plate the samples and standards must be mixed 
in the goat-serum blocking agent and for the gp120 plate the standards and samples 
must be mixed with the dilution buffer. See dilution series template example below. 
8) Wash x 4 in PBS/Tw20 solution. 
9) Add human IgG standard to top of 
scale and proceed to do serial dilution. 
3µl in 300µl goats serum mix. 
9) Add gp120 to top of scale and proceed 
to do serial dilution.  9µl in 900µl dilution 
buffer. 
10) Add samples to IgG plate diluted in 
goats serum blocking agent. Proceed to 
do serial dilution according to scale of 
dilution series e.g. 1:50 (3µl in 150µl). 
10) Add samples to gp120 plate diluted 
in dilution buffer. Proceed to do serial 
dilution according to scale of dilution 
series. 
11) Add 50ul of the sample dilution from the sample plate to each the IgG and gp120 
ELISA plates 
12) Incubate 1hr at 37°C. 
13) Wash x 4 in PBS/Tw20 solution. 
14) Add goat anti-human total Immunoglobulin-Biotin titrated to 1:1000.  
4µl antibody in 12mls dilution buffer, 50µl per well 
15) Incubate 1hr at 37°C. 
16) Wash x 4 in PBS/Tw20 solution. 
17) Add Anti-biotin-peroxidase antibody produced in goat 50µl per well (optimal 
concentration 1:1000) 
18) Incubate 1hr at 37°C, remove TMB from fridge. 
19) Wash x 4 in PBS/Tw20 solution. 
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20) Add 100µl TMB substrate and wait 2-5 mins for colour to develop. 
21) Stop with 25µl of H2SO4 (1 molar). 
22) Read on ELISA plate reader at 450nm (NB. Plates stable to be re-run for 
15mins). 
 
Dilution series: 
 
For standard curve – use from 4 to 16 standards. Fill top well only with standard 
and dilution e.g. 3µl human IgG and 300µl goats serum blocking agent.  
For a 3-fold dilution series: 
- Fill the remaining wells with 60µl dilution buffer 
- Take 30µl from top well (Std1) and add to second well (Std2).  
- Mix 10x to resuspend the solution. 
- Take 30µl from the second well and add to the third (Std3) etc. 
- No need to change tips. 
- Example: for a 4-fold solution, fill each well with 90µl and add 30µl to mix. 
 
For the samples – use 8 dilutions or more. Use judgment to estimate the scale of 
dilution (initial and fold-series). Note IgG will always be far more concentrated than 
gp120 and therefore will need more dilution i.e. 5 or 6-fold dilution whereas gp120 
may only require 3-fold dilution. As per standards, fill top well only with standard and 
dilution e.g. 3µl sample in 150µl dilution buffer. 
 
Std1 Std9 Sample1 Sample2 3 4 5 6 7 8 9 10 
Std2 Std10 Sample1 Sample2         
Std3 Std11 Sample1 Sample2         
Std4 Std12 Sample1 Sample2         
Std5 Std13 Sample1 Sample2         
Std6 Std14 Sample1 Sample2         
Std7 Std15 Sample1 Sample2         
Std8 Std16 Sample1 Sample2         
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Dilution series by plate: 
 
IgG Plate: 
2/198 30/60 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 1/1000 
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 1/1000 
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 1/1000 
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120  
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120  
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120  
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120  
 
gp120: 
           
5/95 30/60 3/147 3/147 3/147 3/147 3/147 3/147 3/147 3/147 3/147 3/147 
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 3/147 
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 3/147 
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 3/147 
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120  
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120  
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120  
30/60 30/60 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120 30/120  
 
Setting up the ELISA reader and interpreting the results: 
• Computer will calculate the dilution series, only the labels and scale of dilution 
need to be entered.  
• Standard curve must be visually sigmoid, one or two points may be excluded 
if necessary. No official parameters to be met. 
 
Storage and Aliquots: 
Item Aliquot size 
(Enough for 1 plate) 
Storage Function 
Anti-Human IgG 12µl -20°C Plate-coating 
Goat anti-human total Ig Biotin 4.5µl -20°C Detection 
antibody 
Anti-biotin peroxidase 12µl -20°C Capture antibody 
IgG from Human Serum 3.5µl -20°C IgG standard 
curve 
Goat serum 2ml -20°C For buffers 
GP120 clade C monoclonal 
antibody 
9.5µl -20°C For standard 
curve 
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APPENDIX XIII: Standard operating procedure for HIV proviral DNA 
quantification 
 
Reagents/Equipment: 
PDHTaq1 primer 5’ -TGA AAG TTA TAC AAA ATT GAG GTC ACT GTT -3’ 
PDHTaq2 primer 5’- TCC ACA GCC CTC GAC TAA CC -3’ 
PDHTaqPR probe 5’- JOE-CCC CCA GAT ACA CTT AAG GGA TCA ACT CTT 
AAT TGT TAMRA-3’ 
HIV1LTRTaq1 
primer 
5’- GCC TCA ATA AAG CTT GCC TTG A- 3’ 
HIV1LTRTaq2 
primer 
5’ -GGC GCC ACT GCT AGA GAT TTT- 3’ 
HIV1TaqPR probe 5’- FAM -TGT GAC TCT GGT AAC TAG AGA TCC CTC 
AGA C TAMRA-3’ 
 
• Qiagen EZ-1 robot and virus kit 
• Applied Biosystems Taqman 7500 
• Abgene PCR plates Thermo-fast 96 non-skirted clear (Cat no: AB-0600^) 
• Abgene Absolute QPCR plate seal (Cat no: AB-1170) 
• Gilson Pipettes and barrier tips (p2/p20/p200/p1000) 
• Qiagen carrier RNA 
• Qiagen Multiplex PCR Master Mix (with ROX dye) Kit (Cat no: 204543) 
• Mol. Grade nuclease free water 
• Extracted DNA from 8E5 cell line 
• Use between 10,000 and 5x106 cells (use carrier DNA if <10,000 cells) 
• 100,000 cells yields 600ng DNA (PCR max) 
 
After DNA extraction record nanodrop results in the following table and calculate 
precise volume of DNA extract to achieve maximum sensitivity of the assay by 
quantifying 600ng of DNA per reaction well. 
 
• A non-template control for every run 
• Each standard and sample to be run in triplicate with average values used  
• Samples were re-run when less than the 3 reactions amplified or values 
differed by greater than 2 sd.  
• The explicit quantity of provirus per 105 PBMCs is the output value of LTR 
divided by PDH. 
 
Sample ID Nanodrop 
(ng/ul) 
260/280 260/230 Vol for 600ng 
= 600ng/sample 
Vol H20 to  
make 11µl 
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Quantitative HIV Proviral PCR  
• Carrier RNA, Standards, Samples, Qiagen mix, Mol H20, Plate and adhesive, 
Primers/probes 
 
8E5 standard curve (e.g. 8E5 stock = 1x10^5/µl) 
Make the 1:10 dilution series using Carrier RNA: 5ug/ml so do a 1 in 200 dilution = 1.5µl + 
298.5µl nuclease-free water. For example:  
1. Std 1 = 10^5 = 3.4µl stock + 30.6µl carrier RNA 
2. Std 2 = 10^4 = 4µl Std 1 + 36µl carrier RNA 
3. Std 3 = 10^3 = 4µl Std 2 + 36µl carrier RNA 
4. Std 4 = 10^2 = 4µl Std 3 + 36µl carrier RNA 
5. Std 5 = 10 = 4µl Std 4 + 36µl carrier RNA 
6. Std 6 = 1 = 4µl Std 5 + 36µl carrier RNA 
 
Make the 25µl PCR mastermix 
a. Make working stock 
b. Make mastermix 
c. Add mastermix to plate (14µl per well) 
d. Add water to standards, NTC and one sample well 
e. Add standards 
f. Add sample DNA 
Reagent Volume 
per well 
Working 
stock 
required 
Stock [100µM] 
and calculation 
to get to working 
[10µM] 
Final 
concentration  
Volume 
x 
__wells 
PDH forward 
primer 
0.25µl 10µM …µl working 
stock + …µl H20 
100nM  
PDH reverse 
primer 
0.25µl 10µM …µl working 
stock + …µl H20 
100nM  
PDH probe 0.25µl 10µM …µl working 
stock + …µl H20 
100nM  
HIV1LTRTaq
1 primer 
0.25µl 20µM …µl working 
stock + …µl H20 
200nM  
HIV1LTRTaq
2 primer 
0.25µl 20µM …µl working 
stock + …µl H20 
200nM  
HIV1TaqPR 
probe 
0.25µl 10µM …µl working 
stock + …µl H20 
100nM  
Qiagen MM 12.5µl 2 x - 1x  
8E5 Stds  11µl total (10µl 8E5 +1µl H20) 
600ng DNA 11µl total (DNA+H20) 
 
Set up PCR Taqman  / Applied Biosystems7500 : 
 1  2 3 4 5 6 7 8  9  10  11 12 
A             
B             
C             
D             
E             
F             
G             
H             
Dyes: Joe and Tamra (PDH)  Cycling: 95oC for 15 mins x 45                        
Fam and Tamra (LTR)    95oC for 60s 
       60oC for 60s 
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APPENDIX XIV: Gating strategy for Panel A 
 
From left to right (plots 1-7):  
1) Forward-height versus forward-area scatter, gated on single cells. 
2) From single cells on plot 1: Forward versus side scatter, gated on lymphocytes. 
3) From lymphocytes on plot 2: Forward scatter on x-axis, viabliity marker on y-axis, gated on 
live cells (%viability). 
4) From live cells on plot 3: Forward scatter versus CD3-PECy7, gated on CD3+ (CD3%). 
5) From plot 3: CD4-PerCP on x-axis versus CD3-PECy7 on y-axis, gated on CD4+CD3+ 
(CD4%) and CD4-CD3+ (CD8%). 
6) From plot 3: CD4-PercP on x-axis versus CD45RA-FITC on y-axis, gated on 
CD4+CD45RA+ lymphocytes (naïve CD4+ T-cells). 
7) From plot 6: Ki67-PE on x-axis versus forward scatter, gated on CD4+CD45RA+Ki67+ 
lymphocytes (%proliferation to be used in thymic output formula).  
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From left to right (plots 8-16): 
8) From CD4 population on plot 5: CD45RA-FITC on x-axis versus CD4-PerCP on y-axis, 
gating on CD4+CD45RA- (left, CD4 memory) and CD4+CD45RA+ (right, CD4 naive). 
9) From CD4 population on plot 5: Ki67-PE on x-axis versus CD4-PerCP on y-axis, gating on 
CD4+ Ki67+ lymphocytes. 
10) From CD4 population on plot 5: HLADR- pacific blue on x-axis versus CD4-PerCP on y-
axis, gating on CD4+HLADR+ lymphocytes. 
11) From CD8 population on plot 5: CD45RA-FITC on x-axis versus forward scatter on y-axis, 
gating on CD3+CD4-CD45RA- (left, equivalent CD8 memory) and CD4+CD45RA+ (right, 
equivalent CD8 naive). 
12) From CD8 population on plot 5: Ki67-PE on x-axis versus forward scatter on y-axis, gating 
on CD3+CD4-Ki67+ lymphocytes (equivalent CD8 Ki67). 
13) From CD8 population on plot 5: HLADR-pacific blue on x-axis versus forward scatter on y-
axis, gating on CD3+CD4-HLADR+ lymphocytes (equivalent CD8 HLADR). 
14) From CD3 population on plot 4: CD45RA-FITC on x-axis versus CD3-PECy7 on y-axis, 
gating on CD3+CD45RA- (left, CD3 memory) and CD3+CD45RA+ (right, CD3 naive). 
15) From CD3 population on plot 4: Ki67-PE on x-axis versus CD3-PECy7 on y-axis, gating on 
CD3+Ki67+ lymphocytes. 
16) From CD3 population on plot 4: HLADR- pacific blue on x-axis versus CD3-PECy7 on y-
axis, gating on CD3+HLADR+ lymphocytes. 
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From left to right (plots 17-22): 
17) From CD4+CD45RA- population on plot 8: Ki67-PE on x-axis versus CD4-PerCP on y-
axis, gated on CD4+CD45RA-Ki67+ lymphocytes (proliferation of memory CD4). 
18) From CD4+CD45RA+ population on plot 8: Ki67-PE on x-axis versus CD4-PerCP on y-
axis, gated on CD4+CD45RA+Ki67+ lymphocytes (proliferation of naïve CD4). 
19) From CD4-CD45RA- population on plot 11: Ki67-PE on x-axis versus forward scatter on y-
axis, gated on CD3+CD4-CD45RA-Ki67+ lymphocytes (proliferation of memory CD8). 
20) From CD4-CD45RA+ population on plot 11: Ki67-PE on x-axis versus forward scatter on y-
axis, gated on CD3+CD4-CD45RA+Ki67+ lymphocytes (proliferation of naive CD8). 
21) From CD3+CD45RA- population on plot 14: Ki67-PE on x-axis versus CD3-PECy7 on y-
axis, gated on CD3+CD45RA-Ki67+ lymphocytes (proliferation of memory CD3). 
22) From CD3+CD45RA+ population on plot 14: Ki67-PE on x-axis versus CD3-PECy7 on y-
axis, gated on CD3+CD45RA+Ki67+ lymphocytes (proliferation of naive CD3).
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APPENDIX XV: Gating strategy for Panel B 
 
From left to right (plots 1-9): 
1) Forward-height versus forward-area scatter, gated on single cells. 
2) From single cells on plot 1: Forward versus side scatter, gated on lymphocytes. 
3) From lymphocytes on plot 2: Forward scatter on x-axis, viability marker on y-axis, 
gated on live cells (%viability). 
4) From live cells on plot 3: CD3-FITC on x-axis versus CD56-PECy7 on y-axis, gated on 
CD3-CD56+ (NK-cells) and CD3+CD56- (T-cells). 
5) From live cells on plot 3: CD3-FITC on x-axis versus CD19-PerCP on y-axis, gated on 
CD3-CD19+ (B-cells). 
6) From B-cells on plot 5: Ki67-PE on x-axis versus CD19-PerCP on y-axis, gated on 
CD19+Ki67+ lymphocytes (proliferation of B-cells). 
7) From NK-cells on plot 4: Ki67-PE on x-axis versus CD56-PECy7 on y-axis, gated on 
CD56+Ki67+ lymphocytes (proliferation of NK-cells). 
8) From B-cells on plot 5: CD27-BV421 on x-axis versus IgD-BV510 on y-axis, gated on 
CD19+IgD+CD27- lymphocytes (naïve, unswitched B-cells). 
9) From naïve unswitched B-cells on plot 8: Ki67-PE on x-axis versus IgD-BV510 on y-
axis, gated on CD19+IgD+CD27-Ki67+ (proliferation of naïve, unswitched B-cells). 
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APPENDIX XVI: Publication 1 
 
 
Observed full blood count and lymphocyte subset 
values in a cohort of clinically healthy South 
African children from a semi-informal settlement 
in Cape Town.  
 
South African Medical Journal 
July 2015; 105(7): 589-595 
 
 
